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I. Abstract 
CDK1 belongs to the family of serine/threonine kinases that require cyclin binding and 
phosphorylation for activation. CDK1 is partnered by cyclin A or cyclin B and is the only 
essential CDK that is required to drive the eukaryotic cell cycle. Because of their roles 
in driving cell growth and division, the activities of some members of the CDK family 
are upregulated in different cancer types making them attractive targets for therapy. 
The structure of monomeric CDK1 bound to CKS1 and in a complex with cyclin B are 
presented. These structures confirm the conserved inactive monomeric CDK fold and 
show how it can be remodelled by cyclin binding. These structures have revealed 
important insights for our understanding of CDK function and regulation as well as for 
the development of new more potent and specific drugs. A range of biophysical and 
biochemical techniques have been used to confirm and develop hypotheses as to the 
regulation and activity of CDK1 proposed by the structures. The melting temperature 
of CDK1 was estimated and compared to that of the cyclin B bound complex, CDK2 
and CDK2-cyclin A to determine if the smaller interface between CDK1 and cyclin B 
may have implications for protein stability. The CDK1–cyclin B structures also reveal 
potential novel protein interaction sites that might regulate CDK1 activity. These 
findings inspired further investigations to explore binding sites by structural biology 
methods. CDK1 can phosphorylate the largest number of substrates in comparison to 
other CDKs. This relaxed substrate specificity was explored with reference to the 
insights provided by the CDK1-cyclin B-CKS2 structure. The similarities in sequence 
and secondary structure exhibited by the CDK family pose challenges for inhibitor 
design. The binding modes of a diverse set of inhibitors were characterized by a range 
of biophysical methods and their structures were determined by X-ray crystallography. 
The results of these experiments highlight the importance of conformational plasticity 
of the whole molecule in shaping the ATP binding site. 
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 Introduction 
1.1 Regulation of the eukaryotic cell cycle  
The cell cycle is the series of cellular events that leads to duplication of genetic material 
and cell division. This process is the only way to fulfil the reproduction and development 
of unicellular and multicellular organisms. The oscillating activity of the Cycle 
Dependant Kinases (CDKs) acts as a master regulator of cell cycle progression in 
eukaryotes. Since a number of seminal discoveries were made in the 1970s and 1980s 
using cell lines and model organisms (Hartwell et al., 1970; Johnson and Rao, 1970; 
Rao and Johnson, 1970; Nurse et al., 1976; Nurse and Thuriaux, 1980; Standart et al., 
1987; Hartwell and Weinert, 1989) enormous progress has been achieved in this area. 
This work lead to an appreciation of the organisation of the cell cycle and the 
mechanisms that regulate it. For example, an emphasis on the existence of 
checkpoints and surveillance mechanisms (Weinert and Hartwell, 1988; Hartwell and 
Weinert, 1989); the activities of different cyclins that can activate CDKs at different 
stages of the cell cycle to ensure ordered progression (Enoch and Nurse, 1990; Surana 
et al., 1991) and finally the importance of quantitative oscillations of CDK activity 
(Surana et al., 1991; Stern and Nurse, 1996). 
The cell cycle has five distinct phases (Morgan, 2007). During G1 and G2 phases cells 
grow and accumulate cellular components, during S phase replication of DNA takes 
place and during mitosis the cell divides.  After mitosis, the cell can continue to 
proliferate or enter quiescence (G0 phase) (Figure 1-1). Prior to cell cycle entry, 
mitogenic pathways are triggered by growth factors. The well characterised pathways 
triggering the cell cycle are mitogen-stimulated protein kinase (MAPK) and 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathways (Balmanno and 
Cook, 1999). ERK1/2 is also important as it promotes transcription of D-type cyclins 
(Balmanno and Cook, 1999). Cyclin D activates CDK4 and CDK6 for phosphorylation 
of various substrates, most importantly retinoblastoma tumour suppressor protein (Rb) 
as well as p107 and p130 that collectively bind and repress E2F transcription factors.  
Rb family phosphorylation relieves E2F inhibition to activate genes important for G1 to 
S transition, DNA replication, chromatin structure and the spindle assembly checkpoint 
(SAC). CDK4/6 also bind to CDK inhibitors (CKIs) that prevent activation of CDK2-
cyclin E. Two families of CDK inhibitors regulate the cell cycle, the INK4 and Cip/Kip 
inhibitors (Pavletich, 1999; Jeffrey et al., 2000). 
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Figure 1-1 Regulation of cell cycle progression.   
Mitogenic signals lead to transcription of cyclin D isoforms that form complexes with 
CDK4 and CDK6 which activate by phosphorylation a number of substrates including 
Rb. Phosphorylation of Rb leads to activation of the family of E2F transcription factors. 
Growth inhibitory signals upregulate CIP/KIP and INK4 inhibitors that control 
progression from one phase to the next. Progress through S phase and G2 phase is 
controlled by CDK2 complexes together with kinases of the Aurora family and polo-like 
kinases (PLK). DNA damage is recognised by checkpoint kinases 1 and 2 (CHK1 and 
2) with p53 involved. Kinases and cyclins are identified by different colours, grey ovals 
identify negative regulators of cell cycle. Red P means active phosphorylation, grey P 
means dephosphorylation. CDC25, cell division cycle 25. Picture adapted from (Otto 
and Sicinski, 2017). 
Proteins of the INK4 family, p16INK4a, p15INK4b, p18INK4c and p19INK4d inhibit 
mainly members of the CDK4 subfamily and bind preferentially to monomeric CDKs 
resulting in stabilisation of molecule which decreases CDK affinity for their cyclin 
partners and ATP  (Jeffrey et al., 2000). Proteins of the CIP/KIP family, p21CIP1, 
p27KIP1 and p57KIP2, in contrast bind to CDKs in complex with their respective cyclins 
offering another level of CDK regulation (Pavletich, 1999). Activation of E2F1 and 
FOXM1 by CDK4/6 leads to the increased expression of cyclins E1 and E2 which leads 
to CDK2 activation. At this point the cell has passed the restriction point and further 
progress through the cell cycle is no longer dependent on the continuous presence of 
growth factors. E2F1 also stimulates expression of cyclin A in S phase which becomes 
the regulator of CDK2 in S phase. The important CDK2 substrates that promote S 
phase entry are Rb and NPAT and to terminate it – CDC6 and E2F1. Cyclin A also 
binds CDK1 in late S/G2 stage activating transcription factors FOXM1 and FOXK2 
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which are involved in mitotic progression (Laoukili et al., 2008; Sadasivam et al., 2012). 
Cyclin A is degraded prior to anaphase (Furuno et al., 1999). Cyclin B accumulation at 
the G2-M transition mainly occurs in the nucleus as CDK1 has a number of nuclear 
substrates that lead to nuclear re-organisation and fragmentation and also nuclear 
envelope breakdown (Peter et al., 1990). CDK1 also has a number of targets in the 
cytoplasm. CDK1 in contrast to CDK2, CDK4 and CDK6 has a different inhibitory 
mechanism. It is kept in the inactive state mainly by inhibitory phosphorylation by 
WEE1 and MYT1 kinases. Inhibitory phosphorylation is removed when the cell is ready 
to enter mitosis by phosphatase CDC25 (Figure 1-1). Polo-like kinase (PLK-1) and 
Aurora kinases are also involved in G2 phase progression.  
 Importance of checkpoints in cell cycle regulation  
Surveillance mechanisms existing in cells have been named checkpoint pathways 
(Hartwell and Weinert, 1989; Elledge, 1996). They monitor progression through the cell 
cycle though the relative importance of different pathways and their ability to impact 
cell survival differs.  For example, in budding yeast, due to the organisation of their cell 
cycle, where S phase overlaps with M phase, cells regulate the cell cycle primarily at 
START (Li and Murray, 1991). Consequently if DNA replication advances slower than 
normal due to DNA damage, mitosis starts anyway before completion (Lengronne and 
Schwob, 2002). In contrast, the organisation of the cell cycle in fission yeast has 
distinctive G1 and G2 phases and is primarily controlled by the G2/M checkpoint 
(Hartwell and Weinert, 1989).  
Mammalian cells have rigorous regulatory networks in place to ensure that progression 
of the cell cycle occurs with a minimal number of errors. One well understood pathway 
is the DNA damage checkpoint which arrests cells in G1 transition in response to 
damaged DNA. Depending on the type of damage, ataxia telangiectasia and Rad3-
related (ATR) or ataxia telangiectasia mutated (ATM) protein kinases phosphorylate 
and activate checkpoint kinases 1 or 2 (CHK1, CHK2) (Zhao and Piwnica-Worms, 
2001) can activate p53 (Matsuoka et al., 2000) which in its turn induces expression of 
the CDK2 inhibitor p21CIP1 and leads to G1 arrest (Figure 1-1). Activation of CHK1 
can also lead to S/G2 arrest by inactivation of CDC25A, CDC25B and CDC25C 
(Sanchez et al., 1997)  and enhanced activation of WEE1. As a result of WEE1 and 
CDC25 phosphorylation, inactive CDK1 or CDK2 would remain phosphorylated on the 
inhibitory residue Thr15 which would lead to G2 arrest (O'Connell et al., 1997). Growth 
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inhibitory signals can lead to inhibition of CDK2 and CDK4/6 which can cause G1 or S 
phase arrest. 
Another important mitotic checkpoint is the spindle assembly check point (SAC). This 
sophisticated pathway includes 15 proteins known to date (Musacchio, 2015) and the 
main function of it is to monitor correct sister chromatid cohesion to prevent premature 
chromosome segregation.  Without it, cells enter anaphase prematurely which causes 
problems with chromosome segregation and can lead to errors in copy numbers 
(Dobles et al., 2000; Musacchio, 2015). The SAC is also very important for mitotic exit 
as it affects the activity of the mitotic checkpoint complex (MCC) which targets APC/C. 
By inhibiting APC/C, the MCC stabilising its components preventing transition  from 
metaphase to anaphase and the cell leaving mitosis (Chang and Barford, 2014).  
1.1.2 CDKs and the cell cycle 
CDKs are a family of protein kinases that phosphorylate their substrates on 
serine/threonine residues. CDKs are regulated by their partner cyclins which control 
kinase activity and substrate specificity. The important feature responsible for the 
activation of the CDK family members is a catalytic core which comprises the ATP 
binding pocket, the activation segment (also called the T-loop) and the cyclin binding 
surface. The ATP binding pocket is highly conserved (Figure 1-2). For full activation of 
most CDK-cyclin complexes, phosphorylation by CDK activating kinase (CAK) on a 
conserved threonine residue (Thr161 in CDK1) within the activation segment (T-loop) 
is also required (Fisher, 2005). Once active, CDKs mainly have preferences for 
substrates containing the consensus sequence S/T-P-X-K/R (single letter amino acid 
abbreviations). Most CDKs also possess inhibitory phosphorylation sites (Thr14 and 
Tyr15 in CDK1) from the P-loop which interfere with the proper alignment of ATP in the 
ATP binding site (Mueller et al., 1995). CDK-cyclin complexes are also regulated by 
CDK inhibitors (CKIs) that can execute checkpoints to stop cell cycle progression if 
conditions are unfavourable (Morgan, 2007). 
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                                 P-loop 
 
CDK1    ---------------MEDYTKIEKIGEGTYGVVYKGRHKT-TGQVVAMKKIRLESE---E 41 
CDK2    ---------------MENFQKVEKIGEGTYGVVYKARNKL-TGEVVALKKIRLDTE---T 41 
CDK4    -------------MATSRYEPVAEIGVGAYGTVYKARDPH-SGHFVALKSVRVPNGGGGG 46 
CDK6    ------MEKDGLCRADQQYECVAEIGEGAYGKVFKARDLKNGGRFVALKRVRVQTG---E 51 
CDK9    MAKQYDSVECPFCDEVSKYEKLAKIGQGTFGEVFKARHRK-TGQKVALKKVLMENE---K 56 
                        . :  : :** *::* *:*.*.    *. **:* : : .      
             αC helix                                     Hinge region 
 
CDK1    EGVPSTAIREISLLKE---LRHPNIVSLQDVLM--------QDSRLYLIFEFLSMDLKKY 90 
CDK2    EGVPSTAIREISLLKE---LNHPNIVKLLDVIH--------TENKLYLVFEFLHQDLKKF 90 
CDK4    GGLPISTVREVALLRRLEAFEHPNVVRLMDVCATSRT---DREIKVTLVFEHVDQDLRTY 103 
CDK6    EGMPLSTIREVAVLRHLETFEHPNVVRLFDVCTVSRT---DRETKLTLVFEHVDQDLTTY 108 
CDK9    EGFPITALREIKILQL---LKHENVVNLIEICRTKASPYNRCKGSIYLVFDFCEHDLAGL 113 
         *.* :::**: :*:    :.* *:* * ::           .  : *:*:.   **    
                                                                
CDK1    LDSIPPGQYMDSSLVKSYLYQILQGIVFCHSRRVLHRDLKPQNLLIDDKGTIKLADFGLA 150 
CDK2    MDASALT-GIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLA 149 
CDK4    LDKAPPP-GLPAETIKDLMRQFLRGLDFLHANCIVHRDLKPENILVTSGGTVKLADFGLA 162 
CDK6    LDKVPEP-GVPTETIKDMMFQLLRGLDFLHSHRVVHRDLKPQNILVTSSGQIKLADFGLA 167 
CDK9    LSNVLVK--FTLSEIKRVMQMLLNGLYYIHRNKILHRDMKAANVLITRDGVLKLADFGLA 171 
        :.       .    :*  :  :*.*: : * . ::***:*  *:*:   * :******** 
              Activation segment 
 
CDK1    RAFGIPI----RVYTHEVVTLWYRSPEVLLGSARYSTPVDIWSIGTIFAELATKKPLFHG 206 
CDK2    RAFGVPV----RTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPG 205 
CDK4    RIYSYQM----A-LTPVVVTLWYRAPEVLLQS-TYATPVDMWSVGCIFAEMFRRKPLFCG 216 
CDK6    RIYSFQM----A-LTSVVVTLWYRAPEVLLQS-SYATPVDLWSVGCIFAEMFRRKPLFRG 221 
CDK9    RAFSLAKNSQPNRYTNRVVTLWYRPPELLLGERDYGPPIDLWGAGCIMAEMWTRSPIMQG 231 
        * :.          *  ******* **:**    *.  :*:*. * *:**:  :  :: * 
 
CDK1    DSEIDQLFRIFRALGTPNNEVWPEVESLQDYKNTFPKWKPG-SLASH--VKNLDENGLDL 263 
CDK2    DSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQ-DFSKV--VPPLDEDGRSL 262 
CDK4    NSEADQLGKIFDLIGLPPEDDWPRDVSLPR--GAFPPRGPR-PVQSV--VPEMEESGAQL 271 
CDK6    SSDVDQLGKILDVIGLPGEEDWPRDVALPR--QAFHSKSAQ-PIEKF--VTDIDELGKDL 276 
CDK9    NTEQHQLALISQLCGSITPEVWPNVDNYELYEKLELVKGQKRKVKDRLKAYVRDPYALDL 291 
        .:: .**  *    *      **                    . .   .   :  . .* 
 
CDK1    LSKMLIYDPAKRISGKMALNHPYFNDLDNQIKKM-------------------------- 297 
CDK2    LSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLR-----------L------------- 298 
CDK4    LLEMLTFNPHKRISAFRALQHSYLHKDEGNPE---------------------------- 303 
CDK6    LLKCLTFNPAKRISAYSALSHPYFQDLERCKENLD-----------SHLPPSQNTSELNT 325 
CDK9    IDKLLVLDPAQRIDSDDALNHDFFWSDPMPSDLKGMLSTHLTSMFEYLAPPRRKGSQITQ 351 
        : : *  :* :**..  ** * :: .                                   
 
CDK1    --------------------- 
CDK2    --------------------- 
CDK4    --------------------- 
CDK6    --------------------- 326 
CDK9    QSTNQSRNPATTNQTEFERVF 372 
 
Figure 1-2 Sequence alignment of members of the CDK family. 
Represented sequences of human CDK2 (Uniprot entry P24941), human CDK1 
(Uniprot entry P06493), human CDK4 (Uniprot entry P11802), human CDK6 (Uniprot 
entry Q00534),   human CDK9 (Uniprot entry P50750). P-loop identified with a dark 
blue bar, αC-helix identified with the gold bar, hinge region is identified with coral bar, 
activation segment is identified with red bar, DFG motif is coloured pink, APE (in CDK2) 
motif is coloured magenta, phosphorylation site is identified red. Sequence identities 
for the examples shown here range from 64% between CDK1 and CDK2 to 32% 
between CDK1 and CDK9. 
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The human CDK family is composed of twenty protein kinases (Malumbres, 2014) that 
play roles in regulation of the cell cycle, gene transcription, protein cellular localisation 
and protein degradation. CDKs have undergone significant evolutionary divergence 
and specialisation (Figure 1-3) with their numbers increasing during evolution. For 
example, yeasts have up to 6 CDKs, whereas flies and Echinodermata contain 11. 
Their structure has also evolved reflecting adaptations for wider function. Mammalian 
CDKs range in size from 250 amino acids to proteins that are 1500 residues in length 
with carboxy- and amino- terminal extensions of variable length and locations.  
CDKs can be classified into two large groups, CDKs that have a role in cell cycle 
promotion and CDKs that regulate transcription. The first group consists of CDKs 1-4 
and CDK6. CDKs that belong to the second group – CDK5, CDK8, CDK9, CDK11, 
CDK12, and CDK13 are mainly involved in transcription regulation. CDK7 is unique as, 
together with its partners cyclin H and MAT 1, it has roles both in cell cycle regulation 
(by phosphorylating and activating other kinases) and in initiation of transcription (by 
phosphorylation of the large subunit of RNA polymerase II) as well as in Nucleotide 
Excision Repair (NER) (Fisher, 2005).  
Regulation of CDK activity is complex and depends on different factors. For example, 
allosteric regulators including cyclins can influence substrate specificity (Loog and 
Morgan, 2005; Bloom and Cross, 2007), CKIs can act as positive or negative 
regulators, and protein degradation via the ubiquitin proteasome pathway helps to 
control the expression of regulators and substrates (Cheng et al., 1999). Regulation 
also depends on the timing of substrate accumulation, relative affinities for the different 
CDKs (Loog and Morgan, 2005) and also intracellular location.  
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Figure 1-3 Evolutionary relationships between different mammalian CDK 
subfamilies. 
CDKs that primarily regulate the cell cycle are drawn in the orange part of the figure, 
the ones that are involved in transcription are highlighted by the green background. 
The name of the sub-family is depicted in bold. The kinase catalytic domain is identified 
as a red box, proline rich region - green, arginine/serine rich- blue, glutamic acid rich – 
lilac, glutamine rich – grey. Figure used with permission of (Malumbres, 2014).  
 
1.1.3 Cyclins as partners that activate CDKs 
Cyclins were first discovered in embryos of marine invertebrates and amphibians and 
given the name because of their cyclical accumulation and destruction through the cell 
cycle (Evans et al., 1983; Murray and Kirschner, 1989). Although it was subsequently 
discovered that some cyclins do not oscillate. For example, cyclin D accumulates in 
G1 phase and remains present throughout the cell cycle (Matsushime et al., 1994) 
(Figure 1-4). 
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Figure 1-4 Oscillation of cyclin concentration during the cell cycle. 
 
Clarification as to how CDK controls G1-S phase transition in budding yeast came with 
the discovery of the Cln1-Cln3 cyclins (Nash et al., 1988; Richardson et al., 1989), 
followed by the identification  of Clb1-Clb4 which are required for mitosis and are more 
similar to metazoan cyclins (Ghiara et al., 1991). Cyclins Clb5 and Clb6 are required 
for the correct timing of the onset of DNA replication in S phase (Epstein and Cross, 
1992; Schwob and Nasmyth, 1993) . The requirement for different cyclins at different 
stages of the cell cycle in yeasts where only one CDK is available suggests that cyclins 
play a significant role in substrate recognition.  It has been shown that budding yeast 
cyclins modulate the active site of CDK and change its substrate specificity.  A model 
has been proposed according to which binding of different cyclins to CDK1 determine 
the strength of its activity and direct it to substrates required at specific stages of the 
cell cycle (Koivomagi et al., 2011). A number of experiments have been performed in 
budding and fission yeasts to identify the importance of cyclins at different stages of 
the cell cycle. The main conclusion that emerges is that G1 and S-phase cyclins are 
replaceable and that their removal by gene deletion can be rescued by mutation or 
introduction of other genes encoding cyclins. For example, deletion of the CLN1-3 
genes in budding yeast leads to cell death and arrest in G1 but can be rescued by 
deletion of SIC1 (a CDC28 inhibitor) and by ectopic expression of CLB5, a mitotic cyclin 
(Richardson et al., 1989; Epstein and Cross, 1992). In fission yeast mutation of the 
G1/S-phase genes puc1, cig1 and cig2 that collectively encode the S. pombe G1 
cyclins can lead to delay in G1 but can be rescued by deletion of rum1 (a negative 
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regulator of CDK1) (Martin-Castellanos et al., 2000). Although deletion of the mitotic 
cyclin gene cdc13 prevents cells from entering mitosis (Hagan et al., 1988). In budding 
yeasts none of the mitotic cyclins are essential but disruption of CLB1-3, CLB2-4, or 
CLB1-4 genes together leads to cell death (Fitch et al., 1992). 
Cyclins are very diverse in their sequences and are mainly characterised by the 
presence of a region comprising around 100 amino acids called the cyclin box. The 
cyclin box encodes a compact fold (the cyclin box fold, CBF) formed of five α-helices 
that plays a significant role in CDK interactions (Minshull et al., 1989; Pines and Hunter, 
1989). Most cyclins have two CBFs but only the N-terminal one interacts with the CDK 
partner, the C terminal CBF is required for the proper folding of the molecule. 
Sequences outside the cyclin box allow functional diversity and differences in 
regulation. The cyclin family comprises 29 proteins involved in the control of a variety 
of functions (Table 1-1). They are divided into 16 sub-families and three major groups. 
The first cyclin B group contains cyclins A, B, D, E, F, G, J, I and O. The second, the 
cyclin Y group includes partners of the CDK5 subfamily; and the third cyclin C group, 
cyclins C, H, K, L and T (Ma et al., 2013; Cao et al., 2014). 
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Cyclin 
 
Established function 
 
Emerging function 
Kinase 
activity 
for 
emerging 
function 
Cyclin A Control of M phase of cell cycle 
in complex with CDK2 or CDK1 
FoxM1 and FoxK2 transcription 
in complex with CDK2 
yes 
Cyclin B Control of S phase of cell cycle 
in complex with CDK1 
FoxM1 and FoxK2 transcription 
in complex with CDK1 
yes 
Cyclin C RNAPII transcription in complex 
with CDK8 
Wnt/β-catenin pathway and 
inhibition of lipogenesis in 
complex with CDK8 
yes 
Cyclin D Control of G1 phase of cell cycle 
in complex with CDK4/6; 
Rb/E2F transcription 
HR-mediated DNA damage 
repair 
Epigenetic regulation through 
Mep50 
no 
yes 
Cyclin E Control of G1-S phase of cell 
cycle in complex with CDK2; 
Rb/E2F transcription 
Inhibition of neuronal function of 
CDK5 
no 
Cyclin F  DNA damage response 
SCF mediated proteolysis 
no 
no 
Cyclin H CDK-activations kinase (CAK) 
and RNAPII transcription 
 yes 
Cyclin K  RNAPII transcription in complex 
with CDK12 and CDK13 
DNA damage response in 
complex with CDK9 and CDK12 
yes 
Cyclin L RNAsplicing in complex with 
CDK11 
 yes 
Cyclin T RNAPII transcription in complex 
with CDK9 
 yes 
Cyclin Y  Wnt/β-catenin pathway in 
complex with CDK14 
Spermatogenesis in complex 
with CDK16 
yes 
Table 1-1 Established and emerging roles of cyclins 
Table is adapted from (Lim and Kaldis, 2013). Kinase activity is associated with the 
established roles of each of the cyclins. This is not the case for all their emerging 
roles as indicated in column 4. 
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In metazoans, control of cell cycle progression is orchestrated by different members of 
the CDK family that bind to cyclins with clear preferences both in vivo and in vitro 
(Figure 1-5) (Table1-2) (Malumbres and Barbacid, 2005). Most cyclins in vertebrates 
are dispensable for cell cycle progression but some of them have essential roles at 
particular stages of development. For example, cyclin D1-/- D2-/- D3-/- mice develop until 
mid/late gestation but then die from heart abnormalities and anemia (Kozar et al., 
2004). S-phase cyclins E1 and E2 are essential for embryonic development  as cyclin-
deficient mice mutants show endoreplication of  trophoblast giant cells and 
megakaryocytes (Geng et al., 2003). CDK1 pairs with cyclin A1 and A2 for activation 
in G2 phase and with cyclins B1 and B2 to promote mitosis, but only CDK1-cyclin B1 
has been shown to be vital for early embryonic cell division (Brandeis et al., 1998). 
 
 
Figure 1-5 Cell cycle regulation by cyclin dependant kinases (CDKs) and their 
role in transcription. 
CDKs are represented by the ovals and cyclins as parallelograms of different colours. 
P represents atom of phosphor. 
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Table 1-2 CDKs of most studied biological models and cyclins activating them 
at different stages of the cell cycle. 
 
 
 
 
Species Name Original name Size Cyclins activating CDKs at 
different stages of the cell 
cycle 
S. cerevisiae CDK1 Cdc28, p34 
protein kinase 
298 G1 -  Cln3          
G1/S – Cln1,2 
S – Clb5.6 
M – Clb1,2,3,4 
S. pombe CDK1 Cdc2 297 G1 -  Puc1           
G1/S – Puc1, Sig1 
S – Sig2, Sig1 
M – CDC13 
D. melanogaster CDK1 
 
CDK2 
 
CDK4 
Cdc2 
 
Cdc2c 
 
CDK4/6 
297 
 
314 
 
317 
S – cyclin A 
M – cyclin A, B, B3 
G1/S – cyclin E 
S – cyclin E, A 
G1 – cyclin D 
X. laevis CDK1 
 
CDK2 
Cdc2 301 
 
297 
S – cyclin A 
M – cyclin A, B 
G1/S – cyclin E 
S – cyclin E, A 
H. sapiens CDK1 
 
CDK2 
 
CDK4 
CDK6 
Cdc2 297 
 
298 
 
303 
326 
S – cyclin A 
M – cyclin B 
G1/S – cyclin E 
S – cyclin A 
G1 – cyclin D1,2,3 
G1 – cyclin D1,2,3 
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1.1.4 Role of phosphorylation in CDK activation 
CDK activation minimally requires cyclin binding and also phosphorylation within the 
activation segment (T-loop) of the kinase domain by CDK activating kinase (CAK). The 
distribution of a CDK between different phosphorylated and cyclin-bound states differs 
between organisms and within an organism between different CDKs. These 
differences reflect for example the accessibility of the CDK activation segment to CAK 
and phosphatase activities, CDK-cyclin complex stability and levels of CDK and cyclin 
expression. For example, in budding yeast S. cerevisiae that have a single CDK to 
drive the cell cycle and do not have a sharp G2/M phase transition, monomeric CDK1 
is detectable in a phosphorylated state, from which observation it has been proposed 
that phosphorylation of the CDK1 activation segment occurs before cyclin binding 
(Ross et al., 2000). In fission yeast S. pombe, where a switch-like G2/M transition 
occurs, CDK1 can be activated by two pathways: as in budding yeasts it can be 
phosphorylated before binding to cyclin, and also phosphorylation can occur after 
cyclin binding (Morgan, 2007). In metazoans that contain a number of CDKs and 
cyclins, different pathways for CDK activation are present. CDKs exist in cells as 
unphosphorylated monomers and unphosphorylated complexes accessible for 
phosphorylation by CAK. CDK2 for instance is reported to undergo phosphorylation 
prior to cyclin binding, but in contrast CDK1 requires phosphorylation by CAK before 
further activation by cyclin (Figure 1-6) (Desai et al., 1995; Merrick et al., 2008). 
Monomeric human CDK2 has been shown to be phosphorylated in solution in vitro 
leading to the same conclusion (Merrick et al., 2008). Phosphorylated CDK2-cyclin A 
(T160pCDK2-cyclin A) is circa 300-fold more active towards a model substrate than 
CDK2-cyclin A (Russo et al., 1996b) as unphosphorylated CDK2 complexes have no 
measurable activity (Desai et al., 1992; Desai et al., 1995). Nevertheless in some cases 
the combined effects of cyclin binding and phosphorylation are not sufficient for CDK 
activation and complexes require additional adjustments. It has been proposed that 
the activity of CDK4-cyclin D complexes is substrate-assisted and the Michaelis 
complex is only formed when both ATP and peptide substrates are bound (Day et al., 
2009; Takaki et al., 2009). Some CDKs have two phosphorylation sites on the 
activation segment.  For example, CDK7 is phosphorylated on Ser164 and Thr170 
(Lolli et al., 2004). 
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CDKs are also controlled by phosphorylation on a glycine-rich loop also called the P-
loop. These phosphorylations normally inhibit CDK activity (Kornbluth et al., 1994; 
Mueller et al., 1995; Poon et al., 1996). 
 
Figure 1-6 Model for CDK activation in Metazoans. 
CDK2 differs in its kinetic of activation from the other CDKs. It is phosphorylated by 
CAK on the activation segment in a monomeric state with cyclin binding to follow, 
contrary to CDK1 for example. CDK1 can be phosphorylated only in a complex with 
cyclin. Picture adapted from (Merrick et al., 2008). 
 
 
1.2 Structural characterisation of the CDK family 
1.2.1 A structural paradigm for CDK activation 
The structures of several CDKs have been determined and their comparison has 
revealed common structural features. Within the kinase catalytic domain the active site 
is sandwiched between an N terminal lobe mainly consisting of β sheets and a single 
α helix (often named the C-helix or PSTAIRE helix after the conserved cyclin binding 
motif within it) connected via a linker to a larger C terminal lobe (Jeffrey et al., 1995; 
Endicott and Noble, 2013). Another important feature of the N-lobe is a glycine-rich 
sequence (GXGXXG) also called the P-loop which recognises ATP and includes Thr14 
and Tyr15 residues that keep CDK in an inactive state if phosphorylated. These 
modifications prevent peptide substrate but not ATP binding (Welburn et al., 2007), 
and subsequent hydrolysis (Solomon et al., 1990).  The C-terminal lobe is mainly α 
helical and includes the activation segment which is located between the conserved 
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DFG (145-147 in CDK2) and less well conserved APE (170-172 in CDK2) motifs 
(Figure 1-7) (Endicott et al., 2012). The activation segment includes the 
phosphorylation sensitive residue (Thr160 in CDK2) consequently it is also termed the 
T-loop. 
Monomeric CDKs normally adopt an inactive conformation, which is defined by the 
organisation of the C-helix, the DFG motif and the activation segment. Monomeric 
CDK2 is defined by an inactive “C-helix out, DFG-in” conformation. Residues within 
the C-helix and DFG motif help create the ATP binding site and contribute to the 
regulatory and catalytic spine (Figure 1-7 A). These spines are sets of interacting 
residues that readout the conformation of the active site to the rest of the kinase fold 
(Kornev and Taylor, 2015). The “DFG-out” conformation has been reported in tyrosine 
kinases in the inactive conformation where the phenylalanine side chain of the DFG 
motif is positioned within the ATP-binding pocket. In the “DFG-in” conformation, a 
conformational switch of this motif displaces the phenylalanine side chain out of the 
active site to contribute to the catalytic spine, and the aspartate residue is appropriately 
positioned to interact with a conserved lysine-glutamate pair to coordinate the 
phosphate groups of ATP (Endicott et al., 2012). All reported structures of inactive 
CDKs with the exception of CDK8 have the DFG motif in the “in” conformation.  
Monomeric CDK2 is in an inactive conformation as a result of C-helix displacement 
(“C-helix out”). The short α-helical structure at the start of the CDK2 activation loop 
(αL12) packs against the C helix causing it to adopt a swung out position (De Bondt et 
al., 1993). This short helix is characteristic of other inactive CDK structures as well 
(Lolli et al., 2004). The movement results in an increased distance between Glu51 from 
the C helix and Lys 33 from β3 that leads to positioning of the triphosphate moiety from 
ATP that isn’t compatible with catalysis. Importantly Leu55 from the regulatory spine 
and R50 that is a ligand for phosphorylated Thr160 are also displaced. Accompanying 
these interactions the catalytic spine residues that include Ala31, Val18, Ile87, Leu133, 
Leu134, Ile135, Ile 192 and Met196 (CDK2 numbering) cannot align appropriately and 
as a result CDK2 even in the DFG-in conformation is not active (Figure 1-7). 
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Figure 1-7 Structural changes during CDK2 activation. 
Crystal structures of monomeric (A) CDK2 (PDB: 1HCK), (B) CDK2-cyclin A (PDB: 
1JST) and (C) pT160 CDK2-cyclin A bound to ATP (PDB: 4EOQ). CDK2 molecule 
coloured ice blue, cyclin A coloured green, CDK2 activation segment (residues 147-
172) coloured red, C–helix (residues 46-55) coloured gold, P-loop (residues 12-16) is 
coloured dark blue, DFG motif (residues 145-147) coloured pink, APE motif (residues 
170-172) is coloured magenta. ATP molecule represented in ball and stick mode with 
carbon atoms coloured green. Residues forming the regulatory spine are coloured 
yellow and the location of the regulatory spine is identified with a yellow oval. Residues 
forming the catalytic spine are coloured green and the position of the catalytic spine is 
identified with a green oval.  
For CDK activation, cyclins bind directly to the C helix and surrounding elements of the 
kinase N lobe. Generally, the active kinase fold is characterised by having a ‘DFG–in’ 
conformation where the C helix, which contains a conserved glutamate residue, turns 
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away from the N terminal lobe, allowing the aspartate of the DFG motif to chelate a 
Mg2+ ion to position the ATP substrate. The process of kinase activation involves a 
network of residues from different parts of the molecule (Jura et al., 2011). A conserved 
glutamate (Glu51 in CDK2) from the C-helix forms a salt bridge with a conserved lysine 
(Lys33 in CDK2) in strand β3 that coordinates the phosphate groups of ATP (Figure 1-
7 B, C). Two more sets of interactions are significant for kinase activation. One set is 
the interactions of the glycine-rich P-loop with the β and ɣ phosphates of ATP. The 
other set positions the catalytic aspartate (Arg127 in CDK2). 
Another crucial feature of an active kinase is the activation segment conformation 
(Figure 1-7 A, B, C). The activation segment is mostly disordered in inactive 
conformations and requires phosphorylation in most CDKs to compose a substrate 
binding platform. The phosphorylation promotes closure of the two lobes to the 
favourable position to accept a peptide for phosphorylation. As more structures have 
been determined it has become obvious that not all elements of CDK2 activation are 
conserved across the family. For example, in case of CDK5 (PDB code: 1H4L), binding 
to its partner p35 is enough for full kinase activation. It adopts the correct conformation 
through an alternative set of CDK5-p35 interactions (Tarricone et al., 2001).  
1.2.2 Structural characterisation of the cyclin family  
The structures of a number of cyclins have been solved revealing shared common 
features including the presence of a cyclin box fold (CBF) (De Bondt et al., 1993; Kim 
et al., 1996; Hoeppner et al., 2005; Baek et al., 2007; Petri et al., 2007). Most cyclin 
structures comprise two five α-helical domains named CBF1 and CBF2 connected via 
a linker (Figure 1-8), although some contain only one CBF. CBF1 is relatively well 
conserved among cyclin A and cyclin E and is responsible for CDK and other protein 
binding (Petri et al., 2007). CBF2 is very similar to CBF1 but has different lengths of 
loops and helices. The arrangements of the hydrophobic residues suggest that either 
domain would be unstable on its own. Four helices within each fold are organised 
around a H3 or H3’ helix and held in place by Van der Waals and hydrogen bonds. 
Both CBF domains are stabilized by additional sidechain–main chain hydrogen bonds 
making the overall structure of the molecule comparatively rigid. The cyclin has been 
proposed to act as a rigid scaffold for the more malleable CDK (Brown et al., 1995). 
This stable structure is important for cyclin function as exemplified by cyclin B where 
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any mutations that destabilise the fold disable binding to its CDK partner (Kobayashi 
et al., 1992). 
 
Figure 1-8 Typical cyclin structure. 
Human cyclin B1 (PDB code: 2B9R) is taken as an example. The molecule comprises 
two parts. CBF1 and CBF2 are each composed of five helices (H1-H5 and H1’-H5’) 
and coloured in shades of blue or red respectively. The MRAIL sequence is coloured 
gold and the RRASK motif is coloured yellow. The N terminal sequence is coloured 
green and the C terminal sequence is coloured red (Petri et al., 2007).  
Apart from the CBFs, cyclins can also have additional N-terminal helices, for example 
two in cyclin K (Baek et al., 2007) and one in cyclins A (Brown et al., 1995) and C 
(Hoeppner et al., 2005) (Figure 1-9).  A distinctive feature of cyclin H is its long C-
terminal helix which is present in cyclin A but of much shorter size (Andersen et al., 
1996). These additional helices disposed differently in different cyclins. Furthermore, 
another modification in the cyclin K structure is an additional helix to H4 and H4’, called 
H4a and H4a’. H4’ and H4a’ from CBF2 differ from their counterparts in CBF1 as they 
form smaller helices due to insertion of extra residues (225-233). Cyclin H has an extra 
helix between H1’ and H2’. 
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Figure 1-9 Structural and topological analysis of human cyclin K, S. pombe 
cyclin C and human cyclin H. 
Corresponding helices are identified by the same colours in the ribbon diagrams. In 
the topology diagrams CBF1 is coloured green and CBF2 is coloured red (Baek et al., 
2007).  
On the opposite side to the CDK binding site of cyclins lies the ‘RXL binding groove` 
or recruitment site (Schulman et al., 1998; Brown et al., 2007; Petri et al., 2007). The 
groove is formed by amino acids of CBF1 and is a docking site for RXL motif (x stands 
for any amino acid)-containing substrates. The RXL motif binding groove has been 
shown to be essential for phosphorylation of substrates such as pRb and p53 
 20 
 
(Schulman et al., 1998; Adams et al., 1999). It is mainly composed of the MRAIL 
sequence that is conserved amongst most mammalian cyclins and conserved residues 
from the H1 helix with contributing residues from the other helices. Interestingly the 
crystal structure reveals that the analogous region on the CBF2 domain is highly 
conserved in all types of B-type cyclins and has the sequence RRASK which is 
important for MYT1 and CDC25c recognition (Goda et al., 2003).  
1.2.3 CDK requirements for substrate selection 
Protein kinase sequence preferences around the site of phospho-transfer have been 
well studied (Ewen et al., 1992; Songyang et al., 1994; Cheng et al., 2006). The protein 
kinase active site cleft can accommodate an extended peptide of circa 7-8 residues 
permitting sequence-specific interactions to be made with circa 3-4 residues either side 
of the phosphosite (Brown et al., 2007; Takaki et al., 2009). A study using a CDC6 
peptide revealed possibilities of different occupation of the catalytic site by a substrate 
(Cheng et al., 2006) (Figure 1-10 A). CDK substrates also bind to the cyclin RXL 
recruitment site through well studied interactions (Brown et al., 1999) (Figures 1-10 B). 
The fate of the linker between the two sites has not been distinguished in the structures 
determined by X-ray crystallography due to a lack of supporting electron density 
(Figure 1-11) (Cheng et al., 2006). 
The canonical CDK phosphorylation site consists of a S/T*-P-X-K/R sequence 
(Ubersax et al., 2003) where S/T is the phosphorylatable residue and X is any amino 
acid. Although CDKs can target the minimal consensus site comprising only serine or 
threonine residue followed by proline S/T*-P (Rudner and Murray, 2000).  The 
preference of CDKs for a proline in position P+1 was elaborated by a structure of 
CDK2-cyclin A bound to a short substrate peptide (Brown et al., 1999). There is a 
hydrophobic pocket near the catalytic site that can accommodate proline as a result of 
Val164 in the activation loop adopting an unusual left-handed conformation. CDK2 as 
well as CDK5 displays strong preferences towards the canonical sequence. However, 
CDK1 can tolerate residues other than K/R in the P+3 position (Brown et al., 1999). 
CDK4 has shown similar levels of phosphorylation towards canonical S/T*-P-X-K/R 
and non-canonical S/T*-P-X-X sequences (Takaki et al., 2009). An explanation of 
these alternative CDK4 substrate preferences cannot be offered because the CDK4 
structure in complex with cyclin D is in an inactive conformation. 
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Figure 1-10 CDC6 peptide bound to the recruitment site of pCDK2-cyclin A 
complex. 
(A) CDC6 peptide bound to the catalytic site of a pCDK2-cyclin A complex. (B) CDC6 
peptide bound to the recruitment site of cyclin A. Figures taken from (Cheng et al., 
2006) (PDB code: CCH).  Difference maps based on mFo - DFc coefficients were 
calculated and contoured at 0.1 e/Å3. 
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Figure 1-11 Possible position of the peptide linker between the catalytic site 
and the RXL recruitment site. 
Linker has been modelled into the pCDK2-cyclin A structure and identified as a green 
line. Parts of the peptide bound at the catalytic site and at the RXL recruitment site are 
drawn in ball and stick mode (Cheng et al., 2006). 
Transcriptional CDKs, CDK7 and CDK9 have also been reported to have no preference 
for a positive residue in the P+3 position. This flexibility for CDK7 might be required as 
it has a dual role in the cell cycle, acting as a CDK activating kinase, and in 
transcription, phosphorylating the C terminal domain of Pol II (Lolli, 2005). Substrate 
selectivity for these two processes are known to be different. It has been proposed that 
for phosphorylation of the activation loop of other CDKs, CDK7 binds to sequences 
remote from the phosphorylation site and so is not as dependent on residues 
surrounding the site of phosphotransfer (Garrett et al., 2001; Larochelle et al., 2001). 
Contrary to the sequence requirements for its transcriptional function CDK7 (as well 
as CDK9) can autophosphorylate at a YINRVVT sequence which makes specificity to 
proline redundant (Baumli et al., 2008). 
Another important sequence that plays a role in substrate recognition is the substrate 
recruitment motif RXL. In the presence of this motif CDK2 and CDK4 have been shown 
to relax their requirement for proline in the P+1 position (Takaki et al., 2009).  
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1.3 Other regulators of CDK activity 
A number of other proteins have been demonstrated to bind directly to CDKs to 
regulate their activity, although to date, with the exception of the cyclin dependant 
kinase regulatory subunit (CKS) proteins they are not as well studied as the cyclins 
and CKIs. They can be generally grouped into cyclin-like regulators that have a cyclin 
box, for example viral cyclins and Ringo/Speedy (Rapid INducer of G2/M progression 
in Oocytes), and non-cyclin like regulators. 
One well-studied CDK regulator is the CKS1. It was identified as a multi-copy 
suppressor of a Cdc2 temperature-sensitive mutant in S. pombe and called Suc1 
(Hayles et al., 1986a). Loss of the suc1 gene leads to mitotic defects (Hayles et al., 
1986b). Homologues of suc1 were subsequently identified in the budding yeast S. 
cerevisiae (CKS1) (Hadwiger et al., 1989)  and in Xenopus eggs (p9) (Patra, D., et al. 
1999). Later work identified two homologues in higher eukaryotes, CKS1 and CKS2. 
Early experiments in Xenopus demonstrated that p9 promotes the phosphorylation of 
G2/M regulators CDC25, WEE1 and MYT1 (Patra, D., et al. 1999) and Cdc27 (an 
anaphase promoting complex/cyclosome (APC/C) subunit) by CDK1-cyclin B (Patra, 
D., and Dunphy, W. G.1998).  Mice nullizygous for either CKS1 or CKS2 are smaller 
than normal but viable (Spruck et al., 2001). However, disruption of both genes 
simultaneously resulted in embryonic lethality prior to the morula stage, after two or 
four division cycles (Martinsson-Ahlzen et al., 2008). The role of human CKS1 
(CKSHs1) in promoting CDK1 substrate phosphorylation was supported by 
determination of its structure and the identification of a potential phosphate binding site 
(Arvai et al., 1995). Further studies performed to investigate the role of CKS1 and its 
homologues as a phosphoadaptor protein for CDK1 regulation identified hundreds of 
targets (Ubersax et al., 2003). A model has been proposed in which CKS1 and cyclins 
coordinate their activities to provide docking sites for multiply phosphorylated CDK 
substrates to ensure timely G1/S transition (Koivomagi, Valk et al. 2011). 
CKS family members share high sequence identity from yeasts to humans (Figure 1-
12). The crystal structures of human CKSHs2 (Parge et al., 1993), S. pombe Suc1 
(Bourne et al., 1995; Endicott et al., 1995), S. cerevisiae Cks1 (Bourne et al., 2000) 
and human CKSHs1 (Arvai et al., 1995) have been solved on their own or for HsCKS1 
bound to CDK2 (Bourne et al., 1996). Interestingly structures for Suc1 identified two 
different conformations, a single compact domain fold (Endicott et al., 1995) and β-
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strand exchanged dimer (Bourne et al., 1995). The two human homologs CKSHs1 and 
CKSHs2 have also been reported to adopt respectively the compact  fold (Arvai et al., 
1995) or the β-interchanged dimer (Parge et al., 1993) (Figure 1-13). Analysis of CKS 
in both conformations lead to the conclusion that only the compact fold can bind to a 
CDK (Bourne et al., 1996).  
The structure of CDK2 in complex with CKSHs1 has revealed the binding site which is 
located on the C-lobe of CDK2 (Bourne et al., 1996). Four β strands (β1-β4), the β1-
β2 loop also called L1 and the β hinge region of CKSHs2 interact with the α5 helix and 
L14 loop of CDK2 (Figure 1-13, 1-14). The major difference between the compact fold 
and the dimer is the conformation of the β hinge region/β-hairpin that plays a role in 
CDK binding. 
 
                        α0            β1         β2     α1 
CKS1   MSHK----------------------QIYYSDKYDDEEFEYRHVMLPKDIAKLVPKT--- 35 
CKS2   MAHK----------------------QIYYSDKYFDEHYEYRHVMLPRELSKQVPKT--- 35 
Suc1   M-SK-SG-VPRLLTASERERLEPFIDQIHYSPRYADDEYEYRHVMLPKAMLKAIPTDYFN 57 
Cks1   MYHHYHAFQGRKLTDQERARVLEFQDSIHYSPRYSDDNYEYRHVMLPKAMLKVIPSDYFN 60 
       *                         .*:** :* *:.:********: : * :*.     
                     α2          β3           β4 
CKS1   ------HLMSESEWRNLGVQQSQGWVHYMIHEPEPHILLFRRPLPKKPKK------- 79 
CKS2   ------HLMSEEEWRRLGVQQSLGWVHYMIHEPEPHILLFRRPLPKDQQK------- 79 
Suc1   PETGTLRILQEEEWRGLGITQSLGWEMYEVHVPEPHILLFKREKDYQMKFSQQRGG- 113 
Cks1   SEVGTLRILTEDEWRGLGITQSLGWEHYECHAPEPHILLFKRPLNYEAELRAATAAA 117 
             ::: *.*** **: ** **  *  * ********:*    . :         
 
Figure 1-12 Sequence overlay of Human CKS1 and CKS2, S. pombe Suc1 and 
S. cerevisiae Cks1. 
Uniprot entries are P61024, P33552, P08463, C7GY17 respectively. β strands and α 
helices that mediate CDK binding are colored red and those participating in ion binding 
are blue. β strands and α helices are identified with green and red boxes respectively. 
Stars represent identical residues, conserved residues marked with (:) or (.)  
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Figure 1-13 Crystal structure of monomeric Suc1 and the β-interchanged dimer 
conformations. 
(A) Structure represents β interchanged dimer fold (coral and gold subunits) with β-
hinge region (His88 to His93) coloured blue. (B) Single domain fold represented by 
gold and lilac subunits. Zn ions are represented as small spheres and labelled.  
 
Figure 1-14 Crystal structure of a CDK2-CKSHs1 complex. 
CDK2 structure color coded ice blue, α5 helix is labeled and color coded green, L14 
loop is colored red, CKSHs1 is colored gold, β1  is colored cyan, β2 is colored yellow, 
β3  is colored light green, β4  is colored light blue, region between β1 and β2 called 
L1, region between β3 and β4 called L3. C and N terminals are labeled (PDB code: 
1BUH). 
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1.4 CDKs and cancer 
The term “cancer” unites a group of diseases that are characterised by common 
features such as abrupt and uncontrolled proliferation that can spread to other parts of 
the body. Its causes vary depending on the type of cancer and includes tobacco 
smoking, exposure to ionising radiation, infections, poor diet and lack of physical 
activity. Solid tumour cancers usually consist of neoplasts formed from multiple distinct 
cell types that atypically interact with each other. The process of changing normal cells 
into ones that can form cancer is called malignant progression and occurs in multiple 
steps. These cell transformations are the outcome of changes in mitogen signaling 
caused by either excessive exogenous signaling as growth factors and nutrients 
(Massague, 2004) or oncogenic mutations in genes (Knudson, 1971).  
Cancer has been known to people through history. Nowadays, despite great progress 
in cancer treatment achieved since the 1970s, it remains a significant research area 
due to the growing incidence of disease around the world (Cancer Research UK 
statistics). After analysis of knowledge accumulated through years of research, 
distinctive and complementary characteristics of cancer cells that promote tumour 
growth and metastatic dissemination and known as “hallmarks of cancer” have been 
described (Figure 1-15) (Hanahan and Weinberg, 2011).  
One of the most fundamental hallmarks of cancer cells is their ability to initiate and 
sustain unlimited proliferation as well as evade growth suppression. As proliferation 
depends on cell cycle progression, mutations that lead to malignancies converge to 
deregulate CDK activity. Oncogene induced errors in the cell cycle can instigate errors 
in DNA replication and can lead to genomic instability as well as defects in spindle 
assembly checkpoints which result in abnormal chromosome segregation (Malumbres 
and Barbacid, 2009). The functions of key CDKs and their involvement in cell cycle 
regulation in normal tissue and in malignancies is described below. 
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Figure 1-15 Hallmarks of cancer and therapeutic approaches to its targeting 
(Hanahan and Weinberg, 2011). 
 
1.4.1 CDK4/6 and cancer 
In most normal adult tissues, cells exist in a G0 state which can be transient or 
permanent. From the transient state, cells can re-enter the cell cycle under the 
influence of mitogenic factors. Most of these factors initiate signalling pathways that 
result in activation of CDK4 and CDK6. CDK4 and CDK6 have largely overlapping sets 
of target proteins (Anders et al., 2011) although they are very important for specialised 
cell types. CDK4-/- mice develop defects in endocrine cells (Rane et al., 1999) and 
CDK6 is more important for hematopoietic cells (Malumbres et al., 2004; Kollmann et 
al., 2013). Consequently, amplification and over-expression of these kinases is 
implicated in tumours often from endocrine and hematopoietic origin (Figure 1-16). 
Upregulation of CDK4 is also reported in gliomas, sarcomas, breast tumours and 
carcinomas of the uterine cervix in a co-amplification with the MDM2 locus as part of 
an amplicon located on chromosome 12(12q13-14) (Lopes et al., 2001; Ortega et al., 
2002; Simon et al., 2002). CDK6 has been found overexpressed in lymphoid tumours 
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(Raffini et al., 2002) and upregulated by gene amplification in squamous cell 
carcinomas and gliomas (Lam et al., 2000). In addition to gene amplification and 
deletion, kinases can also acquire missense mutations according to COSMIC data 
base,(Bamford et al., 2004). CDK6, for example, in breast carcinoma and 
hematopoietic and lymphoid tissue, and CDK4 in cases of human familial melanoma 
(Zuo et al., 1996) and gliomas and several subgroups of sarcomas. Mutations in genes 
encoding cyclin D can cause mantle cell lymphoma, plasma cell leukaemia, chronic 
lymphocytic leukaemia and multiple myeloma, according to COSMIC data base, 
(Bamford et al., 2004).  
 
Figure 1-16 Deregulation of members of CDK4/6  pathway leading to cancer 
(Otto and Sicinski, 2017). 
 
To study the implications of genomic instability-causing mutations that lead to 
misregulation of CDK4 and CDK6 in cancer, various genetically engineered mouse 
models have been developed (Otto and Sicinski, 2017). For example, CDK4 knock-in 
mice were created which were carrying a miscoding mutation (CDK4R24C) found in 
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human melanoma (Wolfel et al., 1995). This mutation did not cause any detectable 
defects during embryonic development, but as adults, mice appeared 10-20% bigger 
than their normal littermates and by 8-16 months developed multiple tumours of 
endocrine origin, sarcomas and epithelial hyperplasias of the liver, gut and breasts 
(Sotillo et al., 2001). Furthermore, mice engineered to overexpress cyclin D1 in 
mammary glands developed mammary hyperplasia and carcinomas (Wang et al., 
1994). These results highlight the oncogenic properties of CDK4/6 and D-type cyclins. 
Further investigation revealed that the levels of CDK4/6 and cyclin D do not need to 
be simultaneously elevated for tumorigenesis. For instance, mice lacking cyclin D1 
were resistant to mammary cancer induced by some oncogenes, such as vHras (an 
oncogenic HRAS mutant) but not others (such as Wnt 1 and Myc)(Yu et al., 2001; 
Bowe et al., 2002).  Ccnd3-null mice were resistant to NOTCH1ICD driven T cell acute 
lymphoblastic leukaemia (T-ALL), whereas CDK6-knockout mice were resistant to 
lymphoma formation induced by AKT (Sicinska et al., 2003; Hu et al., 2009). 
Interestingly, total ablation of Ccnd1 or pharmacological inhibition of CDK4/6 kinase 
activity in mice bearing Erbb2V664E -driven mammary tumours blocked cancer 
progression without having an effect on normal, non-transformed tissues (Choi et al., 
2012). Collectively these results reveal differences in kinase wiring of particular types 
of cancer in contrast to non-transformed tissues. CDK4 and CDK6 as well as D-type 
cyclins are essential for some tumour initiation and maintenance as opposed to non-
transformed tissue, where the absence of CDK4 and CDK6 catalytic activity has no 
major effect on progression of the cell cycle  (Choi et al., 2012). Taken together, these 
results suggest that tumours frequently depend on individual cyclins and CDKs and 
are therefore prone to their targeted inhibition. 
1.4.2 CDK2 and cancer 
 The discoveries that (i) CDK2 has not been found mutated in human cancers, (ii) 
CDK2 knock down cell lines do not go into cell cycle arrest (Tetsu and McCormick, 
2003)  and (iii) knock out mice are viable (Berthet et al., 2003; Ortega et al., 2003) led 
to a doubt about CDK2 being a valid target for cancer therapy. However, recent studies 
employing chemical genetic approaches have suggested otherwise. In these studies, 
wild type CDK2 in a human colon cancer cell line and mouth embryonic fibroblasts 
(MEFs) were replaced with an analog-sensitive version which can be inhibited with 
ATP analogs. The results demonstrated that in both these cellular settings treatment 
with a variety of selective CDK2 inhibitors resulted in a significant reduction in cell 
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growth (Horiuchi et al., 2012a). Additional observations in different cancer types, for 
example BRCA-deficient cancers (Deans et al., 2006), neuroblastoma (Molenaar et 
al., 2009) and ovarian cancer (Yang et al., 2015) (Au-Yeung et al., 2017) have 
identified CDK2 as a potential drug target. These oncogenic features of CDK2 are 
mainly related to its activators cyclin E1 and cyclin E2 (Figure 1-17).  Cyclins E1 and 
E2 are often overexpressed in multiple tumours, particularly in uterine, ovarian and 
breast cancers (Karst et al., 2014) (Kuhn et al., 2014; Au-Yeung et al., 2017). Ectopic 
expression of cyclin E bypasses the physiological requirement for CDK4 and CDK6 to 
prepare cells for S phase (Caldon et al., 2012) and is assumed to be oncogenic. 
Overexpression of cyclin E1 has a prognostic effect in some tumour types, as in breast 
cancer increased expression correlates with the progression of the disease. Likewise, 
cyclin A, another regulator of CDK2, has been shown to be overexpressed due to 
genomic amplification in colorectal (Handa et al., 1999) and breast cancers (Michalides 
et al., 2002) as well as in hepatocellular carcinoma (Chao et al., 1998). 
 
 
Figure 1-17 Deregulation of cyclins E1 and E2 leading to cancers (Otto and 
Sicinski, 2017). 
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1.4.3 Role of CDK9 in cancer 
Another CDK which has emerged recently as an important regulator in some cancers 
is CDK9. CDK9 regulates RNA transcription and it is hypothesized that changes to 
CDK9 activity have a particular effect on the expression of short lived anti-apoptotic 
proteins. It has been shown that in some cancers, particularly in lymphocytic 
leukaemia, CDK9 inhibition reduces the levels of anti-apoptotic proteins such as Mcl-
1 and XIAP and restores the ability of these cancer cells to undergo apoptosis (Wang 
and Fischer, 2008; Bose et al., 2013). A subsequent study concluded that transformed 
cells in contrast to non-transformed cells are addicted to the expression of anti-
apoptotic proteins (Wang et al., 2010).  The use of new techniques such as RNAi 
methods in conjunction with small molecule inhibitors yielded new insights (Lemke et 
al., 2014). For example, transient knock down of CDK9 sensitized HeLa and A549 cells 
to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) yielding a range of 
phenotypes that might be targeted by available mono and combined therapies (Garriga 
et al., 2010). In head and neck squamous carcinoma cell lines, knock down of CDK9 
led to radio-sensitization (Wang et al., 2014). In ovarian cancer cells (A2780), shRNA 
knock down of CDK9 or inhibition with flavopiridol induced apoptosis (Lam et al., 2014). 
The summary of this study suggests that the anti-cancer effect of CDK9 inhibition 
depends on the methods employed, cell type and kinetics of the inhibition. It also has 
been shown that the therapeutic potential of CDK9 is strongest if it is co-inhibited with 
BRD4 (Sonawane et al., 2016). BRD4 targets the P-TEFb complex, that contains 
CDK9, to mitotic chromosomes promoting expression of growth promoting genes 
(Yang et al., 2008). It has been found as a component of chromosomal translocation 
(15;19) of human squamous carcinoma. As a result of this translocation a tandem pair 
of BRD4 N-terminal bromodomains are expressed as a chimaera together with testis 
nuclear protein NUT and has been identified as an oncoprotein (French et al., 2001). 
RNA silencing of BRD4-NUT led to arrest of proliferation (Filippakopoulos et al., 2010). 
Further experiments in human squamous carcinoma xerograft models demonstrated 
that the BRD4 fusion oncoprotein bound to the small molecule inhibitor JQ1 can be 
displaced from chromatin resulting in a antiproliferative effect (Filippakopoulos et al., 
2010). These outcomes show the utility and therapeutic potential of CDK9 and BRD4 
in cancer treatment. 
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1.4.4 CDK1 and cancer 
CDK1 is the only essential CDK and the only CDK that can initiate mitosis (Santamaria 
et al., 2007). If mitosis is initiated before S phase is completed it can lead to G2 arrest 
and cell death (Aarts et al., 2012), whereas inhibition during mitosis results in a quick 
mitotic exit without cytokinesis (Vassilev et al., 2006). CDK1 is constantly expressed 
in a cell but its activity is inhibited by a number of mechanisms until DNA replication is 
completed.  In tumorigenesis, CDK1 behaves differently from CDKs that control S 
phase progression and shows very little evidence of direct genetic alteration.  However, 
other factors such as modifications to DNA damage checkpoints (Bayart et al., 2004) 
and to p53 signalling pathways (Taylor and Stark, 2001) as well as changes in the level 
of cyclin B (Nam and van Deursen, 2014) can influence CDK1 activity. These 
alterations can lead to a rise of CDK1 activity in various cancers, for example colorectal 
cancer (Sung et al., 2014) and prostate cancer (Willder et al., 2013). Elevated 
expression of cyclin B is also associated with more aggressive cancer phenotypes and 
poor survival rates (Aaltonen et al., 2009). 
Although inhibition of CDK1 triggers apoptosis of MYC-driven lymphomas and liver 
tumours (Goga et al., 2007), as well as in human triple-negative breast cancer cells 
(Horiuchi et al., 2012b), the requirement for CDK1 activity for cell survival of non-
transformed cells, and for its elimination to exit mitosis limits its potential as a target for 
cancer therapy. The only realistic approach for CDK1 inhibition which has been 
considered so far is its use in combination therapy. It is hypothesized that CDK1 
inhibition can induce a BRACA-deficient-like phenotype which would sensitise cells to 
DNA damaging agents (Johnson et al., 2009). The most useful approach would be to 
design inhibitors that are selective towards other CDKs but do not inhibit CDK1. 
1.4.5 Role of pharmacological CDK inhibition for cancer therapy 
In the last twenty years several synthetic CDK inhibitors have been designed as 
potential anti-cancer drugs and tested in different clinical trials. First generation 
inhibitors were relatively non-specific although some of them, for example roscovitine, 
were quite effective for some cancers and it is still in clinical trials for Cushing disease. 
Another successful early inhibitor was flavopiridol that underwent 60 clinical trials 
between 1998 and 2014. It is a semi-synthetic compound derived from rohitukine, a 
chromone alkaloid which has been shown to inhibit CDK1, 2, 4, 6, 7 and 9. It was still 
used for cancer treatment until 2012 (Byrd et al., 2007). 
 33 
 
The second generation of inhibitors emerged from the development of flavopiridol and 
roscovitine. Their design was focused on increasing potency and selectivity towards 
CDK1 and CDK2. Many inhibitors of this generation looked promising in preclinical 
studies but did not progress to Phase 1 clinical trials (Payton et al., 2006; Parry et al., 
2010). One of the most studied inhibitors is Dinaciclib which was designed to inhibit 
CDK1, 2, 5 and 9 and has IC50 values in a range of 1-4 nM. It strongly suppresses Rb 
phosphorylation in cell based assays (Parry et al., 2010). Although results of the Phase 
1 clinical trials were promising (Nemunaitis et al., 2013), Phase 2 results in solid 
tumours were disappointing. Dinaciclib monotherapy in non-small cell lung cancer 
showed no activity in previously treated patients (Stephenson et al., 2014). In patients 
with acute myeloid leukaemia or acute lymphoblastic leukaemia no objective changes 
were observed (Gojo et al., 2010). However, in haematological malignancies it has 
shown clinical activity and consequently it remains in Phase 3 clinical trials (Blachly 
and Byrd, 2013). Another inhibitor, AZD5438 (developed by AstraZeneca), was 
reported to be intolerable when administered to patients with advanced solid tumours 
(Boss et al., 2010). The Phase 1 study of AG-024322 (developed by Pfizer), a potent 
inhibitor of CDK1, 2 and 4 was also terminated because of the absence of expected 
therapeutic effect.  
Selectivity is a significant issue for the design of CDK-specific inhibitors. For example 
some inhibitors target CDK1 which is vital for proliferation and CDK9 which is important 
for survival of normal cells, thus achieving a therapeutic window is difficult.  To 
overcome this barrier, CDK inhibitors have been used in combination. For example, 
inhibition of CDK1 with RO3306 (Roche) led to sensitising BRCA proficient cancers to 
poly (ADP-ribose) polymerase PARP inhibition (Johnson et al., 2011). CDK1 has been 
shown to participate upstream of DNA damage response pathways (Ira et al., 2004) 
and in CDK1 depleted cells the function of BRCA1 in the S phase checkpoint was 
compromised (Johnson et al., 2009). BRCA1 and BRCA2 are tumour suppressor 
proteins that play crucial roles in DNA repair (Moynahan et al., 1999). PARP in its turn 
plays a role in single strand DNA repair by homologous recombination. Both BRCA1 
and BRCA2 are necessary for homologous recombination and it is known that BRCA-
deficient cells are hypersensitive to PARP inhibition (Bryant et al., 2005).  
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1.5 Aims of the thesis  
The central aim of this thesis is to provide a better understanding of the function of 
CDK1 based on its structure. Structural information can be very beneficial especially 
in distinguishing highly homologous proteins that are involved into different functions. 
The structure of CDK1 in its inactive conformation has been solved in complex with its 
regulator CKS1 and also bound to its activating partner cyclin B and CKS2.  This work 
is described in Chapter 2. Subsequent to the determination of the structure of CDK1-
cyclin B, the experiments described in Chapter 3 use biochemical and biophysical 
techniques to explore insights into CDK1-cyclin B stability, and substrate preferences 
provided by the structure determination.  
To determine the response of CDK1 to association with different cyclin partners and to 
activation loop phosphorylation, studies to purify various alternative CDK1-containing 
complexes and CDK1 regulatory proteins, and their subsequent crystallisation trials 
are reported in Chapter 4. Ringo/Speedy A is an alternative cyclin-like CDK activator 
that has been characterised in recent years. A series of attempts were made to express 
it in various expression systems and these are also described in Chapter 4. Chapter 4 
also describes preliminary work to characterise another potential CDK1 partner, 
RGC32 in collaboration with the laboratory of Dr Michelle West (University of Sussex). 
CDK upregulation in cancer and in other proliferative diseases has led to interest in 
them as drug targets. Structural insights can make a significant contribution to the 
design of potent and specific ATP competitive inhibitors.  These compounds can be 
used as a chemical probes to distinguish CDKs and as leads for inhibitor design. 
Chapter 5 describes various biophysical and structural studies to understand the 
differing responses of CDK1 and CDK2 to ATP-competitive inhibitor binding.  
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 Structural insights into CDK1-containing 
complexes 
2.1 Introduction 
 Discovery of CDK1  
An understanding of cell cycle control is essential for the fields of biology and medicine. 
Studies to understand the regulation of the cell cycle were started in the 1970s by 
Leland Hartwell who identified genes that control the cell cycle in Saccharomyces 
cerevisiae (budding yeast), the so called cdc-genes (cell division cycle genes) 
(Hartwell et al., 1970; Hartwell et al., 1974). He identified CDC28, to play a role in 
initiation of G1 phase. Hartwell also introduced the idea of checkpoints that was 
expanded and developed by his successors. The genetic approach used in the 
laboratory of Hartwell was taken further by Paul Nurse who discovered the cdc2 gene 
in Schizosaccharomyces pombe (fission yeast) and revealed its essential function in 
cell division (Nurse et al., 1976; Nurse and Thuriaux, 1980). Paul Nurse also 
demonstrated that activation of the protein encoded by the cdc2 gene depends on 
phosphorylation, and identified the corresponding gene in humans (Simanis and 
Nurse, 1986; Lee and Nurse, 1987; Lee et al., 1988). The first cyclin molecule was 
reported in the 1980s by Tim Hunt, who went on to demonstrate its role primarily as a 
component of maturation promotion factor (MPF) and its importance in controlling the 
cell cycle (Evans et al., 1983; Standart et al., 1987; Minshull et al., 1989). For these 
seminal discoveries Leland Hartwell, Paul Nurse and Tim Hunt were awarded a Nobel 
Prize in Physiology and Medicine in 2001.  
To explore the regulation of the cell cycle two approaches have primarily been 
employed. The first approach was cell biological/biochemical, where cell cycle 
progression was studied using cell manipulation techniques and proteins were 
subsequently purified and characterised. Using this approach it was discovered that 
entry into mitosis is controlled by a cytoplasmic factor in the slime mold Physarum 
polycephalum (Rusch et al., 1966). Similar work was also being performed in frog 
oocytes where microinjection of the cytoplasm from an oocyte undergoing the first 
meiotic metaphase into a recipient oocyte not undergoing meiosis was shown to induce 
maturation (Masui and Markert, 1971; Smith and Ecker, 1971). These studies 
suggested the presence of an `intracellular inducer` which stimulated oocyte 
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maturation that has since been named Maturation Promotion Factor (MPF). Further 
research led to the discovery of MPF activity in mitosis as well (Hara et al., 1980). The 
MPF complex was purified in 1988 and shown to be composed of two proteins of 45 
and 32 kDa molecular weight respectively that was able to induce mitosis and was 
activated by phosphorylation (Lohka et al., 1988). These proteins were confirmed as 
CDK1, in both Xenopus and starfish and a cyclin (Labbe et al., 1988). MPF is now 
known as an active complex of CDK1 and cyclin B, key components of cell cycle 
regulation.  
The second mainly genetic approach was used to identify the regulatory genes that 
control the cell cycle primarily in yeasts. Hartwell in 1974 had proposed in the budding 
yeast Saccharomyces cerevisiae the existence of some point in G1 that he named 
‘Start’, when a cell commits to division. He subsequently described the gene regulating 
this event and named it CDC28 (Hartwell, 1974). Work was continued and developed 
by Paul Nurse and colleagues who identified the network of genes acting through 
regulation of the cdc2 gene product, CDC2 (also known as CDK1) which controls entry 
into mitosis (Nurse and Thuriaux, 1980) and S phase (Nurse and Bissett, 1981) in S. 
pombe. The budding yeast cdc2 orthologue CDC28 was subsequently also shown to 
have roles required for successful completion of S-phase and progression through 
mitosis (Piggott et al., 1982). 
The human orthologue of the S. pombe cdc2 gene was identified and described in the 
laboratory of Paul Nurse (Lee and Nurse, 1987). In this work, a gene was identified 
from a human cDNA library, which could rescue a cdc2 deletion in fission yeast. The 
encoded protein proved to be of similar molecular weight to S. cerevisiae CDC28 and 
S. pombe CDC2. Also 62% of the amino acid sequence was identical to S. cerevisiae 
CDC28 and 57% to S. pombe CDC2. Comparison of CDK1 amongst the different 
species demonstrates their similarity, overall showing 41% identity (Figure 2-1), 
suggesting CDK1 conservation through all eukaryotes. 
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Figure 2-1 Comparison of CDK1 protein sequences from the different species 
CDK1 from the different species were aligned using Clustal Omega (Sievers et al., 
2011). Origin of the CDK1 is identified on a left hand side with the Uniprot entries in a 
respective order: P06493 for CDK1 Homo sapiens, P00546 for S. cerevisiae, P04551 
for S. pombe, P39951 for Rattus norvegicus , P23572 for Drosophila melanogaster 
,Q9DG98 for Oryzias luzonensis (Luzon rice fish). Identical sequences marked dark 
purple, lower similarities identified with the lighter shades of purple. Binary comparison 
between CDK1 Homo sapiens and S. cerevisiae revealed 57% identity, 62% between 
CDK1 of Homo sapiens and S. pombe, 97% between CDK1 of Homo sapiens and 
Rattus norvegicus, 71% between Homo sapiens and Drosophila melanogaster, 82% 
between Homo sapiens and Oryzias luzonensis.  
CDK1 is the only essential cell cycle CDK as it can substitute for other interphase CDKs 
by pairing with non-cognate cyclins to promote progression from G1 into S phase 
(Fisher and Nurse,1996) (Mondesert et al., 1996). Cdk1 knockout mouse embryos fail 
to develop beyond the morula stage. Also in the absence of interphase CDKs, CDK1 
can replace them by binding to their respective cyclins and phosphorylating their 
substrates. For example, CDK1 can phosphorylate retinoblastoma protein pRb, 
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p27KIP1 and p57KIP2 to promote cell cycle progression in the developing embryo 
through organogenesis up to mid-gestation (Santamaria et al., 2007). 
 Regulation of CDK1 activity  
A complex regulatory network navigates the activity of the essential cell cycle kinase 
CDK1. Its activity through G2/M transition is regulated by the concentration of cyclin A 
and B (Deibler and Kirschner, 2010), by activating phosphorylation on the activation 
segment Thr161 by CAK and also by inhibitory phosphorylation. The inhibitory 
phosphorylation is controlled by two kinases in metazoans, WEE1 and MYT1, which 
phosphorylate residues Thr14 and Tyr15 on the glycine-rich P-loop and phosphatase 
CDC25 which antagonizes WEE1 and MYT1 activity and de-phosphorylates these 
residues (Hoffmann et al., 1993). Consequently, WEE1 and MYT1 activity delays 
CDK1 entry into mitosis and CDC25 promotes it (Dunphy and Kumagai, 1991; 
Featherstone and Russell, 1991; Gautier et al., 1991). Nuclear WEE1 is present in all 
eukaryotic organisms but MYT1 is only found in metazoans and is known to be 
localised to the endoplasmic reticulum (ER) and Golgi membranes (Kornbluth et al., 
1994; Liu et al., 1997). A homologue of WEE1 named Swe1 in budding yeasts has 
been studied to better understand the mechanism of CDK1 regulation by inhibitory 
phosphorylation. As a result, a model has been proposed where Swe1 binds to Cdc28-
Clb2 inhibiting it by phosphorylating Thr 14 in late G2. Cdc28-Clb2 in its turn activates 
Swe1 by hyper-phosphorylation (Harvey et al., 2005) which allows Swe1 activity 
towards Cdc28.  Removal of the inhibitory phosphate from Cdc28 by Cdc25 allows full 
hyper-phosphorylation of Swe1 by Cdc28-Clb2 and release of the Cdc28-Clb2 
complex. Therefore, Cdc28 is both a positive and negative regulator of Swe1. The large 
pool of Cdc28-Clb2 in complex with Swe1 maintains it in the inhibited state in G2 phase 
but it is ready to be rapidly activated to trigger entry into mitosis.  
Lower activity of CDK1-cyclin B results in higher activity of WEE1 and MYT1. Activation 
of CDK1-cyclin B triggers activation of CDC25 phosphatase which is kept inhibited by 
the kinases CHK1 and CHK2 that operate downstream of the DNA damage checkpoint. 
CDK1 activation leads to further CDC25 phosphorylation initiating a positive feedback 
loop. Polo like kinase 1 (Plk1) also activates CDC25 and might downregulate WEE1 
and MYT1 (Nigg 2001). The increase in active CDK1-cyclin B leads to deactivation of 
WEE1 and MYT1 as CDK1-cyclin B phosphorylation inhibits both these enzymes 
(Figure 2-2), (Okamoto and Sagata, 2007). 
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 It has been proposed that the concerted activity of cyclins A and B can serve as the 
triggering factor for the activation of positive and double negative feedback loops that 
leads to mitosis. In somatic cells the threshold of ~400-500 nM was defined for cyclin 
B above which it causes a dramatic increase in CDK1 activity, mediated by CDC25. At 
the same time, it has been suggested that active CDK1-cyclin A weakens the 
WEE1/MYT1 negative feedback promoting cyclin B activation at lower concentrations. 
CDK1-cyclin A activity is generally much lower than CDK1-cyclin B but the contribution 
of cyclin A is very important. For example, cyclin A is required for timely nuclear 
envelope breakdown (NEB) in HeLa cells (D Gong, 2007).  It participates in the G1/S 
transition but also accumulates through S and G2 phases (Deibler and Kirschner 
2010). Both cyclins are insufficient inducers of mitosis but complexes of both of them 
in collaboration generate sufficient signal for mitotic entry (Winn et al., 2011) 
 
Figure 2-2 Regulation of CDK1 activity by positive and double negative 
activation loops. 
CDC25 activates CDK1 by dephosphorylation of Thr14 and Tyr15. Active CDK1-cyclin 
B activates CDC25 in a positive feedback loop. Active CDC25 is pictured in red, 
inactive in black. WEE1 inactivates CDK1 by phosphorylation on Thr14 and Tyr15.  
The phosphorylation of CDC25, WEE1 and MYT1 is mainly catalyzed by CDK1 and is 
opposed by protein phosphatase 2A(PP2A)-B55δ (Pal et al., 2008). (PP2A)-B55δ 
activity is reported to be high in interphase and low during mitosis (Yu et al., 2006). It 
is regulated by Greatwall (GwI), another kinase which is essential for mitotic entry and 
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successful maintenance of mitotic progress (Figure 2-3) (Yu et al., 2006). For its 
activation GwI requires phosphorylation by CDK1, and once phosphorylated it 
activates a downstream phosphatase Ensa (includes small proteins Arpp19 and 
endosulfine-α) which switches off 2A(PP2A)-B55δ (Mochida et al., 2010). Therefore, 
GwI and Ensa are essential for progression of mitosis due to their ability to inhibit 
phosphatases. In a recently proposed mathematical model (Tyson and Novak, 2015) 
2A(PP2A)-B55δ was suggested as a CDK1- counteracting phosphatase for GwI as 
well. CDK1-cyclin B phosphorylates APC and Cdc20 which form a complex following 
cyclin B destruction. 
 
Figure 2-3 Regulation of CDK1 activity at the G2/M transition. 
Solid arrows represent chemical reactions, dashed arrow represents catalytic activity, 
and solid line with two dots on both sides with an arrow at the middle represents binding 
to form heterodimer. B55 is shorter abbreviation for 2A(PP2A)-B55δ phosphatase 
(Tyson and Novak, 2015). 
  Structures of CDK-cyclin complexes 
CDKs are allosterically regulated by cyclin binding. Monomeric CDKs adopt an inactive 
conformation, and cyclin association accompanied in most examples by activation loop 
phosphorylation leads to CDK activation. The inactive CDK conformation is 
characterised by the αC helix (also called the PSTAIRE helix for the conserved cyclin 
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recognition sequence within) being rotated out of the N-lobe (De Bondt et al., 1993). 
As a result of this shift in the position of the αC helix, a conserved glutamate residue 
(Glu51 in CDK2) is moved out of the active site which leads to the disruption of its 
interaction with the lysine side chain that coordinates ATP (Lys33 in CDK2).  
 A 
 
B 
 
                                  C 
 
Figure 2-4 The structures of pCDK2-cyclinA, pCDK9-cyclinT, pCDK4-cyclinD.   
CDKs are coloured blue and cyclins are green. CDKs N - and C - terminus and Cyclin 
Box Folds are identified. The CDK–cyclin binding surface is encircled red. (A) 
T160pCDK2-cyclin A (PDB code: 1QMZ), (B) T186pCDK9-cyclin T (PDB code: 3BLH), 
(C) T172pCDK4-cyclinD (PDB code: 2W9F). 
The model of CDK2 activation by cyclin A binding and phosphorylation on the activation 
segment became a paradigm for CDK activation (Jeffrey et al., 1995) as described 
earlier. Subsequently, the determination of the CDK5-p25 structure revealed that CDK5 
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can adopt an active conformation without activating phosphorylation (Tarricone et al., 
2001); and in contrast, CDK4–cyclin D complexes even when phosphorylated do not 
fold into an active state in the absence of substrate binding (Day et al., 2009). Apart 
from these reported differences in activation mechanism, the extent to which the CDK 
and cyclin subunits interact can also vary. For example, CDK2 forms a very tight 
complex with cyclin A where residues from both N- and C-lobes participate in cyclin 
binding.  On the other hand, the interaction surface between CDK4 and cyclin D is 
much smaller with residues from the N-lobe of CDK4 and the cyclin D N terminal cyclin 
box mediating the association. As structures of transcriptional CDK-containing 
complexes have been determined, new features that distinguish them from the cell 
cycle CDKs have been reported revealing that there are significant structural 
differences between members of the CDK family (Figure 2-4).    
  Structural features of cyclins A and B 
CDK1 binds to type A and type B cyclins while CDK2 is found in complexes containing 
type A and E cyclins. The first monomeric cyclin structure to be solved was that of 
bovine cyclin A2 (residues 171-433) (Brown et al., 1995). The structure of monomeric 
human cyclin B1 (residues 165-433) was subsequently published in 2007 (Petri et al., 
2007). The structure of human cyclin E1 (residues 81-363) has to date only been 
reported in a complex with CDK2 (Honda et al., 2005). The N terminal cyclin sequences 
were not present in the solved structures as sequence analysis suggested they would 
be unstructured and previous work had demonstrated that they were not required for 
CDK activity (Kobayashi et al., 1992). Cyclins A, B and E share the typical cyclin 
structure comprised of two tandem cyclin box folds - CBF1 and CBF2 ( Figure 2-6 A) 
and together with cyclin D share an ‘RXL binding groove’ or “recruitment site” ( Figure 
2-6 B) (Adams et al., 1996). Both cyclin boxes are organised around a central 
hydrophobic helix named α3 or α3’. The surrounding helices are held by Van der Waals 
interactions but also hydrogen bonds. The recruitment site is formed by amino acids 
from the α1 helix from CBF1 and contains the conserved MRAIL sequence (Figure 2-
5). The site is essential for phosphorylation of substrates such as pRb and p53 and for 
binding of CIP/KIP cyclin-dependent kinase inhibitors (Schulman et al., 1998). In the 
structurally analogous region in CBF2 the RRASK sequence conserved in all types of 
type B cyclins, but not in cyclin A or cyclin E replaces the MRAIL motif. 
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              Cyclin A 
 
Cyclin B 
 
Cyclin E 
 
Figure 2-5 Comparison of structures of cyclins A, B and E. 
 Structures of cyclins A (PDB code: 1VIN), B (PDB code: 2B9R) and E (PDB code: 
1W98) in ribbon representation. Helices of CBF1 are colored α 1 – cyan, α 2 – dark 
cyan, α 3 – light blue, α4 – blue, α 5 – dark blue, helices of CBF2 are colored α 1’ –
purple, α 2’ – lilac, α 3’ – bright pink, α 4’ – pink, α 5’  - red. N-terminus colored green, 
C- terminus – gold (cyclin A), ice blue (cyclin B), orange (cyclin E). The MRAIL motif is 
highlighted in yellow.  
 
The structural comparison of cyclin A, cyclin B and cyclin E highlights their very similar 
structures despite there being little sequence similarity between them. For example, 
the CBF1 sequences of cyclins A and B show 37% amino acid identity and those of 
cyclins B and E, 29% (Figure 2-7 A) and between cyclin A and cyclin E – 42% (Honda 
et al., 2005). As cyclin B and cyclin A both interact with CDK1, and CDK2 interacts with 
both cyclin A and cyclin E, these similarities in the CBF1 folds suggests its role is to 
facilitate CDK binding. As can be seen from an overlay of the three cyclin structures 
CBF1 is very similar for all of them, but CBF2 differs more significantly (Figure 2-6 A). 
The main changes occur in the loop sequences, and in the orientation and lengths of 
the helices. These observations lead to the hypothesis that CBF2 is mainly responsible 
for cyclin-specific functions. 
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B 
 
Figure 2-6 Comparison of structures of cyclins A, B and E 
(A) Structures of cyclin A (gold), cyclin B (ice blue) and cyclin E (coral) were 
superimposed (using CCP4mg program) (McNicholas et al., 2011). The structures 
share very good structural homology over the N-terminal cyclin box (CBF1), but the 
lengths and relative positions of the helices differ in the C-terminal cyclin box (CBF2). 
(B) Position of p27 on a surface of cyclin B was modelled by superposition of cyclin B 
with CDK2-cyclin A-p27 (PDB code: 1JSU). p27 is bound to the RXL binding 
hydrophobic groove. p27 is colored green and the RXL motif is colored orange. Cyclin 
A and cyclin B conserved residues involved in contact with p27 are colored ice blue, 
different residues are colored red. Unfavorable interactions (defined as those where 
the juxtaposition of atoms in the bound state is less energetically favorable than the 
solvation of the atoms in the free state) are colored yellow.   
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Figure 2-7 Sequence alignment. 
(A) Schematic representation of the domain organization of cyclins A, B and E. The 
cyclin box folds (CBFs) are colored grey, the rest of molecule is blue. (B) Multiple 
sequence alignment of bovine cyclin A2 (UniProt entry P20248) human cyclin B1 
(UniProt entry P14635) and human cyclin E1 (UniProt entry P24864) using Clustal 
Omega (Sievers et al., 2011) to illustrate sequence conservation and diversity between 
these cyclins. Identical residues are colored in blue. Helices are represented above 
alignments as red bars and named next to the bar.  
  Analysis of the CDK-cyclin interface  
As mentioned above, an analysis of the structures of various CDK-cyclin complexes 
reveals substantial differences in the CDK-cyclin interface.  However, despite these 
global differences, a number of structural features are conserved. For example, the 
part of the CDK structure that is composed of the sequence that precedes the C-helix 
(β3 to αC), the αC helix and the β4 and β5 sheets, and which makes significant 
interactions with the cyclin, is conserved in all interfaces known to date (Echalier et al., 
2010). Eight positions between β3 and β5 have been found in five complexes (CDK2-
cyclin A, CDK9-cyclin T, CDK4-cyclin D, CDK5-p25, Pho85-Pho80) to mediate the 
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interactions between a CDK and its respective cyclin partner. These positions 
correspond to CDK2 residues Glu41, Ile46, Val49, Val52, Ala53, Arg56, Arg57 and 
Val84.   The interactions are different in different complexes due to the identities of the 
amino acids involved (Figure 2-8). A conserved feature of the CDK-cyclin interface is 
the predominance of hydrophobic interactions enhanced by aromatic residues present 
in the cyclins (Figure 2-8). The residues are not identical but collectively they create a 
hydrophobic surface that is a characteristic of this part of the CDK-cyclin interface.  
 
 
Figure 2-8 Comparison of CDK-cyclin interfaces. 
Top row labelled ‘binary complex’ illustrates CDK-cyclin complexes for which 
structures have been determined.  CDKs are coloured grey and cyclins green – cyclin 
A2, light green – cyclin T, magenta – cyclin D1, purple – Pho80. Activation segments 
are shown in red and C-helices in blue. Interface residues of CDKs are represented in 
ball and stick mode and coloured red. Interface residues of cyclins are coloured black. 
Interface areas are calculated by Pisa (Krissinel and Henrick, 2007). The Figure is 
redrawn with permission from (Echalier et al., 2010). 
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There are also a number of notable differences between the various CDK-cyclin 
interfaces. For example, the C-terminal part of αE and the activation segments of 
CDK2, CDK5 and Pho85 contact their respective cyclin partners (Figure 2-9). The first 
N-terminal residues of CDK9 contact cyclin T, and CDK2 residues between helices αJ 
and αK interact with cyclin A. CDK2 is notable for interacting with both the N- and C-
CBFs of cyclins A, B and E, whereas cyclin D and cyclin T only use the N-terminal 
CBFs to contact respectively CDK4 and CDK9.  
 
pCDK2-cyclinA 
 
pCDK2-cyclinE 
 
pCDK9-cyclin T 
 
pCDK4-cyclin D 
 
 
Figure 2-9 Hydrophobic interactions at the CDK-cyclin interface.                                                   
C-helix of CDKs shown in grey, helix H 5 of cyclins represented in different colours, 
cyclin A – green, cyclin E – orange, cyclin T – light green, cyclin D – magenta.  Figure 
redrawn with permission from (Echalier et al., 2010). 
  Aims and objectives 
Determination of the structures of a number of CDK-cyclin complexes has shown that 
not all the features of CDK2 activation by cyclin A binding are conserved across the 
CDK family. The primary aim of the work described in this Chapter was to assess to 
what extent the structural model for CDK activation proposed from studies of CDK2 is 
applicable to activation of its close relative CDK1. CDK1 and its binding partners cyclin 
B and CKS2 were expressed and purified to generate complexes for structural studies. 
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Structures of monomeric CDK1 and CDK1 bound to a cyclin partner can provide 
insights into features which make it the essential CDK and explanations for its flexibility 
towards its substrates. It also would allow investigation of residues involved in cyclin 
binding. The activation segment and ATP binding site are the important features of all 
kinases. An examination of the CDK1 active site can provide valuable insights into the 
mechanisms of CDK1 activation and of substrate phosphorylation.  
 
2.2 Materials and Methods  
 Chemicals and Reagents 
All chemicals listed in the material and methods section were of the analytical grade 
and obtained from Sigma Aldrich, St Louis, MO, USA, unless otherwise stated. 
  Purification buffers  
Extraction buffer 1:  50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.01% MTG 
(monothioglycerol), 0.01 mg/ml DNase, 0.05 mg/ml RNase, 0.25 mg/ml Lysozyme, 
5mM MgCl2, one EDTA-free complete protease inhibitor tablet (Roche, Basel, 
Switzerland)/50 ml. 
Extraction buffer 2:  50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.01% monothioglycerol 
(MTG), 0.01 mg/ml DNase, 0.05 mg/ml RNase, 0.25 mg/ml  Lysozyme, 5 mM MgCl2 , 
one complete protease inhibitor tablet (Roche, Basel, Switzerland)/ 50ml. 
Extraction buffer B: 50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 20 mM imidazole, 0.01%    
MTG, 0.01 mg/mlDNase, 0.05 mg/ml RNase, 0.25 mg/ml Lysozyme, 5 mM MgCl2, one 
EDTA-free complete protease inhibitor tablet (Roche, Basel, Switzerland)/ 50 ml. 
Binding / SEC buffer 1: 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.01% MTG. 
Binding / SEC buffer 2: 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.01% MTG. 
Binding / SEC buffer B: 50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 0.01% MTG. 
Elution buffer B: 50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 200 mM imidazole, 0.01% 
MTG. 
SEC buffer 1/B/2: 50 mM Tris-HCl, pH 8.0, 1 M NaCl, 0.01% MTG. 
Peptide HBS: 40 mM Hepes, pH 7.5, 200 mM NaCl, 0.01% MTG. 
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Binding Peptide MES: 25 mM MES, pH 6.5 
Elution Peptide MES: 25 mM MES, pH 6.5, 500 mM NaCl.  
All buffers were filtered and degassed before use. 
 Constructs used for in vitro experiments 
CDK1 and CAK1 constructs were kindly generated by N. Brown. CDK1 (Uniprot entry 
P06493) was cloned by the In-Fusion method (Clontech) into the pVL1393 vector 
modified by N terminal insertion of the GST-3C sequence. Prior to CDK1 insertion the 
expression vector was linearized by Sma I and EcoRI digestion (NEB) and the CDK1 
insert was amplified by PCR. GSTCAK was cloned in a similar manner although it 
contains a non-cleavable GST tag. Cyclin B (residues 165-433, Uniprot entry P14635) 
with mutations C167S/C238S/C350S in the pET28 -(a+) vector with thrombin cleavable 
6xHis tag was a kind gift of E. Petri (hereafter called pET28cyclinBcs, (Petri et al., 
2007)). CKS1 (Uniprot entry P61024) and CKS2 (Uniprot entry P33552) constructs 
were kind gifts from Prof. J. Endicott. CKS1 was amplified by PCR and sub-cloned into 
the pET21-(d+) vector with an N terminal 6xHis tag (pETCKS1). CKS2 was cloned into 
pGEX6P-1 to generate a construct with a 3C Precision cleavable GST tag 
(pGEXCks2). The following vectors were available in the laboratory: CDK2 (Uniprot 
entry P24941) and Saccharomyces cerevisiae CAK cloned as GST fusions into 
pGEX6P-1 to generate CDK2 phosphorylated on Thr160 (pGEXCDK2-CAK1, (Brown 
et al., 1999)), and pET21d modified to express 6xHis-tagged bovine cyclin A2 
(pETBvcyclinA, Uniprot entry P30274) (Table 2-1). 
Protein 
name 
Names of constructs  Uniprot 
entry 
Residue 
range 
Vector 
backbone 
Tag Molecular 
weight 
(Da) 
CDK1 pVL1393CDK1 P06493 1 - 297 pVL1393 GST 34095 
Cyclin 
B1 
pET28CyclinBcs P14635 165- 433 pET28-(a+) 6xHis 30918 
GST 
CAK1 
pVL1393CAK1 P43568 1-368 pVL1393 GST 68186 
CKS1 pET21CKS1 P61024 1-79 pET21-(d+) 6xHis 9660 
CKS2 pGEX6P1CKS2 P33552 1-79 pGEX6P-1 GST 9860 
CDK2 pGEX6P1CDK2 P24941 1 - 298 pGEX6P-1 GST 33930 
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Cyclin 
A2 
pET21dCyclinAHis P30274 171- 433 pET21d 6xHis 29833 
160T 
pCDK2 
pGEX6P1CDK2CA
K1                    
P24941 
P30274    
1–298   
1-368   
pGEX6P-1 GST   
GST 
 
Table 2-1 Summary of constructs used to express CDK1 and associated 
regulators 
 
  Cell culture 
Human CDK1 and S. cerevisiae CAK1 were expressed using the baculoviral 
expression system. The pVL1393 vector containing GSTCDK1 or GSTCAK1 was used 
to prepare recombinant baculovirus with the flashBAC system (OET, Oxford, UK). 1.5 
x 106 SF9 cells in 2 ml of media per 35 mm dish were left for 30 minutes to form a sub-
confluent monolayer. Meanwhile transfection mix was prepared in a polystyrene tube 
as follows - 1000 μl Lonza InsectXPRESS with L-Glutamine media (Lonza), 100 ng 
virus DNA from the flashBAC kit (5 µl), 500 ng of transfer vector containing gene of 
interest, and 5 µl of GeneJuice (Novagen, Merck Group, Darmstadt, Germany) were 
mixed and left at room temperature for 15 minutes. Once the SF9 cells had formed a 
monolayer, medium was drained and the transfection mix was added drop by drop to 
equally distribute it over the plate. 35 mm dishes containing SF9 cells and transfection 
mix were then sealed by parafilm and placed into sandwich boxes and incubated at 
28°C for between 5 and 24 hours. After the initial incubation, an additional 1 ml of 
SF900 medium was added to each well and the plates were replaced into the sandwich 
boxes and incubated for a further 4 days at 28°C. As a result of homologous 
recombination within the insect cells, the GSTCDK1 and GSTCIV1 sequences were 
inserted into the viral DNA under the control of the polyhedrin promoter. Recombinant 
viruses were selected by restoration of the essential ORF1629 gene. Culture medium 
was harvested after five days in total and stored at 4°C. This sample constituted the 
P0 stock and was used for further amplification. P3 stock was used for protein 
production. 
  Optimisation of protein expression  
Protein production was optimised by screening different virus stock:cell ratios.  
Generally, 30 ml of SF9 cells at 1.0 x 106 cells per ml were infected with different 
volumes of viral stock, typically 30 µl, 150 µl or 300 µl and incubated at 27°C with 
shaking at 120 rpm for a total of 98 hours. Cells were counted after 48 and 72 hours 
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to check if they were still doubling every 24 hours. After they have stopped dividing it 
is assumed that the optimal concentration of virus has been achieved.  2 ml samples 
of each cell culture infected with viruses were harvested by centrifugation at 646 x g 
for 15 min after 48, 72 and 98 hours incubation and frozen at -20°C for further 
expression tests. Optimal conditions for infection were used for subsequent protein 
expression. 
 Expression tests 
The frozen cell pellets were re-suspended in 1ml of BugBuster (Merck Millipore) with 
addition of 0.25 mg/ml Lysozyme, 50 μg/ml RNase, 10 μg/ml DNase and 5 mM MgCl2. 
The cells were incubated with rotation for 20 min at room temperature for cell lysis. 3 
μl of each lysate was analysed by SDS-PAGE and the rest was transferred into 
Eppendorf tubes and centrifuged for 20 min at 6500 x g. 50 μl of Glutathione Sepharose 
4B beads (GE Healthcare) were equilibrated in TBS buffer (50 mM Tris-HCl, pH 7.5, 
0.15 mM NaCl, 0.01% MTG), and supernatants of each sample were added and 
incubated for 1h at +4°C. Beads were then washed with ice-cold TBS 3 times in 0.5 ml 
volume and pelleted by centrifugation at 4°C at 1610 x g.  After the final wash, 30 µl of 
RunBlue LDS Sample buffer (Expedeon) was added to the pelleted beads and proteins 
were eluted by heating at 95°C for 5 minutes. 15 µl of each sample was analysed by 
SDS-PAGE as described in Section 2.2.10. 
  Bacterial transformation and protein expression in bacterial 
cells 
For protein expression E. coli RosettaTM2(DE3)pLysS cells were transformed using the 
manufacturer’s protocol. Briefly, circa 10 ng of pET28cyclinBcs or pGEX6PCks2 was 
incubated with cells (50 µl) on ice for 5 min. The mix was heat shocked for 30 sec and 
left on ice for a further 2 min. After one hour incubation in SOC media, cells were plated 
on LB agar containing kanamycin (30 μg/ml) and chloramphenicol (34 μg/ml) and 
incubated overnight at 37°C. For each construct, one colony was picked and grown 
overnight in 10 ml of Lysogeny Broth (LB) supplemented with appropriate antibiotics 
and then added to 1l LB containing kanamycin and chloramphenicol. The cultures were 
grown at 37°C at 220 rpm in a shaking incubator until the optical density at 600 nm 
(OD600) reached 0.6-0.8 (cyclin B) or 0.5-0.6 (CKS2). The cultures were cooled to 20°C, 
induced with 0.3 mM IPTG and then left to grow overnight. Cells were harvested by 
 52 
 
spinning at 4000 x g and re-suspended in either binding/SEC buffer B (cyclinB) or 
binding/SEC buffer 2 (CKS2) and then fast-frozen in dry ice at -80°C for future use. 
For bovine Cyclin A expression, pET21CyclinA (Brown et al., 1995) was transformed 
into RosettaTM2(DE3)pLysS cells according to the manufacturer’s instructions and 
colonies resistant to ampicillin and chloramphenicol were harvested for the initial 
culture growth in 10 ml of LB o/n. Starter culture was added to 1 L LB containing 50 
µg/ml of ampicillin and 34 µg/ml chloramphenicol and inoculated at 37°C at 220 rpm 
until the OD600 nm reached 0.7. The flasks were cooled down to 20°C and cells were 
induced with 0.1 mM IPTG overnight at 220 rpm. Cells were pelleted by centrifugation 
at 5000 x g for 20 minutes and re-suspended in 20 ml of 300 mM NaCl, 0.01% MTG, 
50 mM Tris-HCl pH7.5, 5 mM MgCl2, protease Complete tablets minus EDTA (1 tablet 
for 50 ml). Re-suspended pellets were flash frozen in dry ice and stored at -80° C until 
further use. 
For the expression of phosphorylated CDK2, RosettaTM2(DE3)pLysS cells were 
transformed with the pGEX6PCDK2CAK1 (Brown et al., 1999) according to the 
manufacturer’s instructions. Cells were inoculated in 1 L LB at 37°C and incubated until 
the optical density at 600nm OD600 nm has reached 0.8 and then induced by addition of 
80 μM IPTG and left to grow for 20 hours at 20°C. This incubation generates CDK2 
phosphorylated on Thr160 by CAK1. Cells were harvested and frozen as described 
above.  
 Protein purification 
Cell pellets were thawed under running cold water and then kept on ice and sonicated 
in the presence of 0.25 mg/ml Lysozyme, 50 μg/ml RNase, 10 μg/ml DNase and 5 mM 
MgCl2 for 10 cycles totalling 1.5 min with 15 sec intervals for insect cells, and 3 min 
with the same intervals for bacterial cells. Cells were centrifuged at 60,000 x g, the 
supernatants collected and kept on ice. Glutathione Sepharose 4B was used to isolate 
GST-tagged CDK1, CAK1 and CKS2 proteins. The Glutathione Sepharose 4B resin 
was packed into a gravity flow column and washed with 10 column volumes of 
binding/SEC buffer 1 for CDK1 and GSTCIV1 or binding/SEC buffer 2 for CKS2. The 
supernatant was applied to the column under gravity flow and then the column was 
washed to baseline with 10 column volumes of buffer. Bound protein was eluted using 
the same buffer supplemented with 20 mM reduced glutathione adjusted to pH 7.4. 
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CDK1 and CKS2 were cleaved from their GST tags by overnight incubation with 3C 
protease (1:50 w/w) at +4°C. 
Cyclin B and Cyclin A are hexahistidine tagged and were purified by affinity 
chromatography using Ni-NTA resin. Beads were packed into a column and washed 
with 10 column volumes of binding/SEC buffer B supplemented with 20 mM imidazole 
to reduce non-specific binding for cyclin B and with buffer N (300 mM NaCl, 50 mM 
Tris-HCl, pH 7.5, 0.01% MTG, 25 mM imidazole) for cyclin A. Bacterial lysates 
supplemented with 20 mM and 25 mM imidazole respectively after thawing were 
applied under gravity flow to the prepared columns. Beads were washed with 10 
column volumes of respective buffers and then cyclin B eluted with binding/SEC buffer 
B containing 200 mM imidazole. Cyclin A was eluted by step increasing the 
concentration of imidazole at 100 mM, 150 mM, 200 mM and 500 mM intervals to 
increase the purity of the protein. MgCl2 was added to cyclin A fractions to a final 
concentration of 0.1 M to prevent protein aggregation. Thrombin clean cleave kit 
(Sigma) was used to remove the hexahistidine tag from cyclin B. Beads containing 
thrombin were equilibrated into binding/SEC buffer B. Cyclin B eluted from the Ni-NTA 
resin was buffer exchanged into the same buffer as imidazole affects thrombin 
cleavage. Cyclin B was incubated for a minimum of 3 hours at 4°C with thrombin clean 
cleave beads (200 µl of 50 % slurry cleaves 1 mg of fusion protein). The efficiency of 
the cleavage was checked by SDS-PAGE.  
  Protein purification by size-exclusion chromatography  
Size-exclusion chromatography (SEC) was used as a final purification step. A 
Superdex 75 26/60 column was equilibrated into the appropriate buffer: binding/SEC 
buffer 1 for CDK1 purification, binding/SEC buffer 2 for CKS2 purification and 
binding/SEC buffer B for cyclin B purification. SEC was carried out at room temperature 
at a flow rate of 2.5 mls/min. Samples (between 5 and 10 mls) were filtered through a 
0.45 μm filter before loading. Four ml fractions corresponding to every peak were 
collected and the protein content estimated by OD280 measurement (Nanodrop) prior 
to analysis by SDS-PAGE. 
 SDS-PAGE  
Protein samples were prepared by mixing with an equal volume of 4xsample buffer 
(40% glycerol, 4% LDS, 0.8 M Triethanolamine-Cl pH 7.6, 4% Ficoll-400, 0.025% 
Phenol Red, 0.025% Coomassie Brilliant Blue G250, 2 mM EDTA-2Na) and 0.25 M 
 54 
 
DTT as a reducing agent (15 mM final) and then heated for 3 min at 95°C. Between 
10-20 μl of sample was loaded onto 12% polyacrylamide gels (Expedeon, 
Cambridgeshire, UK) alongside a pre-stained protein ladder (Fermentas, Waltham, 
Massachusetts). Following electrophoresis (1 h at 180 V), proteins were visualised with 
Instant Blue (Expedeon, Cambridgeshire, UK). 
 Preparation of complexes 
Fractions containing CDK1, cyclin B and CKS2 were further purified by affinity 
chromatography to remove GST and uncleaved proteins respectively. Proteins were 
concentrated (Sartorius Vivaspin concentrators (10 kDa and 3 kDa cut-off)) and further 
analysed by SDS-PAGE for the presence of impurities. CDK1-cyclin B-CKS2 and 
CDK1-cyclin A–CKS2 were mixed in a ratio of 1:1.5:2. The NaCl concentration was 
again adjusted to 1 M prior to a 1 hr incubation on ice and then the ternary complexes 
were purified using a Superdex 75 26/60 column. In each case, the peaks 
corresponding to complexes of CDK1-cyclin B-CKS2, CDK1-cyclin A and CDK1-cyclin 
A-CKS2 were collected and analysed by SDS-PAGE. Fractions of CDK1-cyclin A were 
concentrated to 1 mg/ml using 30 kDa cut-off concentrators (Vivaspin) and frozen in 
100 µl aliquots. Pooled fractions of CDK1-cyclin B-CKS2 and CDK1-cyclin A-CKS2 
were concentrated in the presence of either 0.2 mM AMPPNP or a 3-fold molar excess 
of ATP-competitive inhibitors to 10 mg/ml using 30kDa cut-off concentrators (Vivaspin) 
prior to crystallisation trials. 
  Protein crystallography 
Sitting drop vapour diffusion crystallization trials were performed using homemade 
screens designed from an initial hit from the Morpheus screen (Molecular Dimensions, 
Newmarket, Suffolk, UK) condition B4 (0.1M MES/imidazole buffer (pH 6.7), 6.5% MPD, 
5% PEG 4K, 10% PEG1K)). Drops were dispensed by a TPP Labtech Mosquito LCP 
into MRC 96 wells plates by mixing 0.2 µl of complex and 0.2 µl of mother liquor. Plates 
were incubated at +4°C and monitored for 4 weeks.  Final crystallisation conditions 
were identified as 0.1 M MES/imidazole buffer (pH 6.7), 6.5% MPD, 5% PEG4K, 10% 
PEG1K. Crystals were mounted into a nylon crystal loop and flash cooled in liquid 
nitrogen prior to data collection.  
 Data collection and analysis 
Datasets were collected at the Diamond Light Source (Didcot, UK) on I04 and I24 
beamlines supplied with detector PILATUS 6M (Broennimann et al., 2006) at 100 K at 
 55 
 
the range of wavelength 0.69-2.07Å by Dr A. Basle. Typically 2000 images were 
collected from a single crystal with an oscillation angle of 0.1° per image and an 
exposure time of 0.1 s. Data were imported from Xia (Winter, 2010) and processed 
using programs of the CCP4 suite (Pointless/ Aimless (Evans, 2006; Evans, 2011)). 
The structures of CKS2 (PDB code 1BUH), CDK2 (PDB code 1HCK), human cyclin B 
(PDB code 2B9R) and cyclin bound CDK2 (PDB code 1QMZ) were used as search 
models for molecular replacement by Phaser (McCoy et al., 2007). The structures were 
refined using cycles of manual rebuilding in COOT (Emsley et al., 2010) followed by 
refinement by Refmac5 (Murshudov et al., 1997). The final models were evaluated 
using Molprobity (Chen et al., 2010). 
 
2.3 Results and Discussion 
 Purification of CDK1, cyclin B and CKS2 and complex 
assembly 
To assemble CDK1-containing complexes, proteins were expressed and purified 
separately. CDK1 was produced in insect cells following recombinant baculovirus 
infection (as described in Material and Methods, Section 2.2.4). This virus produced 
circa 12 mg CDK1 /l of SF9 cell culture. The yield was improved by changing the media 
from SF900 III SFM (Life Technologies) to Lonza Insect XPRESS with L-Glutamine 
(Lonza). Cyclin B and CKS2 were successfully expressed and purified from 
recombinant E. coli cells.  Typical yields for cyclin B and CKS2 were around 3 mg/l LB 
and 5 mg/l LB respectively. Representative size-exclusion chromatograms for the final 
purification step in the preparation of CDK1, cyclin B and CKS2 are shown in Figures 
2-10, 2-11 and 2-12 respectively. Dimerization of GST generates a complex of a similar 
size to CDK1 and as a result the two proteins are not completely resolved by SEC 
(Figure 2.10 A). After cleavage of the GST tag, two bands can be seen in the expected 
positions because insect cells express their own endogenous GST of a slightly higher 
molecular weight of 27614 Da over the tag mass of 26000 Da. Consequently, the 
fractions containing CDK1 had to be pooled and re-applied to Glutathione Sepharose 
beads in order to get rid of residual GST. 
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Figure 2-10 CDK1 purification. 
(A) SEC chromatogram of the final CDK1 purification step. Absorbance at 280 nm is 
plotted against elution volume in ml. Fractions collected for SDS-PAGE analysis are 
identified with a red bar.  (B) Peak fractions (labelled with a red bar) were analysed by 
SDS-PAGE. Identified proteins are labelled on the side of the gel. The gel was 
subsequently stained with InstantBlue. 
Cyclin B has a thrombin cleavable C-terminal 6 x His tag that was exploited using metal 
chelate chromatography as a first purification step. After the elution step, cyclin B was 
buffer-exchanged into SEC/Binding buffer B to remove imidazole that would prevent 
thrombin cleavage. After the His tag was successfully cleaved, cyclin B was subjected 
to SEC for further purification (Figure 2-11 A). As can be seen (Figure 2-11 B, C) the 
His tag was successfully cleaved so all fractions were pooled and concentrated for 
further use.  
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Figure 2-11 Cyclin B purification. 
(A) SEC chromatogram of cyclin B following cleavage of the 6xHis tag. Absorbance at 
280 nm is plotted against elution volume in ml.  Fractions identified with a red bar were 
analysed by SDS-PAGE (B). (C) Comparison of cyclin B tagged with 6xHis and cyclin 
B cleaved from its tag. Gel has been spliced although positions of the bands relative 
to the ladder remains unchanged. 
 
CKS2 was also successfully purified using an affinity chromatography step with 
Glutathione Sepharose 4B beads to pull CKS2 out of solution by its GST tag, followed 
by size-exclusion chromatography to buffer exchange the sample and remove the 
excess GST and aggregates (Figure 2-12). All CKS2 containing fractions were pooled 
together for further experiments. 
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Figure 2-12 CKS2 purification.                                                                                                      
(A) SEC chromatography of CKS2. Absorbance at 280 nm is plotted against elution 
volume in ml. The first peak comprises GST dimer and is identified with a blue bar. The 
second peak is pure CKS2 identified with a red bar. (B) Fractions identified by the blue 
and red bars analysed by SDS-PAGE. Lane 1 contains the cleaved GSTCKS2 complex 
that has been injected into the Superdex 75 26_60 column. 
 
To assemble the CDK1-cyclin B-CKS2 complex, proteins were individually 
concentrated to circa 0.5 – 2 mg/ml and then mixed in a ratio of 1:1.5:2 CDK1:cyclin 
B:CKS1. Subsequent size-exclusion chromatography resolved the complex from the 
excess of individual components (Figure 2-13). Fractions containing the complex were 
combined and concentrated to 10 mg/ml for crystallisation trials. 
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Figure 2-13 Separation of CDK1-cyclin B-CKS2 complex. 
(A) Proteins were mixed together in a 1:1.5:2 ratio and subjected to Size Exclusion 
Chromatography (SEC). Absorbance at 280 nm is plotted against elution volume in ml. 
The complex elutes first and is identified with a red bar on the chromatogram.  Cyclin 
B and CKS2 were confirmed by SDS-PAGE and are identified with yellow and green 
bars respectively. (B) Fractions analysed by SDS-PAGE.  Proteins are identified on 
the side of the gel. 
 
 
 Structure determination of CDK1-containing complexes 
Sitting drop crystallization trials were initially performed for CDK1-CKS1 and CDK1–
cyclin B–CKS2 complexes as described in Materials and Methods using a variety of 
commercially available screens by Dr N. Brown. Attempts to crystallise CDK1 on its 
own and CDK1–cyclin B were not successful (Dr N. Brown, personal communication).   
Addition of proteins of the CKS family improved crystallisation significantly.  Drops were 
set in ratios of 1:1 and 2:1 (protein : well solution) in volumes of 200 nl or 400 nl and 
incubated at 4°C. Single crystals of CDK1–CKS1 were identified in 16-18% PEG 10K, 
0.1 M imidazole pH 8.2- 8.4. Small diffracting crystals were observed in Morpheus 
(Molecular Dimensions) condition B4 (12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 
12.5% v/v MPD, additive mix included 0.03 M of halide, 0.1 M MES/imidazole pH 6.5) 
which was further optimized by changes to the concentrations of PEG 1000, PEG 
3350, MPD and the pH of MES and to variations in the molecular masses of the PEGs. 
Few crystals grew from the optimized screens. The best diffracting ones came from a 
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well containing 5% PEG 4K, 10% PEG1K, 6.5% MPD and 0.1 M MES pH 6.7. Crystals 
of CDK1-CKS2 were cryo- protected by 30% ethylene glycol in mother liquor. The 
CDK1-cyclin B-CKS2 mother liquor does not require cryoprotection. Crystals were 
flash cooled in liquid nitrogen before data collection. 
A    
 
B 
 
Figure 2-14 Crystallisation trials of CDK1-cyclin B-CKS2 complex                       
Crystals from the first hit from Morpheus condition B4. Crystal size around 0.1 mm. (B) 
Crystals from the optimized screen. Crystal size around 0.25 mm. 
 
Datasets complete to 99.7% for CDK1-CKS1 and 99.6% for CDK1-cyclin B-CKS2 
respectively at 2.8 Å were processed using programs from the CCP4 suite (Bailey, 
1994) by Dr N. Brown and Professor M. Noble. Structures were solved by molecular 
replacement using program Phaser (McCoy et al., 2007). CDK2, cyclin B and CKS2 
were used as search models. Crystal structures were determined to a resolution of 2.8 
Å. A summary of the statistics for data collection and subsequent structure 
determination and refinement are presented in Table 2-2 and Table 2-3. 
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 CDK1-CKS1 CDK-cyclin B-CKS2 
Data collection 
Space group P21 P21 21 21 
Cell dimensions   
a, b, c (Å) 66.8, 147.5, 87.3 69.2, 70.2, 156.2 
α, β, ɣ (°) 90.0, 92.1, 90.0 90.0, 90.0, 90.0 
Resolution (Å) 75.10-2.80 (2.91-2.80) 52.19-2.80 (2.95-2.80) 
Rmerge 0.08 (0.89) 0.15 (0.57) 
I/δ(I) 15.3 (1.8) 7.2 (2.0) 
Completeness (%) 99.7 (98.8) 99.6 (97.9) 
Redundancy 5.9 (5.2) 3.6 (3.2) 
Refinement 
Resolution (Å) 75.10 – 2.80 78.10 - 2.80 
No. reflections 41.491 (1.787) 19.278 (1.014) 
Rwork /Rfree 0.234 (0.269) 0.209 (0.282) 
No. atoms   
Protein 23.200 10.377 
Ligand/ion 0 0 
Water 0 33 
B-factors   
Protein 36.2 39.2 
Ligand/ion NA NA 
Water NA 14.8 
Root mean-squared 
deviations 
  
Bond lengths (Å) 0.012 0.013 
Bond angles (°) 1.679 1.696 
Table 2-2 Summary of CDK1-CKS2 and CDK1-cyclinB-CKS2 X-ray data 
collection and refinement statistics 
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 Structural details of the CDK1-CKS1 complex 
The CDK1-CKS1 crystals contain four heterodimers with a large interface between the 
pairs in the asymmetric unit (Figure 2-15).   
A                                                                      B 
 
Figure 2-15 Crystal lattice of the CDK1-CKS2 complex. 
(A) CDK1–CKS1 ribbon (PDB code 4YC6) diagram representing the crystal lattice that 
contains 4 copies of a CDK1-CKS1 dimer in the crystallographic asymmetric unit. 
CDK1 molecules are coloured blue, with the C-helix (residues 47-57) in gold, the 
activation segment (146-173) in purple and the pre C-helix hairpin (40-46) coloured 
pink. CKS1 is coloured orange. (B) Schematic representation of the crystallographic 
asymmetric unit. Proteins are represented in the same colour scheme (Figure prepared 
by M. Noble). 
 
The CDK1 and CDK2 sequences show 65% similarity and a high degree of sequence 
conservation (Figure 2-16).  The sequences are conserved throughout their lengths, 
but there are three regions of around 10 amino acids long, Ser93—Ser103, Lys245-
Asn255 and the C terminal tail starting at Leu290, that diverge. These sequences are 
on the CDK1 surface. The first sequence is found on a loop linking αD and αE and 
includes the peptide sequence before the start of αH and is involved in CKS1 binding 
(Figure 2-16). The other two sequences lie away from that binding site but their high 
degree of conservation across CDK1 orthologues suggests that they may identify a 
binding site for other proteins.  
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Figure 2-16 Sequence alignment of human CDK1 and CDK2. 
Sequence alignment was performed by Jalview (Waterhouse et al., 2009) and identical 
sequences are highlighted in dark blue. Sequences that differ between CDK1 (Uniprot 
entry P06493) and CDK2 (Uniprot entry P24941) Ser93—Ser103, Lys245-Asn255, 
Leu290-Met297 of CDK1) are labelled with a green bar. 
 
 Comparison of the CDK1-CKS1 and CDK2-CKS1 structures 
Monomeric CDK1 adopts a classical bi-lobal protein kinase fold in an inactive 
conformation. The C helix is displaced out of the active site cleft and the non-
phosphorylated activation segment (defined as the sequence between the DFG and 
SPE motifs starting at Asp146 and finishing at Glu173) is positioned in a way which is 
not capable of substrate recognition (Figure 2-17). 
The major differences between CDK1-CKS1 and CDK2-CKS1 were observed in the 
activation segment, the loop that precedes the C helix and at the C-termini. In most 
CDK2 structures the activation segment is relatively mobile, but in some it forms a β-
hairpin that reaches the glycine-rich loop and occludes the active site from solvent (De 
Bondt et al., 1993). The glycine-rich loop of CDK1 is similar to CDK2 in its mobility but 
electron density for residues 156-162 was missing suggesting that the CDK1 activation 
segment is unstructured in this region. Both molecules form a short α-helical structure 
(αL12) before the DFG motif that displaces the C–helix from the active site (Figure 2-
17). The only difference between the two CDKs in this region is the location of the 
phenylalanine sidechain of the DFG motif. In CDK1 it is rotated towards the carbonyl 
moiety of Val64, whereas in CDK2 it points into the active site towards Asp185. There 
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are no visible differences between the structures at the end of the activation segments, 
but most of the CDK1 activation segment cannot be traced as it is not supported by 
the electron density map. After the activation segment the structures are well ordered 
and composed of a number of helices. Towards the C-terminus, after Leu290, the 
CDK1 sequence is disordered in all four CDK1 molecules in the asymmetric unit, but 
in CDK2 the comparable residues bend along the back of the fold towards the hinge. 
A 
 
B 
 
Figure 2-17 Comparison of CDK1-CKS1 and CDK2-CKS1. 
The complexes are shown in identical views and coloured in the same colours, CDK1 
(PDB code: 4YC6) (A) and CDK2 (PDB code: 1BUH) (B) are presented blue and CKS1 
is coral. Key regulatory elements are highlighted as follows, the C-helix (residues 46-
57) is coloured gold, the activation segment (CDK1, 146-173, CDK2, 145-172) is 
coloured red, and the αL-12 helix at the beginning of the activation segment is identified 
with an arrow. The pre C-helix hairpin (40-46) and the P- loop (13-16) are coloured 
pink and dark blue respectively. DFG and SPF motifs at the beginning and end 
respectively of the activation segment are represented in sticks and balls. Figure 
prepared using CCP4mg (McNicholas et al., 2011). 
 
The CKS1 binding site is highly conserved between CDK1 and CDK2 with very few 
different residues participating in the interaction (Figure 2-18). The positioning of CKS1 
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in both complexes is very similar. CKS1 binds to the CDK C-lobe using all four β 
strands, the β1-β2 loop and the β-hinge region to form a saddle-shaped interface 
between helix α5 and loop L14  (Bourne et al., 1996). The localisation of the binding 
site to the CDK C-terminal lobe suggests that binding to CKS2 is unlikely to trigger any 
conformational change in the CDK. This has been confirmed for CDK2 by comparison 
with structures that are not bound to CKS (Cox et al., 1994; Goldsmith and Cobb, 
1994). From the CKS1 side, most of one face across the whole molecule contributes 
residues to the CDK2 interaction.  
 
A 
 
B 
 
Figure 2-18 CDK-CKS2 binding interface. 
(A) The binding interface is highly conserved between CDK1 or CDK2 (PDB entry: 
1BUH) and CKS1. CDK residues within 7Å of CKS1 are identified on the surface of 
CDK1. Identical residues are shown in green, conserved residues are yellow and 
residues that are different between CDK1 and CDK2 are red. Figure prepared by Prof. 
M. Noble and used by agreement with (Brown et al., 2015). (B) The CDK molecule is 
represented in ice blue (illustrated with CDK1). The CKS1 β sheets that interact with 
the CDK are represented in different colours and labelled. The CDK L14 loop is 
coloured red and the α5 helix is coloured green. Figure B created using CCP4mg 
(McNicholas et al., 2011). 
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 The overall fold of the CDK1-cyclin B-CKS2 complex 
The structure of CDK1-cyclin B-CKS2 was initially determined by Dr N. Brown at 2.8 Å 
by molecular replacement as described in the Materials and Methods. Further 
optimisation of the protein preparation and crystallisation conditions (by addition of an 
ATP-competitive inhibitors, (Chapter 5) and additional crystal testing improved the 
resolution of the dataset to 2 Å (Table A1). The overall fold of CDK1-cyclin B is different 
to CDK2-cyclin A (Jeffrey et al., 1995) and to CDK4-cyclin D (Takaki et al., 2009). Due 
to changes in the orientation of the C helix in comparison to CDK2-cyclin A, CDK1 
makes less extensive interactions with cyclin B resulting in a 30% smaller binding 
interface.    
The most significant difference in the structure of the CDK1-cyclin B-CKS1 complex to 
that of CDK1-CKS1 is that in the ternary complex the CDK1 C terminal tail forms an 
amphipathic helix that, due to crystal packing, binds to a symmetry-related cyclin B 
molecule (Figure 2-18). As discussed earlier, the residues towards the CDK C termini 
might contain a potential protein binding site as it is a region that differs in sequence 
between the CDKs. It can be observed that the hydrophobic residues Leu290, Ile294 
and Met297 of CDK 1 bind to the cyclin B groove of a neighbouring molecule in the 
lattice. A similar groove exists on the surface of cyclin A which has previously been 
shown to bind to the CDK inhibitor p27KIP1 (Russo et al., 1996a) (Figure 2-19). 
Respective residues Leu41, Leu45 and Cys49 of p27KIP1 bind to cyclin A in a similar 
manner to CDK1 binding to cyclin B. The lattice contact suggests that the C terminal 
tail of CDK1 has a tendency to unfold away from the main fold and that this surface of 
cyclin B has the potential to mediate multiple protein interactions. 
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A 
 
B 
 
Figure 2-19 Interactions between CDK1 C-terminal tail and cyclin B in the 
crystal lattice. 
(A) Complexes labelled as Comp1 and Comp2. The C terminal tail of CDK1 (284-297) 
binds to the groove of cyclin B from the neighbouring molecule in the lattice. CDK1 is 
coloured ice blue, the cyclin B is coloured green and the CKS1 subunit is orange. The 
binding site of C-terminal tail and cyclin B from another symmetry unit is magnified. 
CDK1 hydrophobic residues contributing to the cyclin B interaction, (Leu290, Ile294, 
and Met297) are drawn in ball and stick mode. (B) Structure of CDK2-cyclin A with 
p27KIP1 (PDB code IJSU).  CDK2 is coloured in ice blue, cyclin A is coloured green 
and p27KIP is pink. p27KIP  residues  Leu41, Leu45 and Cys49 bind to cyclin A in a 
manner similar to that observed between the CDK1 C terminal helix and cyclin B. 
Figures prepared using CCP4mg (McNicholas et al., 2011). 
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 Comparison of CDK1-cyclin B-CKS2 with CDK2 and CDK4 
containing structures 
CDK1-cyclin B has a different structure in comparison to CDK2-cyclin A and to CDK4-
cyclin D. Cyclin A binding to CDK2 leads to reorganisation of residues forming the 
active site by melting the αL12 helix and moving the C helix inwards. These re-
arrangements bring residues Arg50 on the C helix, Arg126 of the catalytic loop and 
Arg150 of the activation segment into positions ready to accept peptide substrate 
within the activation segment. Cyclin binding also re-organises the activation segment 
to form a platform for peptide substrate recognition. Once bound to cyclin A, CDK2 
adopts a conformation that requires very little change to be able to accept the two 
substrates for phosphorylation (Figure 2-20).  
A        CDK1 – cyclin B 
 
B         CDK2 – cyclin A 
 
C        CDK4 – cyclin D 
 
D 
 
E 
 
F 
 
Figure 2-20 Comparison of CDK1-cyclin B-CKS2 structure with CDK2-cyclin A 
and unphosphorylated CDK4-cyclin D3. 
 (A, D) CDK1-cyclin B-CKS2, (B, E) CDK2-cyclin A (PDB code 1FIN), (C, F) CDK4-
cyclin D3 (PDB code 3G33). All complexes are shown in the same view. Cyclins are 
depicted green, CDKs are ice blue, C helix of CDKs is coloured gold and activation 
segment is red. CKS2 is coral. Figures prepared using CCP4mg (McNicholas et al., 
2011). 
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CDK4, in contrast to CDK2, does not adopt an active conformation even when bound 
to cyclin D3. In the CDK4-cyclin D3 complex, the C helix remains displaced from the 
active site and the activation segment, although ordered, does not form contacts with 
the cyclin subunit. Respective residues from the C helix, catalytic loop and activation 
segment, (Arg55, Arg139, Arg163), as well as Thr172 (the phosphorylated residue 
equivalent to Thr160 in CDK2), remain dispersed. The activation segment is also not 
in a conformation that would recognise a peptide for phosphorylation.  From these 
observations it has been proposed that CDK4-cyclin D complexes proceed through a 
substrate-assisted catalytic mechanism. 
CDK1-cyclin B is yet different but more similar to CDK2-cyclin A. One major difference 
between the two structures is in the activation segment, which forms extensive 
contacts with cyclin A in the CDK2 complex but shows fewer connections to cyclin B 
in CDK1-containing structures. The distinctive feature of the CDK1 activation segment 
is the β hairpin which has residues Phe153 and Gly154 at its tip. The hairpin sits in a 
hydrophobic groove formed by the aliphatic portion of Arg299, Leu178 and His304 of 
cyclin B. An interesting feature of CDK1 binding to cyclin B is that the cyclin sequence 
forms a loop after residues Met261 and Tyr262 at the end of the α3 helix which then 
occludes Ile155 of CDK1 from solvent (Figure 2-21). This movement of the cyclin 
behind the activation segment creates a solvent filled cleft also seen in the CDK4-cyclin 
D and CDK9-cyclin T structures (Baumli et al., 2008) but not in CDK2-cyclin B (Brown 
et al., 2007). 
 
Figure 2-21 CDK1 interactions with cyclin B. 
CDK1 forms a β hairpin with residues Phe153 and Gly154 at the tip. These residues 
make tight interactions with the cyclin B groove formed by Arg299, Leu178 and His304 
which are characteristic only for the CDK1-cyclin B structure. Cyclin B is coloured 
green, structural features of CDK1 identified as follows: N terminal lobe grey, C 
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terminal lobe, ice blue, activation segment, red, and the C helix is coloured gold. Figure 
prepared using CCP4mg (McNicholas et al., 2011). 
As a result of the movements at the tip of the CDK1 activation loop described above, 
the loop then bends upwards at Ile157 and causes the isoleucine sidechain to point 
towards the C helix. To accommodate the sidechain, the C-helix and DFG motif are 
displaced further out of the active site cleft creating a further difference with the CDK2 
structure in this region. The distance between the side chain carboxylate of Glu51 and 
the Lys33 ε amino group extends to 5.0 Å in CDK1 compared to 3.1 Å in CDK2-cyclin 
A. The arginines that coordinate the activation segment phosphothreonine (Arg50, 
Arg127 and Arg151) are also displaced and form interactions centred around CDK1 
Tyr181 and also with the backbone carbonyl of cyclin B Lys257. 
The activation segment forms the platform that recognises the peptide substrate to 
either side of the phosphoacceptor residue (Brown et al., 1999). Cyclin A binding to 
CDK2 remodels the position of the activation segment so that it requires very few 
changes to adopt the active conformation and be ready to accept and phosphorylate a 
substrate. The smaller CDK1-cyclin B interface forms fewer interactions between the 
activation segment and the cyclin unit and as a result the activation segment requires 
considerable re-arrangement to be able to recognise a peptide substrate.  
To summarise, CDK1, CDK2 and CDK4 in complexes with their respective cyclins 
adopt different structures that may contribute to their different patterns of substrate 
phosphorylation. The fact that CDK1 forms fewer bonds with cyclin B then CDK2 
suggests this feature to be a property of CDK1 rather than the cyclin. A comparative 
study of CDK2 binding to cyclin A (Lee and Nurse, 1987) and cyclin B (Brown et al., 
2007) shows that CDK2 adopts an identical structure bound to either cyclin. 
 Attempts to determine structures for CDK1-cyclin A and 
CDK1-cyclin A-CKS2  
Bovine cyclin A2 was successfully expressed in E. coli cells. After loading on a 
prepacked Ni-NTA column cyclin A was washed with increasing concentrations of 
imidazole to significantly improve its purity (Figure 2-22 A, B). The first peak, eluted 
after washing the column with 50 mM imidazole, contains a substantial mix of other 
proteins as well as cyclin A (Figure 2-22 B). SDS-PAGE analysis of fractions from the 
following two peaks (Figure 2-22 C) shows that cyclin A eluted at 75 mM and 100 mM 
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imidazole contains significantly smaller amounts of other proteins. Fractions of peaks 
2 and 3 were pooled and applied to the Superdex 75 26_60 column for further 
purification. Although MgCl2 was added to prevent aggregation after the elution from 
the Ni-NTA column, slight aggregation did occur as evidenced by the peak around 100 
ml. Fractions of the peak eluting around 170 ml were collected and analysed by SDS-
PAGE gel (Figure 2-22 C, D). Cyclin A appeared very clean on a gel so fractions were 
pooled together for complex assembly.        
CDK1 was expressed and purified and mixed with cyclin A at a molar ratio of 1:1.3 
CDK1:cyclin A and at micromolar concentration so that cyclin A would saturate all of 
the CDK1 in solution. To separate the CDK1-cyclin A complex from the excess of 
unbound cyclin A, the mixture was subjected to another run on the Superdex 75 26_60 
column (Figure 2-23 A) followed by SDS-PAGE analysis.  
 
A 
 
B 
 
C 
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D 
 
E 
 
Figure 2-22 Purification of bovine cyclin A. 
(A) Affinity chromatogram of cyclin A. Absorbance at 280 nm is plotted against elution 
volume in ml. Cyclin A bound to Ni-NTA beads was washed with increasing 
concentrations of imidazole (in 25 mM increments). Two eluted peaks, marked by 
the red and blue bars were collected and analysed by SDS-PAGE (B). (C) SEC of 
cyclin A after affinity chromatography. The second peak is cyclin A identified with 
a red bar and fractions run on SDS-PAGE (D). 
 
A 
 
B 
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C 
 
Figure 2-23 Purification of CDK1-cyclin A. 
(A) Size-exclusion chromatogram of the CDK1-cyclin A complex. The CDK1-cyclin A 
peak is identified with a red bar, excess of cyclin A with a blue bar. Absorbance at 280 
nm is plotted against elution volume in ml. The chromatogram below shows the SEC 
standards (albumin, 66kDa; carbonic anhydrase, 29 kDa; cytochrome C, 12.4 kDa; 
aprotinin, 6.5 kDa) to calibrate the column. (B) SDS-PAGE analysis of fractions from 
the peaks indicated by red and blue bars. The lanes labelled 1, 2 and 3 contain 
respectively pure CDK1, pure cyclin A, and CDK1-cyclin A taken for crystallisation.  
 
The CDK1-cyclin A complex was concentrated to 1 mg/ml and divided into two 
samples. One was concentrated to 10 mg/ml, the second was mixed with 3-fold excess 
of compound 23 (Wyatt et al., 2008) and further concentrated to 10 mg/ml, final DMSO 
concentration 2%. Crystal trays were set using a variety of crystallisation screens. 
Crystals appeared in Tacsimate 70% (Figure 2-24) but did not diffract. The 
crystallisation screens were then widened by exploring different concentrations of 
Tacsimate and addition of NaCl in different concentrations (Figure 2-24 A). In new 
crystallisation conditions, more crystals grew at around 50% Tacsimate, and the results 
indicated the importance of pH. pH 7.0 and 7.5 gave the most promising crystallisation 
conditions. Crystals were harvested but diffraction was very poor. In a subsequent 
round of optimisation ethylene glycol was introduced into the screen at low 
concentrations of NaCl and at a pH of 7.0 with the Tacsimate mixture as the buffer 
(Figure 2-24 B). To stabilize the protein three compounds were added, AZD 5438, RO-
2206 and CGP74514A. These compounds were chosen based on crystallisation trials 
of CDK1-cyclin B-CKS2 where well diffracting crystals were grown with these inhibitors. 
Crystals were harvested but unfortunately did not diffract. 
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B 
 
C 
 
D 
 
Figure 2-24 Home designed crystallisation screens for the CDK1-cyclin A 
complex. 
(A) Screen was designed by changing the concentration of Tacsimate across the plate 
from row A to H from 30 to 70% exponentially, NaCl from 0 to 0.5 M from column 1 to 
column 4, 5 to 8, and 9 to 12 with the plate split into 3 fields with a different pH of 
Tacsimate. (B) Sample of crystals grown in well C8. (C) Homemade screen. Screen 
was set into four fields of repeats, where Tacsimate pH 7.0 was varying from 30 to 
60% in columns 1 to 6 and 7 to 12 and ethylene glycol was screened from 0 to 25% in 
rows A to D and E to H exponentially. The concentration of NaCl was 0.16 M across 
the plate. Different inhibitors were used in each quarter of a plate. (D) Crystals 
produced in well D4. 
 
Because CDK1 in complex with cyclin B or on its own did not form crystals, but addition 
of CKS2 lead to complex crystallisation, the same strategy was applied in an attempt 
to crystallise a CDK1-cyclin A-CKS2 complex. To improve the quality of the crystals 
and increase the possibility of diffraction, CKS2 was introduced to the complex. Purified 
proteins were mixed in a molar ratio of 1:1.5:1.5 CDK1:cyclin B:CKS2 and the complex 
was separated on a Superdex 75 26_60 size exclusion column. The ternary complex 
was successfully separated from the individual components (Figure 2-25). 
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B 
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Figure 2-25 Purification of a CDK1-cyclin A-CKS2 complex. 
(A) Size-exclusion chromatogram of CDK1-cyclin A-CKS2. The elution position of the 
complex is identified by the red bar. Absorbance at 280 nm is plotted against elution 
volume in ml. The chromatogram below shows the SEC standards (albumin, 66 kDa; 
carbonic anhydrase, 29 kDa; cytochrome C, 12.4 kDa; aprotinin, 6.5 kDa) to calibrate 
the column. (B) SDS-PAGE analysis of fractions identified by the purple bar. The first 
three samples labelled on the gel are the individual proteins (1, CDK1; 2, cyclin A; 3, 
CKS2) and the column load (mix of CDK1, cyclin A and CKS2 in ratio 1:1.5:1.5) labelled 
4 on the gel. (C) Crystals grown in the PACT premier TM HT96. Crystal size around 
0.1 mm.  
Fractions of the CDK1-cyclin A-CKS2 peak were pooled together and concentrated 
with or without the inhibitors AZD5438, RO-2206 and CGP74514A. Protein complex 
without added inhibitor formed crystals in three wells of the PACT premier TM HT96 
screen (Molecular Dimensions) incubated at RT. They were E8 (0.2M Sodium 
sulphate, 20% w/v PEG 3350), G8 (0.2M Sodium sulphate, 0.1M Bis-Tris propane pH 
7.5, 20% w/v PEG 3350) and F8 (0.2M Sodium sulphate, 0.1M Bis-Tris propane pH 
6.5, 20% w/v PEG 3350). Crystals were cryo-protected in 30% ethylene glycol in 
mother liquor of a corresponding well followed by harvesting by a nylon loop and flash 
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cooling in liquid nitrogen. Despite their promising appearance, the crystals did not 
diffract well and a dataset was not collected.  
 
2.4 Conclusions 
This chapter focuses on novel aspects of the structures of CDK1 and CDK1-containing 
complexes. One significant difference between CDK1 and CDK2 bound to their 
cognate cyclin partners is the conformation of the activation segment. CDK1 and CDK2 
have a highly conserved activation segment sequence but there are reported 
differences in activatory phosphorylation of both kinases on Thr160 in CDK2 and 
Thr161 in CDK1 by CAK, the CDK7-cyclin H complex. CAK phosphorylates CDK1 and 
CDK2 in a different way. It has been reported that CDK2 can be phosphorylated as a 
monomer before cyclin binding whereas CDK1 requires cyclin binding for activation 
segment phosphorylation (Merrick et al., 2008). The structure of monomeric CDK2 is 
well ordered at the termini of the activation loop but the corresponding region of CDK1 
is disordered. When it comes to the complexes, CDK1 when bound to cyclin B 
undergoes significant changes in this region and its activation segment is better 
ordered but it still cannot be traced completely suggesting that it remains disordered 
around Thr161. CDK1-cyclin B is a better substrate for CDK7-cyclin H than monomeric 
CDK1 (Larochelle et al., 2007). CDK2 in complex with cyclin A is more susceptible to 
phosphorylation as well (Merrick et al., 2008). This observation leads to the model that 
the conformational flexibility of the activation segment is a factor in the efficiency of its 
phosphorylation by CAK.  
The structures of CDK1 that have been solved are not phosphorylated on the activation 
segment. The superposition of the activation segment of CDK2 phosphorylated on 
T160 and unphosphorylated CDK1 also revealed some differences (Figure 2-26). The 
Cα atoms of the threonine phosphoacceptor residues are located 5 Å apart which 
suggests that for engaging CDK7-cyclin H for phosphorylation effectively they have to 
adjust their positions. 
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Figure 2-26 Overlay of the CDK1 and pT160CDK2 activation segments. 
CDK1 is represented in ice blue and pCDK2 in lilac. The CDK1 activation segment is 
dark blue and the CDK2 activation segment is red (PDB entry:1YC3 and 1QMZ 
respectively). Figure prepared using CCP4mg (McNicholas et al., 2011). 
 
Another interesting feature of CDK1-cyclin B that is not present in CDK2-cyclin A but 
is reported in CDK4-cyclin D and CDK9-cyclin T structures (Baumli et al., 2008) is a 
cleft between the C terminal lobes of CDK1 and cyclin B. A similar cleft in CDK9-cyclin 
T has been shown to play role in binding the HIV regulatory protein TAT (Tahirov et al., 
2010). The role (if any) in CDK1 is still to be discovered, but it does suggest a possible 
novel protein binding site that can be investigated in the future. 
To summarise all the data presented, the structures of CDK1-CKS2 and CDK1-cyclin 
–CKS2 have revealed distinct features that can be connected to its function in a cell 
and explain the mechanism of its activation.  The flexibility of the CDK1 activation 
segment and its general plasticity may be characteristics that are required for it to carry 
out its unique functions in the cell.   
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 Functional characterisation of CDK1 
3.1  Introduction 
 Observations from the cellular studies 
The main function of CDKs is phosphorylation of their substrates to orchestrate cell 
cycle progression. Some CDKs can phosphorylate many substrates on few or many 
phosphorylation sites (for example CDK1), whereas others are very specific, such as 
CDK4/6 and their substrate specificity is very limited. Regulation of CDK activity 
towards their substrates has been investigated by different groups. One hypothesis 
proposed based on investigation in fission yeast is that of a threshold or quantities 
model (Stern and Nurse, 1996) (Coudreuse and Nurse, 2010). The regulation of 
substrate specificity based on this model can depend on the affinity of binding sites 
and on their availability (Schulman et al., 1998). For example, where higher affinity 
sites when phosphorylated do not show any effects and only ones phosphorylated later 
do have a biological effect (Kim and Ferrell, 2007). Experiments performed in budding 
yeast which contain only one CDK that is activated by different cyclins has led to 
another model that emphasizes the role of the cyclin partner in substrate choice. A 
number of studies have shown that cyclins in budding yeasts are mostly 
interchangeable. For example, overexpression of Clb5 rescues cells lacking Clns but 
cells in the absence of Clb5 are also viable (Epstein and Cross, 1992). A more recent 
quantitative study has shown that CDK1-Clb5 phosphorylates 24% of chosen 
substrates more efficiently then CDK1-Clb2 (Loog and Morgan, 2005). The 
mechanisms controlling the selection of specific multiple phosphorylation sites by 
CDK1-cyclin-CKS1 have been described (Koivomagi et al., 2013). The importance of 
(i) distances between the phosphorylation sites, (ii) distribution of phosphoacceptors 
along the substrate, and (iii) positioning of cyclin docking motifs were all analysed. 
Different phosphorylation sites on the same protein can be targeted by different 
kinases and result in different outcomes. For example, cyclin E contains three major 
sites for phosphorylation: Ser372, Tyr380 and Ser384 (Welcker et al., 2003). All three 
can be phosphorylated by CDK2 in vitro but in vivo Tyr380 phosphorylation has been 
shown not to be CDK2 dependent (Welcker et al., 2003). It has been shown that for 
cyclin E turnover by Fbw7 it has to be phosphorylated on Ser384 and by GSK3 on 
Tyr380. 
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Animal cells have evolved to have a higher number of CDKs than the yeasts S. 
cerevisiae and S. pombe, but also to have a number of cyclins with more strictly defined 
functions. With CDK1 being the only essential CDK (Santamaria et al., 2007) its 
partners cyclin A and B are important cyclins. cyclin A is required for DNA replication 
and cyclin B for mitosis (Brandeis et al., 1998; Santamaria et al., 2007; Kalaszczynska 
et al., 2009). Cyclin E and cyclin D are not essential for the cell cycle (Geng et al., 
2003; Kozar et al., 2004), however cyclin E is required for chromosome 
endoreduplication and for cell cycle re-entry from quiescence (Geng et al., 2003).  
  Cyclins as CDK1 and CDK2 partners 
CDK1 is partnered by cyclins A and B, and CDK2 is partnered by cyclins A and E.  In 
G2 phase both cyclin A2 and cyclin B1 bind CDK1 as both CDK1-cyclin A2 and CDK1-
cyclin B1 complexes are required for induction of mitosis. Cyclin B is generally 
considered as an essential CDK1 activator for mitotic entry although studies focusing 
on the role of cyclin A have demonstrated its importance for nuclear envelope 
breakdown (D Gong, 2007). At the start of mitosis, cyclin A is degraded and CDK1 
activity is maintained by cyclin B. The cyclins that promote mitotic transition are cyclin 
A2 and cyclin B1 and they cannot be substituted by other cyclins in mammalian cells 
(Satyanarayana and Kaldis, 2009). Type B cyclins are degraded in late mitosis by the 
anaphase-promoting complex also known as the cyclosome (APC/C), a core 
component of the ubiquitin-dependent proteolytic machinery that controls timely 
destruction of securins and cyclins (Hershko and Ciechanover, 1998; Kramer et al., 
2000; Peters, 2002). Degradation of cyclin B leads to inactivation of CDK1 which allows 
chromosome separation, cytokinesis and completion of mitosis. 
In mammalian cells two cyclin A paralogues exist, cyclin A2 is normally expressed in 
most cell types, and cyclin A1 is mainly associated with testis (Sweeney et al., 1996). 
Within the testis where both cyclins are present, they exhibit very different patterns of 
expression (Ravnik and Wolgemuth, 1999). Cyclin A1 in comparison to cyclin A2 has 
a distinctive influence on the biochemical properties of CDK1 and CDK2 and on 
regulation of their activity (Joshi et al., 2009). It also has been demonstrated that the 
activities of CDK1 and CDK2 bound to both cyclins can vary depending on the nature 
of the substrate (Almon et al., 1993). p53 is expressed in pachytene spermatocytes  
and consequently was used as a substrate to compare the kinase activities of CDK1 
and CDK2 in complexes with cyclin A1 and A2. This study showed that in vitro CDK1-
cyclin A1 phosphorylates p53 more efficiently that CDK1-cyclin A2 suggesting that the 
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cyclin can influence the kinase activity towards the substrate, and providing an 
explanation for cyclin A1 expression mainly in testis (Joshi et al., 2009).  
 
A1     METGFPAIMYPGSFIGGWGEEYLSWEGPGLPDFVFQQQPVESEAMHCSNPKSGVVLATVA 60 
A2     ----MLGNSAPGPATREAGSAL----------LALQQTALQEDQ-ENINPEK-------- 37 
           : .   **      *.            :.:**  ::.:  .  **:.         
 
 
A1     RGPDACQILTRAPLGQDPPQRTVLGLLTANGQYRRTCGQGITRIRCYSGSENAFPPAGKK 120 
A2     ----------AAP-VQQPRTRAALAVLKSG-NPRGLAQQQRPKTR-------RVAPLKDL 78 
                  **  *:*  *:.*.:*.:. : *  . *   : *        . *  .  
 
 
A1     ALPDCGVQEP------PKQGFDIYMDELEQGDRDSCS------VREGMAFEDVYEVDTG- 167 
A2     PVNDEHVTVPPWKANSKQPAFTIHVDEAEKEAQKKPAESQKIEREDALAFNSAISLPGPR 138 
        : *  *  *       : .* *::** *:  :.. :       .:.:**:.. .:     
 
                                           »                 αN-term 
A1     TLKSDLHFLLDFNTVSPMLVDSSLLSQSEDISSLGTDVINVTEYAEEIYQYLREAEIRHR 227 
A2     KPLVPLDYPMDGSFESPHTMDMSIILEDEK----PVSVNEVPDYHEDIHTYLREMEVKCK 194 
       .    *.: :* .  **  :* *:: :.*.     ..* :* :* *:*: **** *:: : 
 
                             α1                  α2 
A1     PKAHYMKKQPDITEGMRTILVDWLVEVGEEYKLRAETLYLAVNFLDRFLSCMSVLRGKLQ 287 
A2     PKVGYMKKQPDITNSMRAILVDWLVEVGEEYKLQNETLHLAVNYIDRFLSSMSVLRGKLQ 254 
       **. *********:.**:***************: ***:****::*****.********* 
 
             α3               α4              α5                α1’ 
A1     LVGTAAMLLASKYEEIYPPEVDEFVYITDDTYTKRQLLKMEHLLLKVLAFDLTVPTTNQF 347 
A2     LVGTAAMLLASKFEEIYPPEVAEFVYITDDTYTKKQVLRMEHLVLKVLTFDLAAPTVNQF 314 
       ************:******** ************:*:*:****:****:***:.**.*** 
 
                         α2’                      α3’ 
A1     LLQYLRRQ-GVCVRTENLAKYVAELSLLEADPFLKYLPSLIAAAAFCLANYTVNKHFWPE 406 
A2     LTQYFLHQQPANCKVESLAMFLGELSLIDADPYLKYLPSVIAGAAFHLALYTVTGQSWPE 374 
       * **: :*  .  :.*.** ::.****::***:******:**.*** ** ***. : *** 
 
         α4              α5              αC-term                 « 
A1     TLAAFTGYSLSEIVPCLSELHKAYLDIPHRPQQAIREKYKASKYLCVSLMEPPAVLLLQ 465 
A2     SLIRKTGYTLESLKPCLMDLHQTYLKAPQHAQQSIREKYKNSKYHGVSLLNPPETLNL- 432 
       :*   ***:*..: *** :**::**. *:: **:****** ***  ***::** .* *  
Figure 3-1 Alignment of human cyclin A1 and human cyclin A2 sequences. 
Human cyclin A1 (Uniprot entry P78396) and human cyclin A2 (Uniprot entry P20248) 
sequence alignment. Residues in α helices from the structure of cyclin A2 (PDB: 1VIN) 
are marked red with the helices labelled. MRAIL residues are underlined and the 
crystalized fragment (171-433) is identified by arrows («). Identical residues are 
marked with a star underneath the sequence and conserved residues are highlighted 
with a colon (:) or dot (.). Highly homologous CBF1 is marked with a red box and less 
homologous CBF2 is marked with a blue box. Sequences aligned using Clustal Omega 
(Sievers et al., 2011). Overall, human cyclins A1 and A2 share 43 % identity. 
Despite playing different roles, the sequences of human cyclin A1 and cyclin A2 are 
relatively conserved, sharing 208 identical amino acids (43%) as well as 114 similar 
ones (Sievers et al., 2011). The sequences have 88% identity in a region of CBF1 
(Figure 3-1). However, there are several non-conserved amino acids in the area of 
CDK binding that have been proposed to modulate the CDK-cyclin interaction (Figure 
3-1). 
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Cyclin B, in contrast to cyclin A, only forms a complex with CDK1. Two types of cyclin 
B were identified in mammals, B1 (Chapman and Wolgemuth, 1992) (Pines and 
Hunter, 1989) and B2 (Chapman and Wolgemuth, 1993) and a third more distant cyclin 
B3 in chicken, nematodes, frogs and flies (Kreutzer et al., 1995). Human cyclin B1 and 
cyclin B2 compared by the program Clustal Omega (Sievers et al., 2011) show identity 
at 213 residues (49%) and share similar residues at a further 106 aligned positions 
(Figure 3-2). Although there is not much similarity in the first ~100 residues, the 
following ~300 that encode the tandem CBF1 and CBF2 folds are well conserved.  
Cyclin B3 does not align as well to cyclin B1 and cyclin B2 (8.6% and 8.5% of identical 
positions and 37% and 33% similarity between cyclin B3 and cyclins B1 and B2 
respectively). The presence of cyclin B1 and cyclin B2 in frogs suggests that these 
genes have diverged at an early stage of evolution. In the majority of dividing cells the 
cyclins are co-expressed but at different locations: cyclin B1 is normally associated 
with microtubules and cyclin B2 with intracellular membranes (Tombes et al., 1991; 
Ookata et al., 1993; Jackman et al., 1995). The  fact that cyclin B1 enters the nucleus 
in late G2 phase but cyclin B2 does not, as well as their different expression patterns 
during murine spermatogenesis (Chapman and Wolgemuth, 1993) and in Xenopus 
oocytes (Kobayashi et al., 1991) suggests that these two variants play different roles 
in preparing cells to enter mitosis.  
 
B1     MALRVTRNSKINAENKAKINMAGAKRVPTAPAAT-SKPGLRPRTALGDIGNKVSEQLQAK 59 
B2     MAL--LRRPTVSSDL-ENI--------DTGVNSKVKSHVTIRRTVLEEIGNRVTTRAAQV 49 
       ***   *. .:.::   :*         *.  :. ..     **.* :***:*: :     
  
 
B1     MPMKKEAKPSATGKVIDKKLPKPLEKVPMLVPVPVSEPVPEPEPEPEPEPVKEEKLSPEP 119 
B2     AK-----------KAQNTKVPVQ--------PTKTTNVNKQLKPTASVKPVQMEKLAPK- 89 
                    *. :.*:*          *. .::   : :*  . :**: ***:*:  
 
                                                     » 
B1     ILVDTASPSPMETSGCAPAEEDLCQAFSDVIL-AVNDVDAEDGADPNLCSEYVKDIYAYL 178 
B2     ----GPSPTP---EDVSMKEENLCQAFSDALLCKIEDIDNEDWENPQLCSDYVKDIYQYL 142 
             **:*   .. :  **:*******.:*  ::*:* **  :*:***:****** ** 
 
       αN-term                      α1                  α2               
B1     RQLEEEQAVRPKYLLGREVTGNMRAILIDWLVQVQMKFRLLQETMYMTVSIIDRFMQNNC 238 
B2     RQLEVLQSINPHFLDGRDINGRMRAILVDWLVQVHSKFRLLQETLYMCVGIMDRFLQVQP 202 
       ****  *::.*::* **::.*.*****:******: ********:** *.*:***:* :  
 
                  α3                 α4              α5 
B1     VPKKMLQLVGVTAMFIASKYEEMYPPEIGDFAFVTDNTYTKHQIRQMEMKILRALNFGLG 298 
B2     VSRKKLQLVGITALLLASKYEEMFSPNIEDFVYITDNAYTSSQIREMETLILKELKFELG 262 
       * :* *****:**:::*******: *:* **.::***:**. ***:**  **: *:* ** 
 
              α1’             α2’                        α3’ 
B1     RPLPLHFLRRASKIGEVDVEQHTLAKYLMELTMLDYDMVHFPPSQIAAGAFCLALKILDN 358 
B2     RPLPLHFLRRASKAGEVDVEQHTLAKYLMELTLIDYDMVHYHPSKVAAAASCLSQKVLGQ 322 
       ************* ******************::******: **::**.* **: *:*.: 
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              α4                 α5            αC-term                         
B1     GEWTPTLQHYLSYTEESLLPVMQHLAKNVVMVNQGLTKHMTVKNKYATSKHAKISTLPQL 418 
B2     GKWNLKQQYYTGYTENEVLEVMQHMAKNVVKVNENLTKFIAIKNKYASSKLLKISMIPQL 382 
       *:*. . *:* .***:.:* ****:***** **:.***.:::*****:**  *** :*** 
 
                     « 
B1     NSALVQDLAKAVAKV- 433 
B2     NSKAVKDLASPLIGRS 398 
       **  *:***. :     
Figure 3-2 Alignment of human cyclin B1 and human cyclin B2 sequences. 
Human cyclin B1 (Uniprot entry P14635) and human cyclin B2 (Uniprot entry O95067) 
sequences aligned. Residues in α helices from the structure of cyclin B1 (PDB code: 
2B9R) are marked red with the helix name above. The MRAIL motif is underlined and 
the crystalized fragment (residues 165-433) is identified by the » at the beginning and 
« at the end. Identical residues are marked with a star underneath the sequence and 
conserved are highlighted with a colon (:) or dot (.). Highly homologous CBF1 is 
marked with a red box and less homologous CBF2 is marked with a blue box. 
Sequences aligned using Clustal Omega (Sievers et al., 2011). Overall, human cyclins 
B1 and B2 share 49% identity. 
Cyclin E also plays a crucial role in CDK2 regulation. Cyclin E is known as a regulator 
of CDK2 but is also reported to be associated with other CDKs (Moroy and Geisen, 
2004). Its functions in cells are both CDK dependent and independent. In complex with 
CDK2 it is necessary for the formation of pre-replication complexes on DNA as cells 
re-enter the cell cycle from quiescence (Geng et al., 2003). It also interacts with 
centromeres and stimulates their duplication (Moroy and Geisen, 2004), and plays 
roles in histone synthesis (Ma et al., 2000) and cell cycle progression (Hoffmann et al., 
1994). Cyclin E has a 20 amino acid sequence which plays a role in centosomal 
localisation and promotes DNA synthesis in a CDK-independent manner (Matsumoto 
and Maller, 2004; Geng et al., 2008). Cyclin E has two paralogues in mammalian cells, 
cyclin E1 and cyclin E2. Cyclin E1 was first described in 1991 (Koff et al., 1991) and 
cyclin E2 in 1998 (Lauper et al., 1998). Alignment by Clustal Omega identifies 46.5% 
identity between the two paralogues and 25% similarity (Figure 3-3). 
E1     MPRERRERDAKERDTM----KEDGGAEFSARSRKRKANVTVFLQDPDEEMAKIDRTARDQ 56 
E2     MSRRSSRLQAKQQPQPSQTESPQEAQIIQAKKRKTTQ----DVKKRREEVTKKHQYEIRN 56 
       * *.  . :**::       . : .  :.*:.** .      ::.  **::* .:    : 
                                       »             αN-term 
E1     CGSQPWDN-NAVCADPCSLIPTPDKEDDDRVYPNSTCKPRIIAPSRGSPLPVLSWANREE 115 
E2     C----WPPVLSGGISPCIIIETPHKEIGTSDFSRFTNYRFKNLFINPSPLPDLSWGCSKE 112 
       *    *    :   .** :* **.** .   : . *         . **** ***.  :* 
                            α1                  α2               
E1     VWKIMLNKEKTYLRDQHFLEQHPLLQPKMRAILLDWLMEVCEVYKLHRETFYLAQDFFDR 175 
E2     VWLNMLKKESRYVHDKHFEVLHSDLEPQMRSILLDWLLEVCEVYTLHRETFYLAQDFFDR 172 
       **  **:**. *::*:**   *  *:*:**:******:******.*************** 
 
            α3                α4               α5 
E1     YMATQENVVKTLLQLIGISSLFIAAKLEEIYPPKLHQFAYVTDGACSGDEILTMELMIMK 235 
E2     FMLTQKDINKNMLQLIGITSLFIASKLEEIYAPKLQEFAYVTDGACSEEDILRMELIILK 232 
       :* **::: *.:******:*****:****** ***::********** ::** ***:*:* 
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          α1’                    α2’                    α3’ 
E1     ALKWRLSPLTIVSWLNVYMQVAYLNDLHEVLLPQYPQQIFIQIAELLDLCVLDVDCLEFP 295 
E2     ALKWELCPVTIISWLNLFLQVDALKDAPKVLLPQYSQETFIQIAQLLDLCILAIDSLEFQ 292 
       ****.*.*:**:****:::**  *:*  :****** *: *****:*****:* :*.***  
 
          α4’              α5’                               αC-term 
E1     YGILAASALYHFSSSELMQKVSGYQWCDIENCVKWMVPFAMVIRETGSSKLKHFRGVADE 355 
E2     YRILTAAALCHFTSIEVVKKASGLEWDSISECVDWMVPFVNVVKSTSPVKLKTFKKIPME 352 
       * **:*:** **:* *:::*.** :* .*.:**.*****. *::.*.  *** *: :  * 
 
         « 
E1     DAHNIQTHRDSLDLLDKARAKKAMLSEQNRASPLPSGLLTPPQSGKKQSSGPEMA 410 
E2     DRHNIQTHTNYLAMLEEVNYINTFRKGGQLSPVCNGGIMTPPKSTEKPPGKH--- 404 
       * ****** : * :*::..  ::: .  : :    .*::***:* :*  .      
Figure 3-3 Alignment of human cyclin E1 and human cyclin E2 sequences. 
Human cyclin E1 (Uniprot entry 24864) and human cyclin E2 (Uniprot entry O96020) 
sequences are aligned.Residues in α helices from the structure of cyclin E1 (PDB: 
1W98) are marked red with helix name above the sequence. The MRAIL motif is 
underlined and the crystalized fragment (residues 88-357) are marked » at the 
beginning and « at the end. Identical residues are marked with a star underneath the 
sequence and conserved residues are highlighted with a colon (:) or dot (.).Highly 
homologous CBF1 is marked with a red box and less homologous CBF2 is marked 
with a blue box. Sequences were aligned using Clustal Omega (Sievers et al., 2011). 
Overall, human cyclins E1 and E2 share 46.5 % identity. 
Cyclin E is critically required for development of Drosophila melanogaster (Knoblich et 
al., 1994) and Caenorhabditis elegans (Fay and Han, 2000)  and essential for 
mammalian embryogenesis (Geng et al., 2003). Double knockout mice E1 -/- appeared 
normal through their life and could not be distinguished from wild type. Mice lacking E2 
were initially indistinguishable from control littermates although males displayed lower 
fertility with around 50% sterility. Female littermates did not show any differences. The 
lethality of double cyclin E knockout (E1-/-E2-/-) is not due to embryo abnormalities, but 
rather to placental dysfunction developed as a result of a defect in trophoblast 
development. 
 Sequential comparison of cyclins binding to CDK1 and CDK2  
The determination of the structure of CDK1-cyclin B-CKS2 provided an opportunity to 
compare the residues at the CDK-cyclin interfaces in various CDK1 and CDK2-cyclin 
complexes to attempt to understand the observed pairing specificities. The residues 
within the cyclin A structure that are within 3.6 Å of a cyclin B residue contacting CDK1 
were identified and compared (Figure 3-4).  Of the 18 residues identified, 10 are 
identical in cyclin A and only 5 are identical with the equivalent amino acids of cyclin E. 
It was noted that cyclin B residues Tyr170, Tyr177 and Tyr258 are conserved in cyclin 
A and have large side chains that pack against the CDK1 surface, in contrast to the 
small amino acids Asn112, Ile119 and Leu202 present in the cyclin E sequence. The 
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ability of CDK2 to form a larger interface with its cognate cyclins may lead to the smaller 
side chains present in cyclin E being better tolerated. These observations offer an 
explanation as to why CDK1 prefers to pair with cyclin B and cyclin A rather than with 
cyclin E. 
 
Figure 3-4 Analysis of cyclin residues that participate in CDK binding. 
Amino acids that mediate the CDK1-cyclin B interface were identified using the CCP4 
program CONTACT (Winn et al., 2011). Identical amino acids present in cyclin A and 
cyclin E were identified by superimposing the CDK2-cyclin A (PDB code: 1QMZ) and 
CDK2-cyclin E (PDB code: 1W98) structures in CCP4MG. 
 
 CDK substrates 
A proteomic study focusing on analysis of substrates of CDK in complex with cyclin A2, 
B1 and E1 has been performed to understand the dynamics of the cell cycle. In this 
study CDK-cyclin complexes were purified from different stages of the cell cycle and 
analysed by quantitative mass spectrometry using SILAC (stable isotope labelling by 
amino acid in cell culture) (Ong et al., 2002) and bound substrates were recovered by 
immunoprecipitation (Archambault et al., 2004). A number of substrates were identified 
for complexes of CDK1 with cyclins A2, B1 and E1 that are unique for each of these 
cyclins, but also overlap between cyclins E1 and B1 to some extent, between A2 and 
E1 more and a large number of substrates are phosphorylated by cyclin A2 and cyclin 
B1 (Figure 3-5). The overlapping substrates were demonstrated to be bound by 
different cyclins at different times in the cell cycle even if another potential cyclin that 
can bind it is present in the same cell cycle phase (Pagliuca et al., 2011) (Figure 3-5). 
These results support a model in which cyclins remodel the cognate CDK for 
phosphorylation of specific substrates, and where there is coordination between 
cyclins in targeting the same set of substrates but at a different phases of the cell cycle.  
Most CDK substrates contain S/T*-P-X-K/R sequence (where X is any amino acid) 
(Ubersax et al., 2003) with a different requirements around the site of phospho transfer. 
 85 
 
 
 
Figure 3-5 Partners of cyclin A1, B2 and E1 in interphase. 
(A) Representation of substrates that overlap between cyclins A1, B2 and E1. (B) 
Substrates that bind cyclin A in S phase represented in red and blue in G2, 
substrates that bind cyclin B in mitosis represented green (Pagliuca et al., 
2011). 
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  Substrate recruitment   
The canonical sequence which CDKs phosphorylate is S/TPXK/R, where S is the 
phosphorylatable serine and X is any amino acid. The RXL motif is present in a number 
of CDK substrates including Rb, E2F-1, Cdh1, Cdc6, and the inhibitor proteins 
p21CIP1,p27KIP1 and p57KIP2  (Adams et al., 1999) (Saha et al., 1997; Takeda et al., 
2001; Wohlschlegel et al., 2001; Willder et al., 2013). The RXL motif binds to a 
hydrophobic patch on the surface of cyclins A, B, D and E called the recruitment site 
(Brown et al., 1999; Petri et al., 2007). The presence of an RXL motif is important but 
arginine can be substituted for lysine with a small loss of binding affinity (Lowe et al., 
2002). One of the proposed roles of the RXL motif is in localising the substrate to the 
CDK in a non-specific manner increasing the substrate concentration (Schulman et al., 
1998). The addition of it has been shown to increase phosphorylation of otherwise 
poorly phosphorylated substrates (Adams et al., 1999). The linker between the 
phosphorytable residue and the RXL motif has been shown to be flexible and doesn`t 
have a preferred path on the cyclin surface (Takeda et al., 2001).  
The dependence on the presence of certain residues in the canonical phosphorylation 
site and an RXL motif in different CDK-cyclin complexes for efficient substrate 
phosphorylation has been investigated (Brown et al., 1999). CDK4-cyclin D which does 
not have a strict preference for position P+3 shows a strong dependence on the R/KXL 
motif, in the absence of which CDK4-cyclin D loses activity completely (Takaki et al., 
2009). The special feature of CDK4–cyclin D that it may require substrate binding to 
adopt an active conformation might explain the importance of both recruitment sites. 
An investigation of other CDK-containing complexes would be beneficial. 
  Aims and objectives 
The structure of CDK1-cyclin B revealed different features at the CDK-cyclin interface 
in comparison to the other CDK–cyclin pairs. As the interface between CDK1 and cyclin 
B is smaller than that between CDK2 and cyclin A, it is of interest to determine the 
affinity and nature of this interaction. The structure of CDK1-cyclin B revealed that the 
non-phosphorylated activation segment is more flexible and less well-ordered than that 
of CDK2-cyclin A. Unlike CDK2-cyclin A, CDK4 bound to cyclin D also features a 
disordered activation segment (Day et al., 2009) and it was of interest to determine 
whether a disordered activation segment is also a feature of the phosphorylated CDK1-
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cyclin B complex. Such a structure could influence both the stability of the complex 
(Brown et al., 1999)  and its substrate specificity.  
 
3.2 Description of biophysical methods 
  Isothermal titration calorimetry to measure affinity between 
proteins 
Isothermal titration calorimetry is a biophysical technique that can be used to measure 
protein-ligand, protein–nucleic acid and protein – protein interactions. One component 
is injected at higher concentration in small aliquots into a solution of its interacting 
partner at lower concentration and the energy associated with the interaction is 
measured. Measurement of heat transfer allows accurate determination of change of 
enthalpy (ΔH) which derives from the ITC isotherm. It can be used to determine other 
thermodynamic parameters such as the association constant (Ka), changes in entropy 
(ΔS) and stoichiometry of the interactions (n) in solution using Origin 7.0 software 
(OriginLab Corp.)  
Change of enthalpy can be used for the further determination of thermodynamic 
parameters by using the Wiseman isotherm (stoichiometry 1:1 is specified for 
simplicity): 
𝑑𝑄
𝑑[𝑋]t
= ∆𝐻°𝑉0 [
1
2
+
1 − 𝑋𝑅 − 𝑟
2√(1 + 𝑋𝑅 + 𝑟)2 − 4𝑋𝑅
]  
where 
1
𝑟
= 𝑐 = 𝐾𝑎[𝑀]𝑡 =
[𝑀]𝑡
𝐾𝑑
 
Equation 3-1 Wiseman isotherm for ligand – receptor binding at 1:1 
stoichiometry. 
Abbreviations: X – ligand, M – receptor, V0 – volume of the calorimeter cell, [M]t – total 
receptor concentrator,  
𝑑𝑄
𝑑[𝑋]t
− change of heat/moles ligand added, ΔH – change in 
enthalpy, XR=[X]t/[M]t ratio of ligand to receptor concentration, Ka – association 
constant. 
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The Gibbs-Helmholtz equation is regularly used to determine the entropic contribution 
to binding.  
∆𝐺 = −𝑅𝑇𝑙𝑛𝐾𝑎 =  ∆𝐻 − 𝑇∆𝑆 
Equation 3-2 Gibbs-Helmholtz equation.  
Abbreviations: G – change in Gibbs energy, R – ideal gas constant, T – absolute 
temperature, ΔH – changes in enthalpy, Ka – association constant, ΔS – changes in 
entropy. 
 
3.3 Materials and Methods  
  Protein production 
CDK1 and CAK1 each with an N terminal GST tag, cleavable by 3C protease for 
GSTCDK1 and non-cleavable for GSTCAK1, were expressed in SF9 insect cells as 
described in Section 2.2.4. Phosphorylated CDK2 is generated by CDK2 co-
expression with CAK which phosphorylates CDK2 in bacterial culture as described in 
Section 2.2.7 using the construct described in Table 2-1. Constructs 
pGEX6P1CDK2CAK1, pET21dCyclinAHis, pET28CyclinBcs described in section 2.2.3 
were used to express phosphorylated CDK2, His-tagged cyclin A and cyclin B in 
Rosetta2TM(DE3)pLysS E. coli cells as outlined in Section 2.2.3.  All proteins were 
purified by standard protocols outlined in Sections 2.2.8 and 2.2.9.  
  Peptide synthesis, expression and purification by ion 
exchange chromatography 
To measure kinase activity a panel of eight peptides derived from the previously 
described sequence of p107 (Leng et al., 2002) were prepared. The peptides differ 
systematically at the P+1 and P+3 positions around the site of phosphotransfer (where 
the phosphorylated residue is denoted P) and at the cyclin binding RXL motif (Table 3-
1). All the peptide sequences also contain the following mutations: (i) Pro651 to alanine 
so that the peptides contain only one SP motif and (ii) Tyr648 and Ile674 to tryptophans 
for more accurate determination of protein concentration at 280 nm. DNA sequences 
were gene synthesised by GenScript and subsequently inserted into pGEX6-P1 by In-
Fusion cloning (Clontech, USA) using BamH1 and EcoR1 restriction sites. Plasmid 
DNA was transformed into Stella E. coli cells, following the manufacturer’s protocol 
 89 
 
then plated on to LB plates supplemented with ampicillin and incubated overnight at 
37°C. Plasmid DNA was purified using a QIAprep Spin Miniprep kit (Qiagen, Hilden, 
Germany) from a single colony and verified by sequencing. The peptides were 
expressed in the RosettaTM(DE3)pLysS E. coli strain at 20°C overnight after induction 
by 0.1 mM IPTG.  Pelleted by centrifugation at 5000 x g cells were re-suspended in 40 
mM Hepes, pH 7.5, 200 mM NaCl, 0.01% MTG, protease inhibitors Complete tablet 
and flash frozen in dry ice and stored at -80°C. Cell pellets were thawed under running 
cold water and then kept on ice and sonicated in the presence of 0.01 mg/ml DNase, 
0.05 mg/ml RNase, 0.25 mg/ml  Lysozyme, 5 mM MgCl2 , for 15 cycles totalling 3 min 
with  20 sec intervals. Cells were centrifuged at 60,000xg, the supernatants collected 
and kept on ice. Proteins were purified by sequential affinity chromatography exploiting 
the GST tag followed by ion exchange chromatography. The choice of ion-exchange 
resin (HiTrap Q FF or HiTrap SP FF) was made with reference to the calculated pI of 
each peptide (Table 3-2). Peptides were buffer exchanged into 25 mM MES, pH 6.5 
prior to IEC and eluted by a one step increase in the NaCl concentration to 1M. Peak 
fractions were collected and confirmed by SDS-PAGE, pooled and flash cooled in liquid 
nitrogen in 100 μl aliquots and stored at -80°C. 
Peptide Sequence 
SPIS+RXL GPLGSMHPRVKEVRTDSGSLRRDMQPLSPISVHERWSSATAGSAKRRLFGEDPPKEMLMDKW 
SPIK+RXL GPLGSMHPRVKEVRTDSGSLRRDMQPLSPIKVHERWSSATAGSAKRRLFGEDPPKEMLMDKW 
SPIS-RXL GPLGSMHPRVKEVRTDSGSLRRDMQPLSPISVHERWSSATAGSAAAAAFGEDPPKEMLMDKW 
SPIK-RXL  GPLGSMHPRVKEVRTDSGSLRRDMQPLSPIKVHERWSSATAGSAAAAAFGEDPPKEMLMDKW 
SAIS+RXL GPLGSMHPRVKEVRTDSGSLRRDMQPLSAISVHERWSSATAGSAKRRLFGEDPPKEMLMDKW 
SAIK+RXL GPLGSMHPRVKEVRTDSGSLRRDMQPLSAIKVHERWSSATAGSAKRRLFGEDPPKEMLMDKW 
SPIS-RXL GPLGSMHPRVKEVRTDSGSLRRDMQPLSPISVHERWSSATAGSAAAAAFGEDPPKEMLMDKW 
SAIK-RXL  GPLGSMHPRVKEVRTDSGSLRRDMQPLSAIKVHERWSSATAGSAAAAAFGEDPPKEMLMDKW 
Table 3-1 Sequences of p107 mutant peptides.  
The sequence of p107 (Uniprot entry P28749), residues 618-674 was used as the 
starting point for the peptide set. The sequences contain systematic mutations at the 
SPXK consensus sequence around the site of phospho-transfer and at the RXL motif 
that binds to the cyclin recruitment site (highlighted in bold and underlined).  The 
GPLGS sequence at the start of each peptide is a cloning artefact that remains 
following cleavage of the N-terminal GST tag by 3C protease. The mutations 
Tyr648Trp and Ile674Trp (highlighted in blue) were introduced to aid the determination 
of peptide concentrations and Pro651Ala removes the second authentic SP motif in 
the p107 sequence. Construct SPIS+RXL is the authentic p107 sequence at these 
motifs.  
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 Peptides Molecular    
Weight 
pI             
(GST fusion) 
pI 
(peptide) 
pI          
of GST 
20 SPIS+RXL 7847 6.47 9.9 5.73 
21 SPIK+RXL 7536.5 6.72 10.1  
22 SPIS-RXL 7536.5 5.95 6.9  
23 SPIK-RXL  7577.6 6.1 8.44  
24 SAIS+RXL 7779.9 6.47 9.97  
25 SAIK+RXL 7821 6.72 10.1  
26 SPIS-RXL 7510.5 5.95 6.94  
27 SAIK-RXL 7551.6 6.1 8.44  
Table 3-2 Molecular weights and pIs of p107 mutants.  
Molecular weights and isoelectric points of peptides on their own and GST bound 
calculated by ExPASy Bioinformatics Resource portal (Artimo et al., 2012). 
 
  SDS-PAGE  
SDS-PAGE was performed as described in Section 2.2.10. 
  Phosphorylation of CDK1 
GSTCAK1 (S. cerevisiae) expressed in insect cells was used to phosphorylate  CDK1 
in vitro. Purified CDK1 and GSTCAK1 were mixed in a ratio of 1:4 in binding/SEC 
Buffer 1 (recipe is described in chapter 2.2.2) in the presence of 1 mM ATP and 10 mM 
MgCl2 and incubated overnight at 4°C. Phosphorylated CDK1 (referred as pCDK1 from 
this point) was separated from GSTCAK1 by SEC using a Superdex 200 16/60 column.  
The extent of phosphorylation was determined by HPLC. 
 
 Reverse phase HPLC 
0.1ml of CDK1 (at 0.07mg/ml in binding/SEC buffer 1) was supplemented to 0.01% 
TFA and injected onto a 5 um C4 300A column (Phenomenex, Torrance, California, 
US) equilibrated into 0.01% TFA in water (Buffer A). Proteins were separated by 
applying a gradient of 50% to 60% acetonitrile /0.01% TFA in water over 20 column 
volumes. 
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  Preparation of the complexes 
For preparation of phosphorylated CDK1-cyclin B complex (referred as pCDK1-cyclin 
B from this point), pCDK1 prepared as described in 3.2.4 was first separated from 
GSTCAK1 by SEC, and then mixed with cyclin B in a ratio of 1:1.5, CDK1:cyclin B. The 
NaCl concentration was adjusted to 1 M to stabilise the pCDK1-cyclin B complex, and 
then the complex was concentrated using a Sartorius Vivaspin concentrator 10kDa 
cut-off before further separation of pCDK1-cyclin B from cyclin B on a Superdex 75 
26/60 column. The peak corresponding to the pCDK1-cyclinB complex was collected 
and analysed by SDS-PAGE. Fractions of pCDK1-cyclin B were concentrated to 1 
mg/ml using 10 kDa cut-off concentrators (Vivaspin) and frozen in 100 µl aliquots.  
Phosphorylated CDK2-cyclin A (referred as pCDK2-cyclin A from this point) was 
prepared essentially as described (Brown et al., 1999) with minor modifications.  Briefly, 
a cell lysate of GSTpCDK2 phosphorylated in bacterial cells by co-expression with 
CAK1 was mixed with a cell lysate of cyclin A in a ratio of 1:2 GSTpCDK2:cyclin A to 
ensure binding of all pCDK2 to cyclin A. The complex was loaded onto a Glutathione 
Sepharose 4B column equilibrated in modified HBS (40 mM HEPES, 200 mM NaCl, 1 
mM DTT, pH 7.0, 0.01% MTG) and washed to baseline. The GSTpCDK2-cyclin A was 
eluted by 20 mM glutathione in mHBS and cleaved overnight with 3C protease in a 
ratio of 1:50 (w/w).  The cleaved sample was then loaded onto a Superdex 75 26_60 
size-exclusion column equilibrated in mHBS to remove aggregates and glutathione. 
Fractions containing pCDK2-cyclin A (identified by SDS-PAGE) were pooled and re-
applied to a Glutathione Sepharose 4B column to remove the GST dimer. The complex 
was concentrated using a Sartorius Vivaspin concentrator 10kDa cut-off to 12-15 
mg/ml and fast cooled in 25 µl aliquots in liquid nitrogen and stored at -80°C. 
 
 Isothermal Titration Calorimetry (ITC) 
ITC experiments were carried out at 30°C using a MicroCal ITC 200 (Malvern 
Instruments). Cyclin B1 (165-433) and cyclin A2 (169-430) were used as samples in 
the cell and unphosphorylated CDK1 and CDK2 were used as ligands. Titrations were 
performed in two buffer conditions; 50 mM HEPES pH 8.0, 500 mM NaCl, 0.01% MTG 
(high salt), and 40 mM HEPES, 200 mM NaCl, 0.01% MTG, pH7.4 (low salt). For ITC 
experiments in the higher salt conditions cyclin B and cyclin A were both in the cell at 
140 μM, and CDK1 and CDK2 were added from the syringe at 16 and 18 μM, 
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respectively. In the lower salt and lower pH buffer, cyclin B and cyclin A were in the cell 
at 60 and 200 μM, and CDK1 and CDK2 were added from the syringe at 18 and 30 
μM, respectively. The thermograms were analysed by Origin 7.0 (OriginLab Corp.) 
software. 
 ADP-GloTM Kinase assay 
Kinase reactions (ADP-Glo assay format (Promega) were carried out in 5 µl total 
volume at room temperature using 4 nM pCDK1-cyclin B or 1.5 nM CDK2- cyclin A in 
40 mM Tris-HCl pH 7.5, 20 mM MgCl, 0.1 mg ml-1 BSA buffer. Ten points of two times 
dilutions (94 to 0 µM) of the panel of peptides (Table 3-1) were added to the CDK-cyclin 
solution and the reaction was initiated by the addition of 75 µM ATP. Assays were 
performed in white 384-well plates in duplicate.  Luminescence was detected using a  
PheraStar plate reader (BMG).  Km and Vmax values were derived using PRISM 
(GraphPad) and  were calculated using Michaelis-Menten equation: 
ɣ=Vmax/(1+(Km/[S]) 
Equation 3-3 Michaelis-Menten equation.  
Abbreviations:  ɣ is a reaction rate or speed of reaction, [S] is concentration of a 
substrate, Km is a Michaelis constant which is the substrate concentration at which a 
reaction rate is half of Vmax, Vmax represents the rate achieved by the system at 
saturating substrate concentration. 
 CDK de-phosphorylation  
CDK-cyclin complexes were dephosphorylated using λ phosphatase. Phosphorylated 
CDK1-cyclin B (4 nM) and CDK2-cyclin A (2.5 nM) complexes were incubated for 30 
min at 30 °C in total volume of 60 µl with 32 units of lambda phosphatase in 50 mM 
Tris, pH 8.0, 500 mM NaCl, 0.01% MTG (CDK1-cyclin B) and 50 mM Tris, pH 7.4, 200 
mM NaCl, 0.01% MTG (CDK2-cyclin A) buffers supplemented with 400 µM MnCl2. 
Mock-treated samples were incubated with buffer only. The extent of 
dephosphorylation was assessed by subsequently measuring the residual kinase 
activity by ADP-GloTMassay. 
  Differential Scanning Fluorimetry (DSF) 
Experiments were performed using a ViiA7 Real-Time PCR system (Applied 
Biosystems). 4 µM pCDK1-cyclin B and 6 µM pCDK2-cyclin A were mixed with SyPRO 
Orange (x10) (Invitrogen) fluorescent probe in DMSO (supplied by Sigma Aldrich). The 
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plates were first equilibrated at 25°C for 5 min in the PCR machine before starting the 
thermal melting experiment. The plates were heated at 1°C per 90 sec from 25 to 85°C. 
The fluorescence intensity was recorded using the ROX filters (excitation λ=470 nm, 
emission λ = 586nm) every 90 sec. Results were plotted in PRISM (GraphPad) and 
inflection point ™ was calculated using Boltzmann equation. 
 
3.4  Results and Discussion 
  Determination of CDK-cyclin binding 
The principals of ITC have been described in Section 3.1.4. It is a method that 
measures the heat that is released or absorbed as a result of chemical or physical 
changes in a sample. This method has been employed to estimate the binding affinity 
between unphosphorylated CDK1 and cyclin B in comparison to CDK2 and cyclin A. 
The experiments have been done in collaboration with Dr. Will Stanley. The 
observation that the binding interface between CDK1-cyclin B and CDK2-cyclin A 
differs instigated the idea that this might result in differences in stability of the 
complexes in vitro. All four proteins were prepared separately and subsequently mixed 
to generate the complexes. The direct comparison was difficult as both complexes 
were stable under different buffer conditions. CDK2-cyclin A was stable at near 
physiological conditions (pH 7.4, 200 mM NaCl, T=30°C), yielding a Kd value of 21 nM 
(Figure 3-6 A) but cyclin B was unstable at this salt concentration undergoing 
precipitation which made it hard to interpret the thermograms quantitatively (Figure 3-
6 B). The experiment was repeated in the reverse direction where the Kd of CDK1 
binding to cyclin B was determined at the higher salt concentration and higher pH (pH 
8.0, 500 mM NaCl, T=30°C). This experiment yielded a Kd value of 28 nM, but these 
conditions were not favourable to study interactions between CDK2 and cyclin A. 
These results show that both kinases bind to their respective cyclins with nanomolar 
affinity but that binding can only be reproducibly measured for CDK1–cyclin B in the 
presence of high salt.  
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C 
 
D 
 
Figure 3-6 Isothermal titration calorimetry to assess the formation of CDK1-
cyclin B and CDK2-cyclin A complexes in vitro. 
Thermograms generated by ITC during formation of CDK1-cyclin B (B, C) and CDK2-
cyclin A (A, D) complexes. Experiments were performed at the different buffer 
conditions, (A, B) at a lower salt and lower pH (40 mM Hepes, pH 7.4, 0.01 % MTG 
and (C,D) at a higher salt concentration and higher pH (40 mM Hepes, pH 8.0, 500 
mM NaCl, 0.01 % MTG). 
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The technique employed to explore the stability of the complexes was a DSF assay. 
For this experiment pCDK1-cyclin B and pCDK2-cyclin A were prepared in buffer 
containing 200 mM NaCl. pCDK1 and cyclin B were purified separately as described 
earlier and the complex was assembled by mixing pure proteins in a ratio of 1 (CDK1):2 
(cyclin B). The protein mix was applied to a Superdex 75 26_60 column and fractions 
from peak 1 were collected. Fractions were analysed by SDS-PAGE and then pooled 
together and concentrated to 1 mg/ml then frozen for use in the assay (Figures 3-7, 3-
8).  
A 
 
B  
 
C 
 
 
Figure 3-7 Preparation of a pCDK1-cyclin B complex. 
(A) Size-exclusion chromatography chromatogram of pCDK1-cyclin B. Peak of 
pCDK1-cyclin B labelled 1 and fractions identified with a red bar. Peak 2 contains 
excess of cyclin B. Absorbance at 280 nm is plotted against elution volume in ml.  The 
lower panel shows the elution positions of a standard mix of protein markers to 
calibrate the column. (B) Sample of pooled fractions analysed by SDS-PAGE. (C) Size-
exclusion chromatography chromatogram of standards. 
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Figure 3-8 Separation of pCDK2-Cyc A complex by SEC. 
(A) Chromatogram of pCDK2-cyclin A complex. Peak of pCDK2-cyclin A identified with 
a red bar. Absorbance at 280 nm is plotted against elution volume in ml.  (B) Fractions 
labelled with a red bar were pulled together and identified by the SDS-PAGE. (C) Size-
exclusion chromatography chromatogram of standards. 
 
Analysis by DSF assay showed that pCDK2-cyclin A complex is 11°C more stable then 
pCDK1-cyclin B (Figure 3-9 A). The melting temperature depends on the thermal 
stability of individual proteins as well as the energy of their binding.  However, the 
results do support the hypothesis based on the structural comparison (Section 2.3.5) 
that the extended interface between CDK2 and cyclin A generates a complex that is 
more thermally stable than CDK1-cyclin B. 
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To find out if phosphorylation influences protein stability, pCDK1-cyclin B was treated 
with λ phosphatase or a buffer control and then re-tested in the DSF assay. This 
experiment revealed a small but reproducible difference of 1°C between the 
phosphorylated and non-phosphorylated complexes suggesting that the 
phosphorylated CDK1 complex is more stable (Figure 3-9 B).  
A                                                             B 
 
Figure 3-9 Comparison of thermal stability by Differential Scanning 
Fluorimetry. 
(A) Thermal stability comparison of phosphorylated CDK1-cyclin B and CDK2-cyclin A 
complexes. (B) Thermal stability comparison of phosphorylated CDK1-cyclin B 
complex and λ-phosphatase treated CDK1-cyclin B. Experiment performed in 
duplicate. 
 
 Investigation of CDK1 activity towards the panel of p107 
derivatives 
As the main function of CDKs is to phosphorylate their substrates, the activities of 
phosphorylated CDK1 and CDK2 in complexes with their cognitive cyclins towards a 
panel of peptides was compared.  The panel is composed of seven derivatives from 
retinoblastoma protein p107 to explore the importance of amino acids around the site 
of phospho-transfer and in the RXL motif which plays a role in cyclin recognition. Seven 
mutants were created by replacing proline in position P+1 and the positively charged 
residue in position P+3 of a peptide (Table 3-1). The RXL motif was also eliminated in 
some of the variants. Peptides were expressed and purified as described in Materials 
and Methods. Mutants 20, 21, 23, 24, 25 (Table 3-1) were purified by HiTrap SP 
Sepharose FF column and mutants 22 and 26 by HiTrap Q Sepharose FF (Table 3-2). 
Peptides were eluted from the column by a step increase in the NaCl concentration 
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from 0 to 500 mM to help concentrate the samples. Figure 3-10 shows the purification 
of peptide mutant 23 as an illustrative example.  
A 
 
B 
 
 
Figure 3-10 Separation of p107 mutant 23 from GST by HiTrap SP Sepharose  
FF column. 
(A) Chromatogram of p107 mutant 23. For ion-exchange chromatography 25 mM MES 
pH 6.5 buffer was applied to the column without NaCl and after 35 ml 1M NaCl in 25 
mM MES pH 6.5 was introduced to the column to ensure quick protein release.  
Fractions from both peaks labelled with the blue bar and the red bar were collected 
and analysed by SDS-PAGE. The increase of NaCl concentration is shown as a green 
curve. (B) Peaks from ion exchange chromatography identify GST and p107 mutant 
23 by the SDS-PAGE. 
The ADP GloTM assay (Promega) was employed to measure kinase activity. This assay 
is a luminescent ADP detection assay that measures the amount of ADP produced as 
a result of a kinase reaction (Figure 3-11). This assay is performed in two steps. After 
the kinase reaction is completed, the ADP-Glo reagent is added in equal amounts to 
all sample wells to deplete the remaining ATP. In the next step kinase detection reagent 
is added to transform all ADP into ATP which can produce luminescence as a result of 
a luciferase/luciferin reaction. Luminescence is measured by the luminometer. 
Luminescence is correlated to ADP concentration by using an ATP-to-ADP conversion 
curve which can be prepared for the different proportion of ADP in an ADP+ATP 
mixture. As the luminescence signal is generated according to the ADP concentration 
produced, it is correlated with kinase activity. 
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Figure 3-11 Illustration of the ADP-GloTM assay. 
 
Generally, the results of the assay show that both CDK1 and CDK2 are active against 
the peptides with canonical phosphorylation site SPIK and intact RXL motif and 
demonstrate no activity against the peptides highly compromised in the 
phosphorylation site SAIS with or without an RXL motif. Also in the absence of the RXL 
motif both kinases phosphorylate peptides that have canonical phosphorylation sites 
SPIK (Figure 3-12). 
Despite their similarities, the complexes do have differences in their activity towards 
the mutants (Table 3-3). pCDK2-cyclin A requires proline in position P+1 and a 
positively charged residue in position P+3 as well as the RXL motif for activity 
(SPIS+RXL). However, CDK1-cyclin B remains active even if only proline (SPIS+RXL) 
is present in position P+1 or a positively charged residue (SAIK+RXL) is present at 
position P+3. In the absence of the RXL motif, pCDK1 retains activity towards 
substrates with an impaired phosphorylation site (SPIS-RXL) but CDK2 –cyclin A is 
almost inactive against these substrates. Consequently pCDK1-Cyclin B is more 
accommodating towards variations in the substrate sequence around the site of 
phospho transfer in comparison to pCDK2-Cyclin A. 
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Figure 3-12 Kinase activity of pCDK1-cyclin B and pCDK2-cyclin A towards the 
panel of peptides. 
Seven peptides were generated with introduced mutations around the site of phospho-
transfer in positions P+1 and P+3 and with or without KRXL motif that binds to cyclin 
recruitment site to test the activity of pCDK1-cyclin B (A) and pCDK2-cyclin A (B). The 
side panel identifies amino acids in site of phosphor-transfer and the presence or 
absence of RXL motif. Graphs representing the activity of different peptides shown in 
different colours and calculated using GraphPad Prizm 6 software. Experiments were 
repeated twice and error bars correspond to the range of different values.  
Phosphorylated CDK1-cyclin B Phosphorylated CDK2-cyclin A 
 SPIK SAIK SPIS SAIS  SPIK SAIK SPIS SAIS 
+RXL 0.52 0.17 0.42 0.06 +RXL 0.57 0.03 0.11 0.01 
-RXL 0.45 ND 0.09 0.06 -RXL 0.57 ND 0.01 -0.01 
Table 3-3 kcat /Km, peptide (s-1) for CDK-cyclin complexes on p107 mutants. 
ND – not determined. 
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 Role of activation segment phosphorylation in determining the 
observed substrate preferences 
According to previous work (Takaki et al., 2009) the CDK2-cyclin A activation segment 
is buried in a cluster of positively charged residues and after treatment with λ 
phosphatase CDK2 remains as active as before treatment.  However, active CDK4 
after the same treatment loses its activity suggesting that the phosphorylated Thr172 
is accessible to λ phosphatase and the activation segment is flexible.  A structural 
comparison of CDK1-cyclin B and CDK2-cyclin A shows that the activation segment is 
more open and flexible in CDK1. To investigate this observation pCDK1-cyclin B was 
treated with λ phosphatase under the conditions where the CDK2-cyclin A activity was 
minimally affected and then the treated complex was tested in a kinase assay towards 
the peptide SPIK+RXL (Figure 3-13). The results reveal a significant decrease in 
pCDK1-cyclin B activity after de-phosphorylation which supports the hypothesis that 
the activation segment is locally flexible around Thr161 and therefore accessible to λ 
phosphatase treatment. The results of this experiment suggest that the relaxed 
substrate specificity of the activation segment of pCDK1-cyclin B is a consequence of 
its flexibility.  
 
Figure 3-13 Comparison of CDK1 and CDK2 kinase activity after λ phosphatase 
treatment. 
Phosphorylated CDK1-cyclin B and CDK2-cyclin A complexes were incubated with λ 
phosphatase or incubation buffer at 37°C for 1 h and kinase activity was determined 
towards the optimal peptide (SPIK+RXL) by the ADP-Glo assay. Results were plotted 
in GraphPad Prizm 6. Blue bar indicates kinase activity of pCDK2-cyclin A complex 
against the optimal peptide, red bar – pCDK1-cyclin B complex, green bar – pCDK2-
cyclin A treated with λ phosphatase, purple bar – pCDK1-cyclin B treated with λ 
phosphatase. Error bars indicate the standard deviation of two independent 
measurements. 
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3.5 Conclusions 
Experiments described in this Chapter were mainly stimulated by the structural findings 
and included in vitro assays for biochemical characterisation of CDK1 and CDK1-cyclin 
B complex in comparison with CDK2 and CDK2-cyclin A. CDK2 is a well studied kinase 
which despite its similarities in sequence with CDK1 differs substantially in function. 
Structural analysis of CDK1–cyclin B revealed a 30% smaller interface between CDK1 
and cyclin B in comparison to CDK2-cyclin A and a smaller number of interactions 
involved in binding. The results of DSF confirmed the higher stability of pCDK2-cyclin 
A in comparison to pCDK1-cyclin B although it should be noted that monomeric CDK2 
has a higher melting temperature then CDK1 by circa 5°C (DSF data from Chapter 5). 
The comparison of the residues involved in CDK-cyclin binding between cyclin A, cyclin 
B and cyclin E has offered a possible explanation as to why CDK1 binds preferably to 
cyclin B and cyclin A. It has been noticed that cyclin E has smaller residues Asn112, 
Ile119 and Lue202 in the positions where cyclin B and cyclin A have larger more 
hydrophobic tyrosine residues (Tyr170, Tyr177 and Tyr258 in cyclin B). In the context 
of the smaller CDK1 interface, these residues do not contribute as much binding 
energy with the result that a CDK1-cyclin E complex would not be stable. However, in 
the context of the larger CDK2-mediated interface, additional interactions help stabilise 
the CDK2-cyclin A complex.  
The investigation of pCDK1-cyclin B substrate preferences and comparison with 
pCDK2-cyclin A yielded trends that again agreed with the structural findings.  pCDK1-
cyclin B is more relaxed in its substrate preferences in comparison to pCDK2-cyclin A 
which offers an explanation as to why CDK1 can phosphorylate a much wide range of 
substrates than CDK2-cyclin A. 
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 Diverse CDK regulators 
4.1  Introduction 
As has been discussed in Chapter 1 CDK activity is regulated directly by both protein 
binding and reversible phosphorylation, and indirectly by, for example, mechanisms 
that control its localisation within the cell and the level of expression and degradation 
of its regulators (e.g. via the ubiquitin proteasome pathway). As an example, a number 
of sequence diverse but structurally conserved protein families activate CDKs by a 
mechanism shared with members of the cyclin family, but their levels do not oscillate 
through the cell cycle. Some cyclin-like proteins are expressed in terminally 
differentiated cells that have exited the cell cycle such as p35 that binds to CDK5 in 
neurons, while viruses encode cyclin-like proteins that can hijack the host cell cycle 
machinery to promote an environment that supports viral replication. A number of non-
cyclin CDK binding proteins have been discovered but have not been the subject of 
structural studies. In this chapter, preliminary work to characterise two CDK binding 
proteins, Speedy/RINGO and RGC32 and to establish conditions to study the role of 
sumoylation in controlling CDK activity is described. 
 Ringo/Speedy – a family of atypical CDK regulators  
Ringo/Speedy proteins are a family of atypical regulators of CDK1 and CDK2 which 
have no sequence homology with the cyclins, but are predicted to contain a cyclin box 
fold. Speedy was first described as a gene in Xenopus that can rescue the UV and ɣ -
radiation sensitivity of the Rad1 mutant of S. pombe (Lenormand et al., 1999). RINGO 
(Rapid INducer of G2/M progression in Oocytes) was independently discovered in a 
screen of regulators of G2/M progression in Xenopus oocytes (Ferby et al., 1999). Both 
of these genes were reported to induce mitotic maturation in Xenopus oocytes. 
Subsequently a human homologue was identified by RT-PCR in 293T cells that was 
only expressed during the G1/S phase of a cell cycle and it was named Spy1 (Porter 
et al., 2002). The human sequence has 40% similarity to RINGO/Speedy and it is also 
able to induce oocyte maturation. Additional mammalian homologs have been 
discovered (Porter et al., 2002; Cheng et al., 2005b; Dinarina et al., 2005), although 
most of them, apart from Speedy A orthologues differ substantially in their amino acid 
sequences between different species (Figure 4-1) (Chauhan et al., 2012). 
RINGO/Speedy mRNAs demonstrate different expression patterns in different mouse 
and human tissues, but in both species show high expression in testis suggesting a 
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role in a reproduction process. Interestingly, sequence analyses have failed to identify 
RINGO/Speedy homologues in flies, worms, plants or yeasts. 
 
Figure 4-1 Sequence comparison between members of the Speedy A family 
from different species. 
Speedy A proteins from zebrafish, chicken, rat, mouse, human, african frog, ghost 
shark  (Uniprot entries F1QWB8, E1C1Y3, Q8R496, Q5IBH7, Q5MJ7O, Q9PU13, 
I3PG92) were aligned using Clustal Omega (Sievers et al., 2011) and visualised using 
the Jalview suite (Waterhouse et al., 2009). Identical amino acids are coloured blue, 
conserved residues within the family are represented by the range of colours from 
yellow to brown and identified by the number below. Speedy box, K-, L-, H- and PRGP 
motifs are boxed in different colours. Figure adopted from (Chauhan et al., 2012).   
 
The most significant characteristic of the family is the existence of a conserved region 
termed the ‘speedy domain’ or ‘speedy box’ (Cheng et al., 2005b; Dinarina et al., 2005; 
Chauhan et al., 2012). The sequence that includes the speedy domain, between 
residues 66-206 in human Speedy A, was found to be responsible for Xenopus oocyte 
maturation and also for CDK2 activation (Dinarina et al., 2005). It has 51-67 % 
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sequence similarity amongst the family of mammalian proteins (Figure 4-2 A). A 
phylogenetic tree of full length mammalian RINGO/Speedy presented 85% identity 
between RINGO/Speedy A in human and mice (Figure 4-2 B). The other family 
members are not present in all the species, with RINGO/Speedy C and E present in 
humans but not in mice although RINGO/Speedy B and D are not present in humans. 
The Speedy domain has a different location in different members of the family. For 
example in Speedy A it is located almost in the centre of the sequence, whereas in 
Speedy B it is closer to the C-terminus (Figure 4-2 A). Two motifs that are 100% 
conserved from human to fish were identified within the speedy box and named the K-
motif and the L-motif (Figure 4-1). Their high degree of sequence conservation signifies 
their potential importance for function. Speedy A proteins from different species also 
share two other highly conserved motifs: The H- and PRGP motifs are located at the 
C-terminal end of the speedy domain. 
The flanking regions to either side of the speedy box are reported to be dispensable 
for RINGO/Speedy activity. The N-terminal sequence was reported to control 
expression levels in transfected cells (Cheng et al., 2005b) and the C-terminal 
sequence has in some cases been reported to contribute to CDK regulation (Dinarina 
et al., 2005). As a consequence, the presence and location of the conserved motifs 
might influence the expression and function of Speedy A and B. 
A 
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Figure 4-2 RINGO/Speedy protein family. 
(A) Cyclin box region of mammalian RINGO/Speedy family members have been 
compared and similarity within the speedy domain with XRINGO/Speedy has been 
identified. Cyclin box region coloured yellow and flanking region blue. (B) Phylogenetic 
tree is adopted from (Nebreda, 2006). It identifies 85% similarity between human and 
mouse Speedy A. Not all family members present in both mouse and human. 
 
 Importance of RINGO/Speedy in meiosis 
In Xenopus oocytes Speedy and RINGO can induce meiotic maturation much faster 
than for example progesterone (Ferby et al., 1999; Lenormand et al., 1999). Ablation 
of endogenous XRINGO/Speedy mRNAs also delayed progesterone-induced 
maturation suggesting that it is important for this process (Ferby et al., 1999). Work 
performed in mice confirmed this finding. Ringo A knock out mice are born without 
obvious abnormalities but are sterile and exhibit hypoplastic ovaries and testes 
(Mikolcevic et al., 2016). Interestingly, mouse oocytes and spermatocytes deficient in 
Ringo A show the same phenotype as those deficient in CDK2 (Viera et al., 2009). 
CDK2 is essential for male and female meiosis, and cells deficient in CDK2 arrest in a 
pachytene-like stage of prophase I. They also contain a high amount of ɣH2AX which 
indicates unrepaired DNA and undergo apoptosis due to the pachytene checkpoint 
(Mikolcevic et al., 2016). Recently, it has been suggested that CDK2-Ringo A is 
involved in the regulation of telomere tethering to the inner nuclear membrane by 
phosphorylation of the nuclear membrane protein Sun1 (Mikolcevic et al., 2016). The 
possibility that Ringo controls chromatin methylation has also been investigated as 
Ringo A deficient spermatocytes show decreased levels of histone H3 trimethylated at 
Lys9 (H3K9-3me) and increased methylation on Lys4 (H3K4-3me).  
 RINGO/Speedy and cell proliferation 
Human RINGO/Speedy A/Spy1 (hereafter referred to as Speedy A, uniprot entry 
Q5MJ70)  has been proposed to play a role in proliferation: it is expressed during the 
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G1/S phase transition and activates CDK2 (Porter et al., 2002). Judging by parameters 
such as increased cell number, mitochondrial activity and level of histone H3, 
overexpression of human Speedy A leads to cell proliferation in a number of different 
cell lines. siRNA knockdown of Speedy A resulted in a higher cell population in G1/S 
compared to G2/M supporting a requirement for CDK2 activation for Speedy A-induced 
cell proliferation.  
 CDK1 and CDK2 activation by RINGO/Speedy proteins 
Both CDK1 and CDK2 can be activated by RINGO/Speedy family members in vitro 
and in vivo, though binding of Speedy A to CDK2 is more efficient than its association 
with CDK1 in vitro (Porter et al., 2002; Cheng et al., 2005a). A screen of other CDKs 
has shown that CDK5 binds to RINGO/Speedy but CDK4 and CDK6 do not (Cheng et 
al., 2005b; Dinarina et al., 2005).  
Despite the fact that cyclins and RINGO/Speedy proteins bind to overlapping sites on 
CDKs, the mechanism of CDK activation appears to be different (Nebreda, 2006) 
(Figure 4-3). The canonical CDK activation pathway is cyclin binding accompanied by 
activation segment phosphorylation. Interestingly, activation of CDK1 and CDK2 by 
RINGO/Speedy proteins does not require this additional phosphorylation step. CDK1 
and CDK2 mutants Thr161Ala and Thr160Ala respectively can be activated by 
RINGO/Speedy as effectively as the wild type proteins (Karaiskou et al., 2001). 
However, phosphorylated CDK1/2 can also be isolated bound to Ringo A suggesting 
that Ringo A can work as a conventional cyclin with activation segment phosphorylation 
to regulate CDK activity.  
Another feature of CDK1 or CDK2 bound to RINGO/Speedy is a lower susceptibility to 
inhibition by the CKI p21CIP1 (Karaiskou et al., 2001). In complex with Speedy A CDK1 
and CDK2 can more efficiently phosphorylate MYT1. Phosphorylated MYT1 in turn 
loses its activity towards Thr14 and Tyr15 that are inhibitory CDK1 phosphorylation 
sites. This result has led to speculation about the role of RINGO/Speedy proteins in 
regulating the maturation of Xenopus oocytes (Gutierrez et al., 2006; Ruiz et al., 2008; 
Ruiz et al., 2010).  
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Figure 4-3 Comparison of CDK activation by RINGO/Speedy and cyclins. 
The cartoon shows the different ways in which CDKs can be regulated by cyclins and 
RINGO/Speedy. CDKs in complex with RINGO/Speedy do not require additional 
phosphorylation on the activation segment for full activation in contrast to CDK-cyclin 
complexes. They can phosphorylate the same substrates but also have specific 
substrates. CDKs are depicted blue, RINGO/Speedy, dark orange, and the cyclin is 
drawn in green. Substrates are coloured differently (Nebreda, 2006). 
Investigations of substrate specificity of CDK1 and CDK2 activated by RINGO/Speedy 
has shown different preferences in comparison to cyclin activated complexes (Cheng 
et al., 2005b). It has been suggested that CDK2-RINGO/Speedy would phosphorylate 
different substrates due to the difference in preference in the site of phosphotransfer 
in comparison to CDK2-cyclin A (Figure 4-3). CDK2-cyclin A strongly favours a lysine 
residue in position +3 of the phospho-acceptor site ((S/T)PX(K/R)) of canonical 
substrates, as the phosphate moiety of phosphorylatedT160 contacts it directly (Brown 
et al., 1999). Consequently peptide KSPRK and histone H1 are excellent substrates. 
In contrast, CDK2 in complex with RINGO/Speedy can tolerate most amino acids in 
the +3 position and shows a preference for tyrosine, arginine and tryptophan (Cheng 
et al., 2005a) and therefore can phosphorylate KSPRY and KSPRR peptides. 
Activation loop phosphorylation has no significant effect on substrate recognition. 
CDK2-cyclin A and CDK2-RINGO/Speedy can phosphorylate the same substrates as 
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well. For example, phosphatase CDC25 (A, B and C) have many CDK phosphorylation 
sites which can be phosphorylated with different efficiency by CDK2-cyclin A and 
CDK2-RINGO/Speedy A2 (Cheng et al., 2005a). 
 Sequence and structural analysis of Ringo A/ Speedy 
When this work started the structure of CDK2 in complex with Spy1 has not been 
reported. Previous analysis had suggested that the speedy box in human Speedy A 
starts at residue 74 and finishes at residue 173 (Chauhan et al., 2012). In earlier papers 
(Dinarina et al., 2005) the region responsible for oocyte maturation had been mapped 
to residues 64 to 206. The Speedy A conserved region (Figure 4-1) finishes at residue 
234. HHPred analysis (Soding et al., 2005; Alva et al., 2016) was performed on the 
Speedy A sequence to identify similarities in secondary structure to other proteins. 
HHpred is able to identify very remotely related proteins, by searching alignment 
databases such as Pfam or SMART which reduces the number of hits to families rather 
than single sequences. Cyclin-10 that activates S. cerevisiae CDK PHO85 was 
predicted to share 85% similarity in its secondary structure to Speedy A in a region 
between residues 83 and 189, although there is overall only 7.5 % sequence identity 
between the two proteins (Figure 4-4 A, B).   
 A
 
B 
 
Speedy A   --MRHNQM-----YCE-TPPTVTIHVKSGSNRSH-QTRKPISL---KRPILKDSWEASEN 48 
Cyclin 10  MDMTKNHTTDTEEFDDGDIRPVSLGIVDDYNASFELPLKPKFLQSENFSDLTSEWDQSRS 60 
             * :*:      : :     *:: : .. * *.    **  *   :   *...*: *.. 
 
Speedy A   NAQNNK--SKRPRGPCLIIQRQEMTAFFKLFDDDLIQDFLWMDCCCKIADKYLLAMTFVY 106 
Cyclin 10  NTPGLAEGKTEKAQPCGTTDSSKNRIH--------------------------------- 87 
           *: .    ...   **   : .:   .                                  
 
Speedy A   FKRAKFTINEHTRINFFIALYLANTVEEDEEEAKYEIFPWALGKNWRKLFPNFLKLRDQL 166 
Cyclin 10  ------------------------------------------------------------ 
                                                                                   
 
Speedy A   WDRIDYRAIVSRRCCEEVMAIAPTHYIWQRERSVHHSGAVRNYNRDEVHLPRGPSATPVD 226 
Cyclin 10  -----------------------------VEQLLESANEMNNYLAQNIENI----NNFQV 114 
                                         *: :. :. :.**  :::.       .    
 
Speedy A   CSLCGKKGRYVRLGLSSSSSS--------------------------------------- 247 
Cyclin 10  GLLNGGKGLYSSMGDDSSACINGTNFSSTSNFELSDDELEDTTGCTSSIFDKDLFHQQNG 174 
             * * ** *  :* .**:.                                         
 
Speedy A   ----------------SSDTGELMEKDSQ-------------------ELHSAFSVDTAG 272 
Cyclin 10  LSIPRRRSPLFKSPTASFEIGDATDVEEQDIDDSIFSECSSITSFDMGGLHISLPHDEEE 234 
                           * : *:  : :.*                    ** ::  *    
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Speedy A   DPPHTYSQ------------VANDHQSNKENETNFV----------------------KK 298 
Cyclin 10  DQEKTKSESENPLLHGIPVDVEVPHISVDEALANFKETIELLLKLSGNRKCTGFNTRVEK 294 
           *  :* *:            *   * * .*  :**                       :* 
 
Speedy A   NKSVEWFAESEE------------------------------------------------ 310 
Cyclin 10  KEYSNFYMKSKPTLSSADFLKRIQDKCEYQPTVYLVATFLIDTLFLTRDGNNILQLKLNL 354 
           ::  ::: :*:                                                  
 
Speedy A   ------------------------------------------------------------ 
Cyclin 10  QEKEVHRMIIAAVRLSTKLLEDFVHSHEYFSKVCGISKRLLTKLEVSLLICVCNTKLMVS 414 
                                                                                   
 
Speedy A   ------------------- 
Cyclin 10  NRKLAASKLLLNELRSFCV 433 
Figure 4-4 Identification of primary and secondary structure of similarities of 
Speedy A with another proteins. 
(A) Region of Speedy A1 sequence with high secondary structure homology to cyclin 
10 (Uniprot entry 4krd_B) identified by HHpred (Soding et al., 2005). (B) Sequence 
overlay of Speedy A and cyclin 10. Identical residues are identified by a star under the 
sequence alignment, similar residues identified by two dots. Uniprot entries for Speedy 
A is Q5IBH7 and for cyclin 10 is P53124. 
The structure of cyclin-10 has been solved (PDB code: 4KRD) and was compared to 
that of cyclin A (PDB code: 1VIN) using CCP4MG (Figure 4-5). The CBF of cyclin -10 
overlays well with the cyclin A N-terminal CBF. 
 
Figure 4-5 Overlay of cyclin A with cyclin 10. 
Cyclin A (PDB code: 1VIN) is coloured light green, cyclin-10 (PDB code: 4KRD) is 
coloured lilac. Cyclin A helices are labelled from α1 to α5. Structures were superposed 
and image created using CCP4mg (Winn et al., 2011). 
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 Structural analysis of RINGO/Speedy in complex with CDK2 
While this project was in progress, the structure of human Speedy A referred to as Spy 
1 (McGrath et al., 2017) and comprising the speedy domain (residues 61-213) was 
solved bound to CDK2  The structure revealed some new features of CDK activation 
and provided structural evidence to show that CDK2 could adopt an active structure in 
the absence of activation segment phosphorylation.  
Spy 1 has one cyclin box fold (CBF) comprised of four smaller helices (α1, α2, α4, and 
α5) surrounding a longer central one (α3) (Noble et al., 1997). The CBF of Spy 1 is 
book-ended by one additional helix (α1’) and two shorter additional helices (α6 and α7) 
at its N- and C-termini respectively (Figure 4-6 A, C). Spy1 and cyclin A adopt a very 
similar binding orientation towards CDK2. The Spy1 α helices α3 and α5, the α3-α4 
and α5-α6 loops form contacts with the C-helix of CDK2, α2, and the α3-α4 loop, and 
α6 directs the position of the activation segment (Figure 4-6 B). 
 
 
A 
 
B 
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C 
                      α1’        α1                 α2                   
SPY1   --GPCLVIQRQDMTAFFKLFDDDLIQDFLWMDCCCKIADKYLLAMTFVYFKRAKFTISEH 58 
SPY1C  GNGFLRFRQHQEVQAFLSLLEDSFVQEFLSKDPCFQISDKYLLAMVLVYFQRAHLKLSEY 60 
SPY1E4 --KRASSVLPEHHEAFNRLLGDPVVQKFLAWDKDLRVSDKYLLAMVIAYFSRAGLFSWQY 58 
                 :.  **  *: * .:*.**  *   :::*******.:.**.** :   :: 
               α3              α4                  α5 
SPY1   TRINFFIALYLANTVEEDEEETKYEIFPWALGKNWRKLFPNFLKLRDQLWDRIDYRAIVS 118 
SPY1C  THSSLFLALYLANDMEEDLEGPKCEIFPWALGKDWCLRVGKFLHQRDKLWARMGFRAVVS 120 
SPY1E4 QRIHFFLALYLASDMEEDNQAPKQDIFSFLYGKNYSQR-PLFHKLRYQLLCSMRWRTWVS 117 
        :  :*:*****. :*** :  * :** :  **::      * : * :*   : :*: ** 
           α6         α7 
SPY1   RRCCEEVMAIAPTHYIWQRERSVHHSGAVRNYNR 152 
SPY1C  RQCCEEVMAKEPFHWAWTRDRRPHHGGVQRVCPQ 154 
SPY1E4 PEEMEEIQAYDPEHWVWARDRTLIS--------- 142 
        .  **: *  * *: * *:*              
Figure 4-6 Secondary structure comparison of Spy1 and cyclin A. 
(A) Alignment of Spy1 (light blue) with cyclin A2 (light green) (PDB entries: 5UQ2 and 
1JST respectively). Cyclin A2 box folds are marked, helices are identified by numbers. 
The MRAIL motif of cyclin A is coloured purple. (B) Comparison of overall Spy1 and 
cyclin A2 binding to CDK2 by alignment. CDK2 is coloured coral, CDK2 C helix is 
coloured gold, activation segment is coloured red, Spy 1 helices involved in the 
interaction are identified by numbers. (C) Sequence alignment of Spy1 homologs 
within the speedy domain, Spy1, Spy1C, Spy1E4 (Uniprot entries  Q5MJ70, Q5MJ68, 
A6NLX3). Identical residues are indicated with an apteryx underneath the sequences. 
Sequences folding into helices are identified as red boxes and labelled. Residues of 
Spy1 that bind to the CDK C helix are coloured blue and residues that interactwith the 
CDK activation segment are red.  Structures were superposed and image created 
using CCP4mg (Winn et al., 2011). 
 
The overall structure of CDK2-Spy 1 is very similar to that of CDK2 bound to cyclin A 
(Jeffrey et al., 1995; Russo et al., 1996b; Welburn et al., 2007). It revealed the features 
of an active CDK conformation where the C-helix is rotated inwards and the activation 
segment is moved away from the active site by 5-6 Å when compared to a monomeric 
CDK2 structure (Figure 4-6B, 4-7A). The C-helix of CDK2 forms similar hydrogen 
bonds with Spy 1 as with cyclin A (Jeffrey et al., 1995) although there are notable 
differences in the ways in which Spy1 and cyclin A bind to CDK2. Despite the same 
location on secondary structures of Spy1 A and cyclin A residues that interact with 
CDK2 their chemical properties are different. Spy1 primarily uses Trp168 but cyclin A 
uses Phe304 and Leu299 (Figure 4-7 B). The overall structure supports the findings 
that Spy1 can substitute for the cyclins as a CDK activator (Karaiskou et al., 2001; 
Cheng et al., 2005a). 
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Figure 4-7 Comparison of CDK2 secondary structures 
(A) Structures of monomeric CDK2 (PDB entry: 1HCK), CDK2-cyclin A (PDB entry: 
1JST) and CDK2-Spy1 (PDB entry:5UQ2) were aligned and the CDK2 structures 
extracted. Monomeric CDK2 is coloured ice blue, CDK2 in complex with Spy1 is coral 
and CDK2 in complex with cyclin A is sea green. Movements of the C-helix and the 
activation segment (T-loop) are shown by colour-coded arrows. (B) C-helix (also 
termed PSTAIRE helix) interactions with Spy1 and cyclin A. CDK2 is coloured coral 
and Spy1 is blue, Cyclin A is green. Figures prepared using CCP4mg (McNicholas et 
al., 2011). 
 
However, the most significant functional difference between the CDK2-cyclin A and 
CDK2-Spy1 structures is the conformation of the activation loop. Cyclin A binding to 
CDK2 changes the position of the activation segment moving it out of the active site 
(De Bondt et al., 1993; Jeffrey et al., 1995) (Figure 4-8) and phosphorylation of Thr160 
opens it even further. The position of the non-phosphorylated activation segment of 
CDK2 bound to Spy1 positioned the way that it resembles activated CDK2 although in 
slightly different position then either activated or fully activated CDK2 (Figure 4-8).  
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Figure 4-8 Activation segments comparison. 
Comparison of activation segments of CDK2 in complexes with cyclin A (coloured sea 
green, PDB code: 1JST), phosphorylated on Thr160 CDK2 in complex with cyclin A 
(coloured pink, PDB code: 4EOQ) and bound to Spy1 (coloured coral, PDB code: 
5UQ2). Thereonine 160 is represented in cylindrical form. Figures prepared using 
CCP4mg (McNicholas et al., 2011). 
A complex set of interactions have been proposed to stabilise the CDK2 activation 
segment conformation. Three acidic residues Glu134, Glu135 and Asp136 of the α3-
α4 loop interact within a CDK2 cleft formed between the C-helix and activation 
segment. Important interactions are made between Asp136 and Arg50 of the CDK2 C-
helix and Arg150 of the CDK2 activation segment (Figure 4-9). D136 mimics the 
phosphate moiety of the phosphorylated Thr160 side chain in pCDK2-cyclin A that is 
coordinated by three arginine side chains.  Spy1 also interacts with residues N terminal 
to Thr160 to pull the activation segment even further out of the active site cleft.  Glu135 
of Spy1 forms hydrogen bonds with the amide and side chain oxygen of Thr158 of 
CDK2 and Asp97 forms a salt bridge with Arg157, for which there are no analogous 
interactions observed in the CDK2-cyclin A structure. Interestingly, the Spy1 residues 
involved in T-loop positioning are conserved across the Spy1 paralogs suggesting its 
importance for CDK activation (Figure 4-6C) (McGrath et al., 2017).  
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Figure 4-9 Interactions involved in activation segment positioning. 
CDK2 is coloured coral and  Spy 1 coloured blue, CDK2 activation segment is coloured 
red (PDB code: 5UQ1).  Figures prepared using CCP4mg (McNicholas et al., 2011). 
The structure of a CDK2-Spy1-p27KIP1 complex has also provided a structural 
explanation for why CDK2 bound to Spy1 is not as effectively inhibited by CKI CIP/KIP 
inhibitors as CDK2 bound to cyclin A or cyclin E (McGrath et al., 2017). Spy1 does not 
contain an MRAIL motif that is embedded in the cyclin recruitment site located within 
the N-terminal CBF that binds to CDK substrates and inhibitors that contain a (K/R)XLF 
or (K/R)XLXF motif (Russo et al., 1996b), (Figure 4-6 C). Notably, the α1 and α3 helices 
that help form the recruitment site are shorter in Spy1 (Figure 4-6 A). However, despite 
the structural differences, CDK2-Spy1 can form a weak complex with p27KIP1 and is 
inhibited by the association (McGrath et al., 2017).  
 Aims and objectives 
Structural analysis of a CDK2-Spy1 structure has revealed how Spy1 can activate 
CDK2 in the absence of activation segment phosphorylation. However, a number of 
questions remain. Previous work has shown how the structure of the activation 
segment can dictate CDK sequence preferences around the site of phosphotransfer 
(Brown et al., 2015) . The expression of Spy1 in specialised tissues suggests that it 
may alter CDK substrate specificity for tissue-specific functions. Speedy A also 
activates CDK1 for which there is no CDK1-Spy1 structure. The first aim of this project 
was to express and purify a fragment of Speedy A in order to characterise its binding 
towards CDK1 and CDK2 and to compare the activity of CDK1 and CDK2 bound to 
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cyclin A, cyclin B and Speedy A. The second aim was to determine the structures of a 
CDK1/2-Spy1 complex and compare it to structures of CDK1/2-cyclin B and CDK1/2-
cyclin A. 
 RGC-32 as a CDK1 binding partner 
Another CDK activator for which there is little structural information is the protein 
(Response gene to complement 32) (RGC32). RGC32 was discovered in a screen for 
genes that respond to complement activation in primary rat oligodendrocytes (Badea 
et al., 1998). The complement system is a part of the body’s immune response that 
involves around 20 proteins that act against foreign agents, trigger inflammation and 
remove debris from cells and tissues (Chaplin, 2005). This system must be very 
carefully regulated so that it does not attack the body’s healthy cells.  
The human RGC32 gene is located on chromosome 13 and encodes a 117 amino acid 
protein with 92% sequence similarity to the rat and mouse proteins (Badea et al., 
2002). RGC32 mRNA is over expressed in placenta, skeletal muscle, liver, pancreas, 
kidney and endothelial cells (Badea et al., 2002). The protein has been detected by 
Western blotting in human liver, brain and heart (Badea et al., 2002). It is expressed in 
a wide range of cell lines and in response to different stimuli (Vlaicu et al., 2008). Its 
overexpression can be induced by complement and subsequent formation of the C5b-
9 terminal complement complex, by growth factors (Fosbrink et al., 2003), and by 
steroid hormones (Chen et al., 2005). As a consequence it has been linked to 
inflammation, tissue regeneration and cancer. It has also been implicated in cell cycle 
activation (Badea et al., 1998; Badea et al., 2002) and apoptosis (Tegla et al., 2013). 
To demonstrate its relevance to the cell cycle, experiments have been performed in 
cultured smooth muscle cells, where it was shown that exposure to activated 
complement triggered expression of RGC32 in S-phase and G2/M entry (Badea et al., 
2002). Accordingly, RGC32 silencing in the same cells blocked DNA synthesis induced 
by C5b-9 and growth factors, confirming the importance of RGC32 for S-phase entry. 
Furthermore, the knock down of RGC32 by siRNA resulted in a reduction of C5b-9 
induced activation and Akt phosphorylation (Fosbrink et al., 2009). From these findings 
in cultured cells it can be hypothesized that cell cycle progression induced by C5b-9, 
depends on RGC32 and involves regulation of Akt activity and growth factor release 
(Fosbrink et al., 2009).   
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The inhibitory effect on cell cycle activation induced by receptor/CD28 binding has 
been shown in T-cells of mice (Tegla et al., 2015) (Vlaicu et al., 2010). Because RGC32 
induces cell cycle in primary cells (Badea et al., 1998; Fosbrink et al., 2009) but inhibits 
cell cycle progression in T-cells (Tegla et al., 2015) this protein might play a dual role.  
It also has been shown that RGC-32 expression is dependent on age. Fibroblasts from 
older and younger people were compared and revealed downregulation with age 
suggesting that decreasing levels of RGC32 are associated with cellular senescence 
(Kyng et al., 2003). RGC32 has also been reported to form a complex with CDK1-cyclin 
B and increase its kinase activity. It can be phosphorylated by CDK1 and its 
phosphorylation on Thr91 is critical for its ability to stimulate CDK1 activity (Badea et 
al., 2002).  
 RGC32 sequence analysis 
RGC32 is a small protein of 137 amino acids in humans. It is well conserved through 
the mammalian species with 86% identity (Figure 4-10 A). It has been analysed using 
secondary structure prediction software HHPred (Soding et al., 2005; Alva et al., 2016) 
and Ronn v3.2. The analysis has shown mainly disordered structure by Ronn v3.2 
(Figure 4-10 B) and HHPred suggested probability of 65% of RGC32 forming a helical 
structure between aminoacids 14 and 41 (Figure 4-10 C) due to its similarity to 
proteasome-associated ATPase (Uniprot entry 3M91_B). 
 
A 
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Figure 4-10 Sequence comparison between RGC32 from the different species. 
(A) RGC32 from human (Uniprot entry: Q9H4X1), mouse (Uniprot entry: Q9DBX1) and 
rat (Uniprot entry: Q9Z2P4) have been compared using Clastal Omega (Sievers et al., 
2011). Identical positions coloured dark blue, similar positions are coloured light blue. 
Conservation level is represented by yellow bars. (B ) Results of protein sequence 
analysis by the structure prediction software  Ronn v3.2 (Yang et al., 2005). (C) RGC32 
can form helical structure between aminoacids 14 and 41 with probability of 65% 
calculated by HHPred (Alva et al., 2016). 
 
 RGC32 in cancer 
Since RGC-32 promotes cell proliferation it is perhaps not surprising that its expression 
is upregulated in many cancers, for example in colon (Fosbrink et al., 2005), ovarian 
(Dassen et al., 2007), prostate (Fosbrink et al., 2005) and breast cancers (Kang et al., 
2003). However, in astrocytoma, osteoblastic and colon cancer cell lines 
overexpression of RGC32 was found in contrast to delay G2/M progression. In these 
cell lines, RGC32 was preferentially localised in the cytoplasm during interphase, but 
on centrosomes and spindle poles during prometaphase and metaphase (Saigusa et 
al., 2007). In this regard, RGC32 can also form a complex with polo-like kinase 1 (Plk1) 
suggesting it may in certain settings be a negative regulator of the cell cycle. 
Supporting this potential dual role, studies using gene microarrays have indicated 
RGC32 mRNA expression to be upregulated in some tumours, for example drug 
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resistant glioblastoma (Bredel et al., 2006) or multiple myeloma (Zhan et al., 2006) and 
downregulated in others including ovarian (Donninger et al., 2004) and breast cancer 
(Chen et al., 2006). RGC32 has also been proposed to be a tumour suppressor protein 
(Saigusa et al., 2007). However, data from a colon cancer study that detected RGC32 
in epithelial tissue in tumours but not in normal adjacent tissue argues against this 
hypothesis (Fosbrink et al., 2005).  
 
 Aims and objectives 
RGC-32 is not a very well-studied protein in terms of its structure and interactions with 
members of the CDK family. It is known as an activator of CDK1 but neither its binding 
site on CDK1, nor its mechanism of action have been characterised. In collaboration 
with the laboratory of Professor Michelle West the aim of this project was to 
characterise the interaction of RGC32 with CDK1 and CDK1-cyclin B and assess its 
effect on CDK1 activity.  
 
4.2 Description of biophysical methods 
 Theoretical background of surface plasmon resonance  
Surface plasmon resonance is a very sensitive biophysical method that can measure 
label-free real time interactions between molecules. It measures the association and 
dissociation rates of protein interactions from which dissociation constants can be 
calculated. The basis of this technique lies in the measurement of changes in the 
refractive index of the liquid close to a metal surface to which a protein bait (conjugated 
ligand) is bound. The presence of weight in one position resonates to electrons across 
the whole surface. This change in electron resonance affects the refractive index which 
can be measured by the detector as the change in the angle of the refracted light.  
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Figure 4-11 Schematic representation of surface plasmon resonance.   
An antibody is attached to the gold surface to act as a bait for the protein of interest. 
The protein of interest (which is also called the ligand) in its turn can bind the binding 
partner (analyte) flowed over the chip surface. Due to the change of mass, refractory 
properties of the gold surface change accordingly resulting in the alteration of the 
refractive angle. Changes of refractive angle are measured by the detector. 
 
The first SPR instrument was developed in 1991 using BiaCore technology. Modern 
instruments now use sensor chips with a gold surface that can be modified with 
different matrices depending on the application (Figure 4-11 A). For example, dextran 
can be activated to bind directly to molecules of interest. Molecules of interest that 
attached to the surface of the chip are called analytes and the ones that flow through 
the cell are called ligand. Polarised light from the laser source is directed at a certain 
angle through the half circular prism to the gold surface where the plasmon resonance 
is generated. As ligand binds to the surface it changes the refractive index that affects 
 Light source 
Antibody 
Conjugated Ligand 
Analyte  
Detector 
Polarised 
 light 
Reflected 
 light 
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the angle of reflection recorded by the detector. The mass of bound ligand is 
proportional to the angle of the plasmon resonance. The results of SPR experiments 
are normally represented by a sensogram (Figure 4-11 B). The shape of the curve can 
be used to measure the rate of association (ka). Once the binding reaches an 
equilibrium and the sensor gram plateaus, the rate of dissociation (kd) can be 
measured as the ligand is released during a wash step.  The Kd can be determined 
from the ka and kd values or alternatively from the equilibrium binding determined from 
the injection of a ligand concentration series, the concentration of the bound ligand 
relating to the response units (RU).  
𝐾𝑑 =
𝑘𝑑
𝑘𝑎
 
Equation 4-1 Binding constant determination. 
Abbreviations: Kd –dissociations constant, kd –dissociation rate, ka –association rate. 
 
4.3  Materials and Methods 
 Generation of constructs 
The full length human Speedy A sequence (uniprot entry Q5MJ70) was ordered from 
Open Biosystems, (Clone ID 4839330) in the pBluescriptR vector. Custom designed 
primers were purchased from Eurofins Genomics, purified by a standard desalting 
protocol and re-suspended in nuclease free water (Ambion). The full list of primers is 
provided in Table 4-1.  
PCR reactions were performed to generate DNA inserts for subsequent cloning. Each 
PCR reaction contained 1 x Phusion HF buffer, 200 µM dNTPs, 0.2 µM of forward 
primer and 0.2 µM of reverse primer, 50 ng template DNA and 1U Phusion Hot Start 
DNA Polymerase (NEB). Reactions were started by heating to 98°C for 30 seconds 
and then cycled through the following steps 30 times: (i) 5 sec denaturation step at 
98°C, (ii) 5 sec annealing step at 65°C and (iii) an extension step depending on the 
length of DNA to be amplified, calculated at 30 sec per kb pair.  The final extension at 
72°C lasted for 7 minutes before reactions were held at 4°. To remove methylated 
template DNA, the samples were digested by addition of 0.5 µl Dpn1 (20,000 U/ml) at 
37°C for 1 hour and subsequently purified using a Qiagen QIAquick PCR purification 
 122 
 
kit. The DNA concentration was estimated by Nanodrop Spectrophotometer 2000 
(Thermoscientific). 
Different plasmids were used depending on the expression system required (Table 4-
2, Table 4-3), pGEX6P-1 and pET21dMBP were used for expression in E. coli and 
pACEBac1 was used for virus generation and future expression in insect cells. 
Plasmids were prepared by digesting with the appropriate restriction enzymes in the 
presence of the appropriate restriction enzyme buffer for 3 hours all together but with 
new addition of the restriction enzyme every hour at 37°C followed by enzyme heat 
inactivation at 65°C for 20 minutes. Plasmids were purified using Qiagen QIAquick 
PCR purification kits.  
Purified inserts and plasmids were validated by agarose gel electrophoresis and 
subsequently cloned by in-fusion cloning (Takara Bio USA). 100 nM of DNA fragment 
of interest and 100 nM of linearized vector were incubated for 15 minutes at 50°C in 
the presence of 1x in-fusion enzyme premix. After the incubation reactions were stored 
on ice.  
 
Construct  Cloning 
site 
Forward primer Reverse primer 
HsSpeedyA21-
313/pGEX6P-1 
BamH1 
EcoR1 
GGGGCCCCTGGGATCA
TGAGGCACAATCAGATG
TGTTGTGAGACAC 
GTCGACCCGGGAATT
GTTGGGCCATCTCATT
CTTCACTTCCTG 
HsSpeedyA264-
313/pGEX6P-1 
BamH1 
EcoR1 
GGGGCCCCTGGGATCC
TGGTTATACAGCGTCAG
GATATGACTGC 
GTCGACCCGGGAATT
GTTGGGCCATCTCATT
CTTCACTTCCTG 
HsSpeedyA264-
234/pGEX6P-1 
BamH1 
EcoR1 
GGGGCCCCTGGGATCC
TGGTTATACAGCGTCAG
GATATGACTGC 
GTCGACCCGGGAATT
TCATTTTTTACCACAG
AGTGAACAATCTACTG
GTG 
HsSpeedyA21-
189/pET21dMBP3C 
BamH1 
Xho1 
AGGGGCCCCTGGATCA
GATGAGGCACAATCAGA
TGTGTTGTGAGAC 
GGTGGTGGTGCTCGA
TCATGCAATGGCCATA
ACCTCCTCACAACATC 
HsSpeedyA21-
206/pET21dMBP3C 
BamH1 
Xho1 
AGGGGCCCCTGGATCA
GATGAGGCACAATCAGA
TGTGTTGTGAGAC 
GGTGGTGGTGCTCGA
TCAAGCTCCACTGTGA
TGAACAGAACGTTCTC 
HsSpeedyA21-
313/pET21dMBP3C 
BamH1 
Xho1 
AGGGGCCCCTGGATCA
GATGAGGCACAATCAGA
TGTGTTGTGAGAC 
GGTGGTGGTGCTCGA
GTTGGGCCATCTCATT
CTTCACTTCCTG 
HsSpeedyA227-
189/pET21dMBP3C 
BamH1 
Xho1 
AGGGGCCCCTGGATCA
GCCUAAAAAGCCCAUU
ACUCUGAAGC 
GGTGGTGGTGCTCGA
TCATGCAATGGCCATA
ACCTCCTCACAACATC 
HsSpeedyA227-
206/pET21dMBP3C 
BamH1 
Xho1 
AGGGGCCCCTGGATCA
GCCUAAAAAGCCCAUU
ACUCUGAAGC 
GGTGGTGGTGCTCGA
TCAAGCTCCACTGTGA
TGAACAGAACGTTCTC 
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HsSpeedyA227-
313/pET21dMBP3C 
BamH1 
Xho1 
AGGGGCCCCTGGATCA
GCCUAAAAAGCCCAUU
ACUCUGAAGC 
GGTGGTGGTGCTCGA
GTTGGGCCATCTCATT
CTTCACTTCCTG 
HsSpeedyA264-
189/pET21dMBP3C 
BamH1 
Xho1 
AGGGGCCCCTGGATCA
GCTGGTTATACAGCGTC
AGGATATGACTGC 
GGTGGTGGTGCTCGA
TCATGCAATGGCCATA
ACCTCCTCACAACATC 
HsSpeedyA264-
206/pET21dMBP3C 
BamH1 
Xho1 
AGGGGCCCCTGGATCA
GCTGGTTATACAGCGTC
AGGATATGACTGC 
GGTGGTGGTGCTCGA
TCAAGCTCCACTGTGA
TGAACAGAACGTTCTC 
HsSpeedyA264-
313/pET21dMBP3C 
BamH1 
Xho1 
AGGGGCCCCTGGATCA
GCTGGTTATACAGCGTC
AGGATATGACTGC 
GGTGGTGGTGCTCGA
GTTGGGCCATCTCATT
CTTCACTTCCTG 
Universal primers 
for pACEBac1 
BamH1 
EcoR1 
CATCGGGCGCGGATCC 
ATGAAAATCGAAGAAGG
TAAACTGGTAATCTGG  
GTAGGCCTTTGAATTC
CCTTTCGGGCTTTGTT
AGCAGCCG 
Table 4-1 Table of primers 
 
 
  E. coli transformation 
DNA from the in-fusion reaction were transformed into StellarTN competent cells 
(Clontech) following the manufacturer’s protocol. Briefly, 2µl of the in-fusion reaction 
were added to 100 µl of thawed competent cells and incubated on ice for 30 minutes.  
Cells were heat shocked for 45 seconds at 42°C followed by cooling down on ice for 2 
minutes. 900 µl of SOC media was added before further incubation at 37°C for 1 hour. 
Cells were plated on agar containing the appropriate antibiotic and incubated at 37°C 
overnight. Single colonies were used for inoculation in 10 ml of LB media containing 
appropriate antibiotic at 37°C while shaking overnight. 5 ml of culture was pelleted by 
centrifugation at 6797 x g for 3 minutes and DNA extracted using a Miniprep kit 
(Qiagen). The DNA concentration was measured by Nanodrop 2000 (Thermo 
Scientific) at 280 nm wavelength. DNA samples were sent for sequencing analysis by 
Eurofins Genomics. The results were analysed using the ExPASy translation tool 
(Gasteiger et al., 2003) and sequence alignment by Clustal Omega (Sievers et al., 
2011). 
Bacmids were produced by transformation of DH10EMBacY cells with 1 µg pACEBac1 
vector containing MBP-tagged truncated variants of the human Speedy A sequence. 
Transformation reactions were incubated for 16 hours at 37°C and then plated on LB 
agar plates containing 50 µg/ml ampicillin, 30 µg/ml kanamycin, 7 µg/ml gentamycin, 
10 µg/ml tetracycline, 100 µg/ml X-Gal and 40 µg/ml IPTG. White colonies were 
selected after 24 hours incubation and used to inoculate 10 ml LB without added 
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antibiotic. Bacteria were pelleted by centrifugation and bacmid DNA prepared using a 
Miniprep kit (Qiagen) with the modification that the column filtration step was 
substituted by isopropanol precipitation followed by a 70% ethanol wash. Recombinant 
bacmid was re-suspended in 20 µl of sterile water and used straight away or stored at 
-20°C for later use to generate recombinant baculo virus.  
 Baculovirus preparation using the MultiBac expression 
system 
20 µl of recombinant bacmid was mixed with 200 µl of Sf900 media warmed to 27°C. 
100 µl of GeneJuiceTM :Sf900 mixture in a ratio of 1:10 was added to each tube and 
left to incubate for 30 minutes. 3 ml of Sf9 cells were seeded into 6-well plates to give 
a total cell number of 0.5 x 106 cells. 150 µl of the DNA/GeneJuiceTM /Sf900 cocktail 
was added to each well and left to incubate at 27°C in the dark for 60 hours. Because 
the bacmid contains the YFP gene, the success of transfection can be monitored by 
fluorescence microscopy (Nikon Eclipse TE2000-U). Further expression tests were 
also required to check the efficiency of transfection. When fluorescence was observed, 
the media was harvested separately from each well as the P0 stock and used for the 
next generation of virus. 
 Insect cell culture and virus amplification  
P0 virus was used to generate P1 stock by infecting 1 x 106  Sf9 cells. 0.5 ml of P0 
stock was used for every 50 ml of cells. Cells where monitored every day and 
harvested 24 hours after arrest of cell proliferation which typically occurred after 96 
hours incubation. P2 was generated from P1 viral stock and was routinely used for 
protein expression. 
 Expression tests  
To identify the optimal volume of viral stock for infection and length of infection all 
viruses were subjected to expression tests. 50 ml of cells were infected with 50, 100 
and 500 µl of P2 virus and incubated with shaking at 27°C. 10 ml aliquots were 
collected after 72, 96 and 120 hours and pelleted by centrifugation at 646 x g for 15 
minutes. Pellets were frozen to test expression at the end of the trial. Optimal 
conditions for infection were used for subsequent protein expression. 
To optimise protein expression in recombinant E. coli cells, DNA sequences of interest 
were cloned into bacterial expression vectors and transformed into Rosetta 
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2TM(DE3)pLysS cells. 10 ml of starter culture was prepared from a single colony in LB 
containing appropriate antibiotic grown overnight at 37°C in a shaking incubator. 1 ml 
overnight cultures were used to inoculate 100 ml of LB media supplemented with 
antibiotic at 37°C with shaking (200 rpm) until the optical density at 600 nm (OD600) 
reached 0.6-0.8. The temperature was then reduced to 20° C for 30 minutes before 
induction with 100 µM IPTG followed by incubation with shaking for 16-20 hours. 
Bacterial cells were pelleted by centrifugation (JLA 8.1000 rotor at 6238 x g, 20 mins) 
and pellets were stored at -20°C for further expression tests. 
Frozen cell pellets were re-suspended in 1 ml of BugBuster (Merck Millipore) with 
addition of 0.25 mg/ml Lysozyme, 50 μg/ml RNase, 10 μg/ml DNase and 5 mM MgCl2. 
The cells were incubated with rotation for 20 min at room temperature for cell lysis. 3 
μl of each lysate was taken for SDS-PAGE analysis and the rest was transferred into 
Eppendorf tubes and centrifuged for 20 min at 6500 x g. 3μl of each supernatant was 
analysed by SDS-PAGE. Amylose beads were equilibrated in TBS buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 0.01% MTG) as a 50% slurry and supernatants of each 
sample were added to 50 μl bead aliquots and incubated for 1h at +4°C on a rotating 
wheel. Beads were washed with ice cold TBS 3 times in 0.5 ml volume and pelleted by 
centrifugation at +4° at 1610 x g. After the final wash 30 µl of RunBlue LDS Sample 
buffer (Expedeon) was added to the pelleted beads and denaturated through heating 
at 95°C for 5 minutes. 15 µl of each sample was analysed by SDS-PAGE as described 
in section 2.2.10. 
 
 Western blotting  
After separation by SDS-PAGE, proteins were transferred by wet transfer onto 
HybondTM –C Extra nitrocellulose membrane (Amersham Bioscience, GE Healthcare, 
Little Chalford,UK) at 200 V for 75 min in Tris-Glycine transfer buffer (Expedeon Protein 
Solutions, Cambridge, UK). The nitrocellulose membrane was blocked in 5% milk in 
Tris-buffered saline with 0.1% Tween 20 (TBS-T) for 20 min followed by 15 hour 
incubation at +4°C with Speedy polyclonal rabbit primary antibody (Bio-Techne, 
Abingdon, UK) in 2.5% milk TBS-T, dilution 1:1000. After the incubation, the membrane 
was washed twice in TBS-T and left at RT on a rocker with gentle agitation for 1 hour 
in Goat Anti-Rabbit IgG, HRP conjugate secondary polyclonal antibody (Dako) diluted 
in TBS-T 1:2000. Unbound secondary antibody were removed by washing in TBS-T 
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twice. Proteins were detected by enhanced chemiluminescence using Amersham ECL 
Western blotting detection reagent (GE Healthcare, Little Chalfont,UK) and visualised 
and analysed in a FujiFil LAS-3000 (Fujifilm,Tokyo,Japan). 
 Surface plasmon resonance (SPR)  
All SPR experiments were carried out on a Biacore S200 (GE Healthcare) system. All 
runs were performed at 25°C using buffer containing 10 mM HEPES, 150 mM NaCl, 3 
mM EDTA, 0.05% TWEEN. CM5 BIAcore sensor chips were prepared by amine 
coupling goat anti-GST antibody to a chip surface using a GST capture kit and following 
the standard protocol provided by GE Healthcare. Protein samples were clarified by 
centrifugation at 10000 x g at 4°C (Beckman Coulter Allegra 22R) and diluted to the 
required concentrations before use. 20 µg/ml GSTCDK1, GSTCDK2 or GSTRGC32 
were captured at 5 µl/min for 400 s (GSTCDK2) or 500 s (GSTCDK1 and GSTRGC32). 
CDK1, RGC32 or CKS1 were used as analytes at different concentrations. CDK1 was 
used at 40 nM, 200 nM, 1000 nM, 2000 nM and 5000 nM; RGC32 at 62.5 nM, 250 nM, 
1000 nM, 2500 nM, 4000 nM; and CKS1 at 0.8 nM, 4 nM, 20 nM, 100 nM, and 500 nM. 
Analytes were flowed over the GST-captured protein at 30 µl/min for 380 s followed by 
dissociation over 720 s. Between each run GST-captured protein was removed from 
the antibody surface by 20 mM glycine pH 2.2 at 30 µl/min for 240 s and then 
recaptured. GST was used as a negative control on a separate lane and was captured 
at 10 µg/ml for 60 s. GST sensogram readings were subtracted from the sample 
sensograms to eliminate bulk effects and non-specific binding. Kd values together with 
association ka and dissociation rates kd  were calculated by Biacore evaluation 
software. 
 
4.4 Results 
 Generation of Speedy/Ringo A constructs 
Based on secondary structure prediction and published data (Dinarina et al., 2005) a 
number of sequences were selected to be cloned into vectors for protein expression 
(Table 4-2 and Figure 4-13). During the first round of cloning, bacterial protein 
expression was assessed. Three different constructs to express the full length protein, 
the speedy box (residues 64-313) and the C-terminal domain (residues 64-234 that 
contains the speedy box and H- and PRGP-motifs) were cloned by in-fusion into 
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pGEX6P-1 which contains an N terminal GST tag. The cyclin box of Speedy A 
according to HHpred starts at residue 83 but earlier published data suggested that 
residues between 64 and 83 were important for function (Dinarina et al., 2005). 
Consequently we chose to start at residue 64 (Figure 4-12). 
10         20         30         40         50 
MRHNQMCCET PPTVTVYVKS GSNRSHQPKK PITLKRPICK DNWQAFEKNT  
60         70         80         90        100 
HNNNKSKRPK GPCLVIQRQD MTAFFKLFDD DLIQDFLWMD CCCKIADKYL  
110        120        130        140        150 
LAMTFVYFKR AKFTISEHTR INFFIALYLA NTVEEDEEET KYEIFPWALG  
160        170        180        190        200 
KNWRKLFPNF LKLRDQLWDR IDYRAIVSRR CCEEVMAIAP THYIWQRERS  
210        220        230        240        250 
VHHSGAVRNY NRDEVQLPRG PSATPVDCSL CGKKRRYVRL GLSSSSSLSS  
260        270        280        290        300 
HTAGVTEKHS QDSYNSLSMD IIGDPSQAYT GSEVVNDHQS NKGKKTNFLK  
       310  
KDKSMEWFTG SEE 
Figure 4-12 Protein sequence of Speedy A. 
Speedy box predicted by HHpred software. Residues 83 – 189 coloured orange, H 
motif – purple and PRGP motif – red (Soding et al., 2005).  
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Figure 4-13 Sequences of Speedy1/Ringo A cloned into pGEX6P-1 vector. 
Sequence Tag Vector Host E. coli strain 
1-313 GST pGEX6P-1 RosettaTM (DE3 )pLysS 
64-313 GST pGEX6P-1 RosettaTM (DE3 )pLysS 
64-234 GST pGEX6P-1 RosettaTM (DE3 )pLysS 
1-313 MBP pET21dMBP3C RosettaTM (DE3 )pLysS 
1-189 MBP pET21dMBP3C RosettaTM (DE3 )pLysS 
1-206 MBP pET21dMBP3C RosettaTM (DE3 )pLysS 
27-189 MBP pET21dMBP3C RosettaTM (DE3 )pLysS 
27-206 MBP pET21dMBP3C RosettaTM (DE3 )pLysS 
27-313 MBP pET21dMBP3C RosettaTM (DE3 )pLysS 
64-189 MBP pET21dMBP3C RosettaTM (DE3 )pLysS 
64-206 MBP pET21dMBP3C RosettaTM (DE3 )pLysS 
64-313 MBP pET21dMBP3C RosettaTM (DE3 )pLysS 
Table 4-2 Ringo/Speedy A constructs 
Constructs have been generated for expression in E.coli and insect cells. GST, 
glutathione-S-transferase; MBP, maltose binding protein. 
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Prepared to identify optimal protein expression conditions, vectors were transformed 
into a set of expression strains, ArcticExpress(DE3) (Agilent Technologies), 
Lemo21(DE3) (NEB), and RosettaTM (DE3)pLysS (Novagen), and grown in Lysogeny 
(LB), Terrific broth (TB) or Auto-induction media (AIM) (Figure 4-14 A,B).  
A 
 
B 
 
Figure 4-14 SDS-PAGE analysis of test expression of Speedy A constructs in 
different E. coli strains in different media. 
(A) Comparison of soluble protein expression in Arctic Express (DE3), marked with a 
red square, RosettaTM (DE3)pLysS, marked with a green square, Lemo21(DE3) (NEB), 
marked with a yellow square. Buffers identified below the gels. AIM is auto induction 
media, TB is terrific broth and LB is Lysogeny broth. Speedy A (residues 1-313) 
constructs are in lanes 1-3, 10-12, 19-21. Molecular weight of GST tagged protein is 
62.5 kDa. Speedy A (residues 64-313) constructs are in lanes 4-6, 13-15, 22-24. 
Molecular weight of GST tagged protein is 55.2 kDa. Speedy A (residues 64-234) 
constructs are in lanes 7-9, 16-18, 25-27. Molecular weight of GST tagged protein is 
46.4 kDa. Expected molecular weights of truncated Speedy A constructs are identified 
at theside of the gels. (B) Comparison of protein bound to glutathione beads assessed 
by pull-downs. Lanes 1-3, 10-12, 19-21 contain Speedy A (residues 1-313), lanes 4-6, 
13-15, 22-24 contain Speedy A (residues 64-313), lanes 7-9, 16-18, 25-26 contain 
Speedy A (residues 64-234) proteins.  
Unfortunately, the results of this experiment (Figure 4-14) were difficult to interpret: 
there are no obvious over-expressed proteins running in the expected places. Analysis 
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of the proteins bound to the glutathione beads revealed multiple species bound for 
each construct, although constructs Speedy A (1-313) and Speedy A (64-313) 
appeared to express better in Arctic Express and RosettsTM (DE3)pLysS cells 
(Compare lanes 1—6 and 10-15  in Figure 4-14 A, B). 
Western blotting was subsequently used to check for Speedy A expression (Figure 4-
15). The full-length protein and construct 64-234 containing the speedy box were 
detected in the whole cell extract (Lanes 1 and 3), as well as in the supernatant (Lanes 
4 and 6) and the pull downs (Lane 7 and 9).  Construct 64-313 had a weaker signal in 
the supernatant and could be detected only after a longer exposure time. As expected, 
this sample then generated a very weak signal by pull down which could be detected 
only after 2 hours development with the FUJI film (Figure 4-15 B, Lane 5).  
A 
 
 
B 
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Figure 4-15 SDS-PAGE gel and Western blotting analysis of Speedy A/Ringo 
expression test. 
GST tagged Speedy A/Ringo constructs 1-313, 64-313, 64-234 were inoculated as 
described and to determine its level of expression the whole cell fraction, supernatant 
and the bead bound protein was run on two gels. One gel was stained with Instant Blue 
(Expedeon). (A) and the another was immunoblotted with polyclonal antibody against 
Speedy A (B). Films were developed for a different length of time, as indicated. 
Expected molecular weights of constructs identified on the side of the gels and films.  
To further assess protein expression, the full-length construct was selected for larger 
scale expression. The protein was expressed in 1L of LB media and purified by 
sequential affinity, ion exchange (results not shown) and size exclusion 
chromatography. Ion exchange has been employed to remove GST and chaperone 
that was identified by SDS-PAGE. Although a peak corresponding to the expected size 
of monomeric Speedy A (1-313) can be seen on the chromatogram (Figure 4-16) the 
yield was very low. From 1L, circa 0.5 mg of GST-Speedy A fusion was prepared.  
 
 
 
 
 
 
 
 
1 – GST Speedy 1-313 (62.5kDa) 
2 – GST Speedy 64-313 (55.2kDa) 
3 – GST Speedy 64-234 (46.4kDa) 
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A 
 
 
B 
 
Figure 4-16 Purification of Speedy A (1-313) by size exclusion chromatography. 
(A) Size-exclusion chromatogram. Fractions from peaks eluting between 100 and 160 
ml were collected. 1 ml of fractions 22-26 (lines 1-5, identified orange) and 34-37 (lines 
6-9, identified red) were incubated for 1 min with 4 µl of protein extracting beads. Beads 
were heated for 2 min at 95°C with LDS to elute the bound proteins which were then 
analysed by SDS-PAGE. (B) A band of the expected molecular weight is eluted as a 
shoulder on the main peak. 
 133 
 
The first round of test expressions demonstrated that further optimisation was required. 
Different protein tags, an increased number of truncations and the alternative insect 
cell based expression system were tested. The maltose binding protein (MBP) tag was 
selected for its ability to improve protein solubility. The MBP sequence was amplified 
from the pMAL-p5X vector together with the polylinker and Factor Xa cleavage site and 
cloned into pET-21d(+). To improve purification options, the 3C cleavage site was 
introduced between the factor Xa cleavage site and the hexahistidine tag (Figure 4-
17).  
 
Figure 4-17 Alignment of MBP sequence from pMAL-5x vector with sequence 
pET21dMBP3C. 
End of MBP sequence marked with the grey line, factor Xa cleavage site IEGR and 3C 
cleavage site underlined red. 
The following MBP-Speedy A proteins were prepared: (i) The speedy box (64-189), (ii) 
the speedy box and the sequence important for oocyte maturation (64-206), (iii) the 
speedy box and C-terminal sequence important for CDK activation (64-313); (iv) the 
speedy box and N-terminal sequences reported to influence protein expression in 
transfected cells (27-189, 27-206, 27-313 and 1-189, 1-206, 1-313) (Cheng et al., 
2005b) (Figure 4-18).  
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Figure 4-18 Graphical representation of MBP and Speedy A2 constructs cloned 
into pET-21d (+). 
The Speedy box is represented by the red bar and the N- and C-terminal flanking 
regions are green. MBP coloured yellow.  
 
Constructs were again transformed into different bacterial strains, this time 
TunerTM(DE3) and RosettaTM (DE3)pLysS, and inoculated in LB and TB media. As 
described earlier, whole cell lysate, supernatant and pull down samples were analysed 
by SDS-PAGE to detect protein expression. As can be seen from the gel (Figure 4-19) 
there was no obvious overexpression in the whole cell lysates or the clarified lysates. 
Although there is an overexpressed protein in the Speedy A (64-313) sample, it is at 
46 kDa and so corresponds to MBP rather than the MBP-Speedy A (64-313) fusion 
(71.02 kDa). More promising are the bands in lane 7 (Speedy A (64-189)) and lane 8 
(Speedy A (64-206)) of the pull downs from RosettaTM (DE3)pLysS competent cells. 
These are running at circa 55 kDa, close to the expected size of the fusion proteins. 
These constructs were selected for larger scale expression and testing for CDK2 
binding in vitro. 
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  A 
 
B 
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C 
 
Figure 4-19 SDS-PAGE analysis of test expression of Speedy constructs. 
Constructs described and numbered in Table 4.3 were transformed into RosettaTM 
(DE3)pLysS and TunerTM(DE3)pLysS E. coli strains for test expression. A – Whole cell 
lysate, each gel has a name of the competent cell strain where protein has been 
expressed. B – Clarified cell lysate, C – Pull- downs of Speedy A2 constructs. 
 
Lane Construct MW of Speedy A 
construct 
MW of MBP 
tagged Speedy A 
1 Speedy A2 1-189 22.6 kDa 64.6 kDa 
2 Speedy A2 1-206 24.6 kDa 66.6 kDa 
3 Speedy A2 1-313 36.7 kDa 78.7 kDa 
4 Speedy A2 27-189 19.5 kDa 61.5 kDa 
5 Speedy A2 27-206 21.5 kDa 63.5 kDa 
6 Speedy A2 27-313 33.4 kDa 75.4 kDa 
7 Speedy A2 64-189 15.2 kDa 57.2 kDa 
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8 Speedy A2 64-206 17.25 kDa 59.25 kDa 
9 Speedy A2 64-313 29.07 kDa 71.02 kDa 
Table 4-3 Table of constructs with molecular weights. 
 
Because only two constructs showed low, detectable expression, the decision was 
taken to assess expression using insect cells. The cassettes to express the MBP-
Speedy A constructs were amplified using newly designed universal primers (Table 4-
1) and cloned into the pACEBac1 vector digested with BamH1 and EcoR1. pACEBac1 
contains elements required for integration into a baculovirus via Tn7 transposition.  It 
also carries the gentamycin resistance gene and contains a very late polyhedrin 
promoter and a terminator sequence from SV40 which can be substituted if required. 
The baculoviral genome called MultiBac is specially engineered to improve protein 
production properties. The two important genes, v-cath and chiA have been disrupted. 
Disruption of v-cath leads to elimination of proteolytic activity triggered by V-CATH 
protease. Disruption of chiA, which encodes chitinase, provides an opportunity to use 
chitin-affinity chromatography to isolate intein-chitin binding domain fused proteins 
without interference from chiA gene product.  The disrupted DNA sequence has been 
replaced with a LoxP site to enable cre-lox recombination. However, in these 
experiments LoxP was not used for insertion of the gene of interest. Instead the 
sequences were transferred into the bacmid via transposition into the mini Tn7 
attachment site located in the LacZα subunit coding sequence (Figure 4-19). Disruption 
of the LacZ gene leads to clones carrying inserted DNA to appear white. White clones 
containing baculoviral DNA were inoculated in LB and then the DNA was purified and 
used for virus production as described in Materials and Methods. 
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Figure 4-20 DH10MultiBacTM and DH10EmBacY baculoviral DNA. 
Baculoviral genome is shown in schematic representation. Tn7 attachment site on 
LacZ gene shown as a black bar. Disrupted genes chiA and V-cath replaced with 
antibiotic resistance marker and gene encoding YFP  (Fitzgerald et al., 2006). 
In contrast to the DNA generated in DH10MultiBacTM, baculoviral DNA produced in 
DH10EmBacY cells expresses yellow fluorescent protein and so infected cells could 
be detected using a fluorescent microscope. Speedy A sequences of interest produced 
using MultiBacTM baculoviral DNA technology (Table 4-4)  were amplified to P2 
generation and were then used to test expression of recombinant proteins in insect 
cells. Unfortunately, as summarised in Figure 4-21, analysis of the whole cell, 
supernatant and bead-bound fractions for each of these constructs failed to identify 
conditions from which a significant amount of Speedy A could be purified.  
 
Sequence Tag Vector 
1-313 GST pACEBac1 
64-313 GST pACEBac1 
64-234 GST pACEBac1 
1-313 MBP pACEBac1 
1-189 MBP pACEBac1 
1-206 MBP pACEBac1 
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27-189 MBP pACEBac1 
27-206 MBP pACEBac1 
27-313 MBP pACEBac1 
64-189 MBP pACEBac1 
64-206 MBP pACEBac1 
64-313 MBP pACEBac1 
Table 4-4 SpeedyA2 constructs for expression in insect cells. 
 
 
 
 
Figure 4-21 Pull downs of Ringo A/Speedy constructs. 
(A) SDS-PAGE gel of Ringo A/Speedy pull downs expressed in insect cells. Constructs 
are labelled and described in Table 4-5. (B) Ringo A/Speedy pull downs transferred to 
a nitrocellulose membrane and blotted with Ringo A/Speedy primary rabbit antibody. 
 
Lane Construct Sample Type of baculoviral 
DNA 
MW of MBP 
tagged Speedy A 
1 Speedy A2 1-313 Whole cell lysate EmBacY 78.7 kDa 
2 Speedy A2 1-313 Clarified lysate EmBacY 78.7 kDa 
3 Speedy A2 1-313 Pull down EmBacY 78.7 kDa 
4 Speedy A2 1-313 Whole cell lysate MultiBacTM 78.7 kDa 
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5 Speedy A2 1-313 Clarified lysate MultiBacTM 78.7 kDa 
6 Speedy A2 1-313 Pull down MultiBacTM 78.7 kDa 
7 Speedy A2 1-206 Whole cell lysate MultiBacTM 66.6 kDa 
8 Speedy A2 1-206 Clarified lysate MultiBacTM 66.6 kDa 
9 Speedy A2 1-206 Pull down MultiBacTM 66.6 kDa 
10 Speedy A2 1-206 Whole cell lysate EmBacY 66.6 kDa 
11 Speedy A2 1-206 Clarified lysate EmBacY 66.6 kDa 
12 Speedy A2 1-206 Pull down EmBacY 66.6 kDa 
13 Speedy A2 1-189 Whole cell lysate EmBacY 66.4 kDa 
14 Speedy A2 1-189 Clarified lysate EmBacY 66.4 kDa 
15 Speedy A2 1-189 Pull down EmBacY 66.4 kDa 
16 Speedy A2 27-189 Whole cell lysate EmBacY 61.5 kDa 
17 Speedy A2 27-189 Clarified lysate EmBacY 61.5 kDa 
18 Speedy A2 27-189 Pull down EmBacY 61.5 kDa 
19 Speedy A2 27-189 Whole cell lysate MultiBacTM 61.5 kDa 
20 Speedy A2 27-189 Clarified lysate MultiBacTM 61.5 kDa 
21 Speedy A2 27-189 Pull down MultiBacTM 61.5 kDa 
22 Speedy A2 27-206 Pull down EmBacY 63.5 kDa 
23 Speedy A2 27-206 Pull down MultiBacTM 63.5 kDa 
Table 4-5 Table of constructs with molecular weights 
 
 Analysis of Ringo A/Speedy affinity to CDK1 and CDK2 
The most successful conditions to express Speedy A were constructs containing 
residues 64-189 and 64-206 expressed from the pET21dMBP vector  in RosettaTM 
(DE3)LysS cells. Protein was bound to MBP resin and washed prior to incubating with 
an excess of CDK2 (0.06 mg total). After incubation, bead bound protein was analyzed 
by SDS-PAGE (Figure 4-22). Although the gels exhibited a few proteins that were non-
specifically bound to the amylose beads, in addition to MBP and the MBP Speedy A 
constructs, a band consistent with the molecular weight of CDK2 appears after 
incubation of MBPSpeedy A (64-189) and MBPSpeedy A (64-206) with CDK2 (Figure 
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4-22A, lanes 4 and 8, etc). To check the non-specific binding of CDK2 to the amylose 
resin or to MBP, a negative control was also run. Results show that CDK2 exhibits very 
weak non-specific binding to the amylose beads (Figure 4-22 B, lane 1).  This binding 
is significantly weaker than in the binding experiment and no binding was observed to 
MBP (Figure 4-22). These results agree with binding between RINGO/Speedy and 
CDK2 reported in vivo (Dinarina et al., 2005), but require further confirmation by more 
sensitive methods. 
A 
 
B 
 
1 – Speedy 64-189(57kDa) supernantant. 
2 – Speedy 64-189 pull down on Amylose resin. 
3 – CDK2 
4 – Speedy 64-189 mixed with CDK2 
5 – Speedy 64-206(59kDa) supernatant. 
6 – CDK2 
7 – Speedy 64-206 pull down on Amylose resin. 
8 – Speedy 64-206 mixed with CDK2 
1 – CDK2 incubated with Amylose 
beads and washed 7 times with HBS 
buffer 
2 – Sample producing MBP incubated 
with Amylose resin, washed 7 times, 
incubated for an hour with CDK2 and 
washed 7 times again. 
Figure 4-22 Investigation of binding between Speedy 64-189 and Speedy 64-206 
to CDK2. 
Lanes are numbered according to the experiments described below the gel.  
 RGC32 binding to CDK1 
Previously it has been reported that RGC32 can bind and activate CDK1 in vivo (but 
not other CDKs) in a manner dependant on Thr91 phosphorylation of RGC32 (Badea 
et al., 2002). To investigate binding in vitro, recombinant proteins were expressed in 
different expression systems. RGC32 and GSTRGC32 were expressed and purified in 
the lab of Professor M. West (Sussex University). CDK1, GSTCDK1, GSTCDK2 and 
CKS1 were purified in our lab as described in Materials and Methods. The purity of the 
proteins was verified by SDS-PAGE (Figure 4-23).  
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Figure 4-23 Purified proteins used for SPR experiments 
12% SDS-PAGE gel stained using InstantBlue. 
Pull down experiments were performed to test the binding of GSTCDK1 to RGC32 and 
GSTRGC32 to CDK1 using cyclin H as a negative control. Results of that experiment 
were not conclusive (results not shown) probably due to the weak affinity between the 
two proteins. Consequently, SPR was chosen as an alternative more sensitive method 
that can detect kinetics of binding in real time and can determine dissociation constants 
(Kd). 
The interactions between GSTCDK1 and GSTCDK2 with their well-characterised  
partner CKS1 were studied as positive controls. Sensograms of binding were analysed 
by the BiaCore S200 software and results revealed tight binding of 28.9  ± 11.2 nM 
between GSTCDK1 and CKS1 and weaker binding of 200 ±  70.7 nM between 
GSTCDK2 and CKS1. Experiment has been performed twice with two different 
biological replicates. As can be seen from the sensograms, CKS1 binds very rapidly to 
both proteins although to a greater extent to GSTCDK2 in comparison to GSTCDK1. 
Consequently the time of association represented in the association constant is slightly 
shorter  for GSTCDK2 in comparison to GSTCDK1 and association constant for 
GSTCDK1 binding to CKS1 is 0.74 M-1s -1x10 5± 0.05x105  in comparison to 0.56 M-1s 
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-1x10 5 ± 0.06x105 for GSTCDK2-CKS1 binding. The level of dissociation of CKS1 
differs quite significantly between two proteins: 0.01 s-1 ±  0.004 for GSTCDK1-CKS1 
and 0.0007 s-1  ± 0.0008 for GSTCDK2-CKS1. It can be seen from the shape of the 
sensorgrams that CKS1 dissociates more slowly and gradually from GSTCDK1 than 
from GSTCDK2 (Figure 4-24). 
A 
 
B 
 
Figure 4-24 Analysis of the interactions between CDK1/2 and binding partners 
by surface plasmon resonance (SPR). 
 (A) SPR plot of response units against time to measure CKS1 binding to GSTCDK1. 
Different colours of sensograms represent different concentrations of analyte. Red 
represents 40 nM of CDK1, green – 200 nM, blue – 1000 nM, pink – 2000 nM, and 
turquoise – 5000 nM. (B) SPR plot of response units against time of CKS1 binding to 
GSTCDK2. Red represents 62.5 nM of CDK1, green – 250 nM, blue – 1000 nM, pink 
– 2500 nM, turquoise – 5000 nM. Measurements were performed once. 
 
Kinetic interactions between CDK1 and RGC32 were studied in two ways. In one set 
of experiments, GSTCDK1 was captured on the anti GST- antibody and RGC32 was 
used as an analyte. In the second set, GSTRGC32 was captured and CDK1 was 
flowing over. Both sets of sensograms (Figure 4-25) have similar profiles characterised 
by slow binding (over 400 s) and slow dissociation, after a dissociation phase of 700 s 
most of the protein remains bound. Association constants are comparable, 0.06 M-1s -
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1x10 4 for CDK1 binding to GSTRGC32, and 0.03 M-1s -1x10 4   for RGC32 binding to 
GSTCDK1. The calculated Kd values are almost identical respectively, 0.18 s -1 x10-3 
in the first case and 0.13 s -1 x10-3 in the second.  The kd values calculated from these 
experiments are similar as well demonstrating the weaker binding of 290 8 nM (CDK1 
– GSTRGC32) and 448 nM (RGC32 – GSTCDK1) in comparison to interactions 
between GSTCDK1 and GSTCDK2 with CKS1. 
 
GST captured protein Analyte ka (M-1s -1x10 5) kd (s -1 x10-4) KD(nM) 
GSTCDK1 CKS1 0.74 ± 0.05 
 
147 ± 45 
 
28.9 ± 11.1 
 
GSTCDK2 CKS1 0.57 ± 0.06 7 ± 8.5 200 ± 70.7 
 
GSTCDK1 RGS32 0.3 1.3 448 
GSTRGC32 CDK1 0.6 1.8 290 
Table 4-6 Summary of SPR kinetic analysis. 
Ka and Kd values are estimated using BiaCore S200 software. SPR to estimate binding 
of GSTCDK1 and GSTCDK2 to CKS1 were performed in biological duplicate. Standard 
deviation is calculated by Excel. 
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B 
 
Figure 4-25 Sensograms representing kinetic interactions by SPR. 
(A) SPR plot of response units against time of CDK1 binding to GSTRGC32. Different 
colours of sensograms represent different concentrations of analyte. Red represents 
40 nM of CDK1, green – 200 nM, blue – 1000 nM, pink – 2000 nM, turquoise – 5000 
nM. (B) SPR plot of response units against time of GSTCDK1 binding to RGC32. Red 
represents 62.5 nM of CDK1, green – 250 nM, blue – 1000 nM, pink – 2500 nM, 
turquoise – 5000 nM. Measurements performed once. 
 
Cyclin H and CDK2 have not been reported to bind to RGC32 and were used as 
negative controls (Dinarina et al., 2005). Neither cyclin H nor CDK2 bind to GSTRGC32 
in vitro (Figure 4-26).  
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B 
 
Figure 4-26 Sensograms representing kinetic interactions by SPR. 
(A) SPR plot of response units against time of cyclin H and CDK2 binding to 
GSTRGC32. Different colours of sensograms represent different concentrations of 
analyte. Red represents 8 nM cyclin H, green – 40 nM, blue – 200 nM, pink – 1000 nM, 
turquoise – 5000 nM. (B) SPR plot of response units against time of CDK2 binding to 
GSTRGC32. Representation of colours of sensograms are the same as for cyclin H 
and GSTRGC32 experiment. Measurements performed only once. 
 
4.5 Conclusions  
This chapter describes experiment to express the two CDK partner proteins RINGO A/ 
Speedy and RGC32 and to investigate their binding properties. The aim of the Speedy 
project was to identify parts of the protein containing the speedy box which would be 
stable and could be expressed in sufficient amounts for biochemical, biophysical and 
structural characterisation. Unfortunately, despite a number of attempts to clone 
different protein truncations and using alternative expression systems, the expression 
of stable protein was not achieved. According to a recently published article (McGrath 
et al., 2017) a truncated version of human Speedy A containing the speedy box 
(residues Gly61-Asp213) can be expressed using a codon optimised sequence 
inserted into the pMBP vector in the SoluBL21 E. coli strain. The next step for this 
project would be to repeat this experiment. Further work is planned that includes 
CDK1-Speedy A crystallisation trials and a more systematic analysis of CDK1 and 
CDK2 sequence preferences around the site of phosphotransfer when bound to cyclin 
A, cyclin B and Speedy A.  
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Using purified proteins, the interaction between RGC32 and CDK1 has been 
confirmed. No binding was detected between RGC32 and CDK2. The results of the 
SPR experiments have shown that RGC32 binds to CDK1 with lower affinity than for 
example CKS1 to CDK1 or CDK2. Further work is planned to investigate binding using 
alternative assays such as homogenous time-resolved fluorescence (HTRF). 
 
 CDK inhibition by ATP-competitive inhibitors 
5.1 Introduction 
 Role of CDK inhibition for cancer therapy 
In recent years a number of synthetic CDK inhibitors have been designed for cancer 
therapy. Most such inhibitors are ATP-competitive type I inhibitors that target the active, 
‘DFG in’ CDK conformation, although type II inhibitors that target a non active CDK 
conformation, known as ‘DFG out’ and believed to be offer more opportunities for 
selectivity (Treiber and Shah, 2013) have started to emerge  (Rzymski et al., 2015). 
First generation inhibitors, pan-CDK inhibitors, were relatively non-specific and acted 
against most CDKs (Figure 5-1). They were designed using different scaffolds such as 
flavonoid, purine, aminothiazole, hymenialdisine, indenopyrasole, indirubin and 
paullone derivatives (Asghar et al., 2015). Some of them, such as roscovitine and 
flavopiridol, are quite effective for some cancers and have been used in over 60 clinical 
trials carried out between 1998 and 2014, although responses were limited due to high 
toxicity prompted by general CDK inhibition in normal tissue (Aklilu et al., 2003; Benson 
et al., 2007; Byrd et al., 2007; Le Tourneau et al., 2010).  
A second generation of the inhibitors emerged from the development of flavopiridol and 
roscovitine. The design of the new generation was focused on the increase of potency 
and selectivity towards CDK1 and CDK2. Many inhibitors of this generation gave high 
expectations in a preclinical study but not many passed Phase 1 clinical trials (Payton 
et al., 2006; Parry et al., 2010). One of the most studied inhibitors is Dinaciclib which 
was designed especially for CDK1, 2, 5 and 9 inhibition, with IC50 values in a range of 
1-4 nM. It has demonstrated strong suppression of Rb phosphorylation in cell based 
assays (Parry et al., 2010). Although results of the Phase 1 clinical trials were 
promising (Nemunaitis et al., 2013), Phase 2 results in solid tumours came up as a 
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disappointment. Monotherapy of non-small cell lung cancer with Dinaciclib has shown 
no activity in previously treated patients (Stephenson et al., 2014). In patients with 
acute myeloid leukaemia or acute lymphoblastic leukaemia no objective changes were 
observed (Gojo et al., 2010). However, in other haematological malignancies Dinaciclib 
has shown evidence of clinical activity, and  consequently it remains in a Phase 3 
clinical trials (Blachly and Byrd, 2013). Another inhibitor, AZD5438 (developed by 
AstraZeneca), was reported to be poorly tolerated when administered to patients with 
advanced solid tumours (Boss et al., 2010). A Phase 1 study of AG-024322 (developed 
by Pfizer), a potent inhibitor of CDK1, 2 and 4, was also terminated because of absence 
of expected therapeutic effect.  
 
Inhibitor CDK1- 
cyclinB 
CDK2-
cyclinA 
CDK4-
cyclinD 
CDK6-
cyclinD 
CDK9-
cyclinT 
Alvociclib(flavopiridol) 27 405 132 395 11 
Seliciclib(roscovitine) 2100 100 13500 23500 950 
Dinaciclib 3 1   4 
AT7519 190 44 67 660 <100 
RGB-286638 480 38 925 >1000 4 
ZK-304709 2 3 4 55 1 
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Voruciclib 50 4 61  5 
P276-00 79 224 63 396 20 
R547 2 3 1   
SNS032/BMS-
387032 
25  90  22 
AZD5438 16 3 449 21 20 
AG-024322 1-3 1-3 1-3   
Milciclib 398 45 160   
Roniciclib 7 9 11  5 
TG02 9 5 >100 >100 37 
Figure 5-1 Structure (A) and activity (B) of pan- or multitarget- CDK inhibitors. 
Table indicates IC50 (nM) values for each compound, except of AT7519 for which Ki 
(nM) values are given. Figure adopted from (Whittaker et al., 2017). 
The third generation of CDK inhibitors came as a result of development targeting more 
selective inhibitors. Palbociclib was designed in 2004 and has shown a high degree of 
specificity towards CDK4 and CDK6, demonstrating 26-fold tighter binding to CDK4 
and CDK6 (Figure 5-2) in comparison to the other CDKs (Cho et al., 2010) and 
additional kinases (Rae et al., 2007). Palbociclib went through many rounds of 
experiments and has been evaluated in several cancers with elevated CDK4 and 
CDK6 levels, finally reaching Phase III trial in patients with ER+/HER2-advanced 
breast cancer (Finn et al., 2016). It has now been approved to be used in combination 
with letrozole for the treatment of postmenstrual women with ER+/HER2-advanced 
breast cancer. Another two promising inhibitors of CDK4 and CDK6 are abemaciclib 
and ribociclib, which have been put into clinical trials in patients with advanced solid 
tumors and lymphomas (Patnaik et al., 2014; Infante et al., 2016). Most recently, 
ribociclib has been licensed for a similar patient population to that specified for 
treatment by palbociclib.  All three inhibitors were crystalized with monomeric CDK6 
(Chen et al., 2016), while Palbociclib has also been crystalized with a CDK6 –cyclin V 
(Lu and Schulze-Gahmen, 2006) complex, revealing binding to both the inactive and 
active forms of CDK6 mainly through amino acids in the hinge region. Drug interactions 
with residues His100 and Thr107 have been proposed as key elements providing 
selectivity to the inhibitors (Chen et al., 2016). 
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Inhibitor CDK1- 
cyclinB 
CDK2-
cyclinA 
CDK4-
cyclinD 
CDK6-
cyclinD 
CDK9-
cyclinT 
Palbociclib >10000 >10000 11 15  
Abemaciclib 1627  2 10 57 
Ribociclib >100000 >100000 10 39  
Figure 5-2 Structure (A) and activity (B) of CDK4 and CDK6 inhibitors. 
Table indicates IC50 (nM) values. Figure adopted from (Whittaker et al., 2017). 
Recently CDK7 and CDK9 emerged as potential cancer drug targets. Inhibition of 
CDK7 has led to ablation of phosphorylation of CTD of RNA polymerase at Ser2, Ser5 
and Ser7 that lead to antitumor effect in neuroblastoma, triple-negative breast cancer, 
small cell lung cancer shown on cell lines and in the animal models (Chipumuro et al., 
2014; Christensen et al., 2014; Kwiatkowski et al., 2014). Inhibiting CDK9 in CLL cells 
is known to induce apoptosis and increase sensitivity to fludarabine which is used as 
a standard treatment for CLL (Walsby et al., 2014). At the moment there a number of 
CDK7 and CDK9 inhibitors have been described with the scope to develop as 
therapeutic targets. 
The problem of many kinase inhibitors is that they display similar toxicity to cancerous 
and healthy tissue, leading to a difficulty to achieve a therapeutic window.  For 
achieving therapeutic effect, the approach of combining drugs aiming at the inhibition 
of different targets is becoming popular for some cancers treatment. For example 
inhibition of CDK1 with RO3306 compound (Roche) led to sensitising BRCA proficient 
cancers to poly(ADP-ribose) polymerase  PARP inhibition (Johnson et al., 2011). CDK1 
has been shown to participate upstream of DNA damage response pathways (Ira et 
al., 2004) and, in CDK1 depleted cells, function of BRCA1 in S phase checkpoint was 
found ot be compromised (Johnson et al., 2009). BRCA1 and BRCA2 are tumour 
suppressor proteins that play crucial roles in DNA repair (Moynahan et al., 1999). 
PARP, in its turn, plays a role in single strand DNA break repair by homologous 
recombination. Both BRCA1 and BRCA2 are necessary for the process of homologous 
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recombination to go through and it is known that cells deficient in BRCA are 
hypersensitive to PARP inhibition (Bryant et al., 2005) ,which opens a new opportunity 
for the treatment of BRCA proficient cancers. 
Because CDKs play a crucial role in the cell cycle and transcription regulation, there 
are sound arguments for targeting them for cancer therapy in suitably chosen patient 
segments. Due to them being easily accessible to the drugs, a number of successful 
inhibitors have been developed into clinical tools; where early compounds have been 
unsuccessful, they have often provided starting points for the development of better 
ones. The positive results where the ATP–competitive inhibitors palbociclib and 
ribociclib have been licensed for treatment provide encouragement for the further 
development of other potential drugs that target the CDK family. 
 ATP binding site 
ATP is used by kinases for phosphorylation of their protein substrates and is bound in 
the ATP binding pocket between the N- and C- lobes (Figure 5-3). This site is also used 
by ATP competitive inhibitors for binding. A number of residues from different parts of 
molecule are involved into this process. The adenine base is positioned by the hinge 
sequence and forms two hydrogen bonds with backbone carbonyl and amide moieties 
(respectively Glu81 and Leu83 in CDK2).  The roof and floor of the adenine binding 
cleft is lined with small hydrophobic residues that interact with the planar adenine ring. 
The ribose ring makes connections with a conserved aspartate (D86 in CDK2) towards 
the C-terminal end of the hinge. Triad of residues, Lys33, Glu51 and Asp134 are 
important in coordination of Mg2+ ions. Lys33 organises the α and β phosphates of ATP 
as well as positioning the αC helix by forming a salt bridge with conserved Glu51. Lys33 
is crucially important as its mutation leads to kinase inactivation (Iyer et al., 2005). The 
glycine rich loop lies between β1 and β2 strands, and is formed by the GXGXXG motif 
comprised from conserved Gly12-Gly17 (in CDK2, Figure 5-3). This loop plays a role 
in positioning the adenine ring and accommodating the phosphates by holding the β- 
and ɣ-phosphates in place. In the absence of ATP the P-loop becomes very flexible. 
One more important residue which plays a role in formation of the catalytic spine is 
Asp127 (in CDK2) (Jura et al., 2011). One Mg2+ ion is crucial for efficient transfer of 
ATP phosphates to the substrates. The side chain of Asp145 (in CDK2), part of DFG 
motif, points towards the phosphate groups of ATP and is responsible for Mg2+ 
coordination. The DFG motif is located at the beginning of the activation segment and 
is known to exist in ‘in’ and ‘out’ states. In the ‘in’ state, which is thought to be 
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entropically less favourable (Shan et al., 2009), the aspartate is positioned in the active 
site, ensuring correct magnesium positioning required for catalysis. Consequently this 
position is more characteristic of an active kinase conformation.  
                12 14 17                  33                    51         
CDK1 MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGVPSTAIREISLLKELRH 60 
CDK2 MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNH 60 
     **:: *:*************.*:* **:***:*****::* *****************.* 
                                82 84    89 
CDK1 PNIVSLQDVLMQDSRLYLIFEFLSMDLKKYLDSIPPGQYMDSSLVKSYLYQILQGIVFCH 120 
CDK2 PNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALT-GIPLPLIKSYLFQLLQGLAFCH 119 
     ****.* **:  :.:***:****  ****::*:      :   *:****:*:***:.*** 
               132 134          146 148 
CDK1 SRRVLHRDLKPQNLLIDDKGTIKLADFGLARAFGIPIRVYTHEVVTLWYRSPEVLLGSAR 180 
CDK2 SHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKY 179 
     *:**************: :*:*************:*:*.***********:**:***.   
 
Figure 5-3 Conserved residues of ATP binding site in CDK1 and CDK2.  
The CDK1 and CDK2 sequences share 93% sequence identity amongst aminoacids 
participating in ATP binding. 
A 
 
CDK1 
B 
 
CDK2 
                               C        
 
Figure 5-4 ATP binding site.   
(A) CDK1 ATP binding site (PDB: 4YC3), (B) CDK2 ATP binding site (PDB: 5if1) (C) 
CDK2 ATP binding site with ATP and Mg2+.  The conserved residues in both CDKs are 
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identified. Activation segment is coloured red, C – helix is gold, G-loop is blue, hinge 
region is coral, DFG residues are marked in lilac, Glu51 in light green, Leu133 (CDK2) 
Leu134 (CDK1) in pink. 
 
 CDK inhibition, exploring the ATP-binding site 
The ATP binding site is a part of a kinase molecule which participates in transfer of the 
terminal phosphate of ATP to a kinase substrate. To date, most described kinase 
inhibitors are ATP competitive, of which type I inhibitors target the active DFG-in kinase 
conformation and present one to three hydrogen bonds to the amino acids located in 
a hinge region similarly to the hydrogen bonds formed by adenine ring of ATP (Liu and 
Gray, 2006). ATP-competitive inhibitors generally have additional functional groups 
that form contacts with less conserved regions of ATP-binding pocket.  Type I inhibitors 
can generally bind both active and inactive enzyme forms as they are normally quite 
small and do not require special arrangements of the αC helix, the DFG motif, or the 
Asp motifs. Type II inhibitors target the inactive DFG-out conformation of a kinase. 
Similar to inhibitors of type I, type II inhibitors form connections to the hinge region but 
also get engaged into DFG and C helix binding (Dar and Shokat, 2011). They also tend 
to bind preferentially to kinases with a small or medium ‘gatekeeper’ residue 
(Hasegawa et al., 2007; Kufareva and Abagyan, 2008). Type II inhibitors, being 
normally bigger, target the ATP binding site of kinases in a DFG-out conformation as 
they need to occupy not only the hinge region where adenine of ATP normally sits but 
also adjacent to an hydrophobic pocket (Janne et al., 2009).  
Because type II inhibitors form more interactions within the ATP binding pocket than 
do type I inhibitors they are expected to be more specific but harder to design and 
develop. A further type of inhibitor, termed type III, bind allosterically to sites that do not 
overlap the ATP-binding site. Type I and II inhibitors represent most of the FDA-
approved kinase inhibitors. 
The CDK inhibitors described in the introduction to this chapter are mainly type I 
inhibitors, and target both active and inactive conformations of the kinase (Whittaker 
et al., 2017). The first successful drug that targets an inactive kinase conformation was 
approved by the FDA in 2001. This drug, which targets BCR-Abl-driven chronic 
myelogenous leukaemia and gastrointestinal stromal tumours, is Imatinib (Gleevec) 
and was developed by Novartis (Druker et al., 1996). The crystal structure of Imatinib 
with the structurally similar kinases Abl and Src revealed binding characteristic of Type 
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II inhibitors (Schindler et al., 2000). Remarkably, despite near identical binding pockets 
Imatinib binds Abl almost 1000-fold more potently then Src (Druker et al., 1996). These 
differences confirm the potential role of conformational flexibility in determining inhibitor 
selectivity. There are not many type II inhibitors designed to the date, although some 
interesting results have emerged in development of inhibitors of CDK8, an oncogene 
in colorectal cancer (Rzymski et al., 2015), from Sorafenib (Schneider et al., 2013) 
 
Figure 5-5 Type I and Type II kinase inhibitors 
Type I inhibitors form bonds with hinge region (PDB code: 1QCF). Type II bind also to 
amino acids of DFG motif and C Helix (PDB code: 1FPU) (Dar and Shokat, 2011). 
For the design of ATP competitive inhibitors that target active and non-active kinase 
conformations, the residues that line the ATP binding pocket and structural plasticity of 
kinase fold are important. The kinase active site is highly flexible and can remodel to 
accommodate binding of a wide variety of different inhibitors that instigate changes in 
the position of the activation loop (Knight et al., 2006; Liu and Gray, 2006). In addition, 
the active site of kinases in general, and CDKs in particular, is highly conserved in 
primary, secondary and tertiary structure, which creates a difficulty for generating 
inhibitor selectivity between kinases. For example, there are 33 amino acids that 
participate in forming the active site in CDK1, CDK2, CDK4, CDK7, CDK9 ( Figure 5-
6) of which 55% are conserved across the family. If the comparison is narrowed to the 
closely related CDK1 and CDK2 family members, there are only two amino acids that 
differ, suggesting complications in designing selective inhibitors which would effectively 
distinguish between the two.  
            8         16 18             31 33                    51 
CDK1 MEDYTKIEKIGEGTYGVVYKGRHKTTGQVVAMKKIRLESEEEGVPSTAIREISLLKELRH 60 
CDK2 MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNH 60 
     **:: *:*************.*:* **:***:*****::* *****************.* 
         64                   80     86  89  
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CDK1 PNIVSLQDVLMQDSRLYLIFEFLSMDLKKYLDSIPPGQYMDSSLVKSYLYQILQGIVFCH 120 
CDK2 PNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALT-GIPLPLIKSYLFQLLQGLAFCH 119 
     ****.* **:  :.:***:****  ****::*:      :   *:****:*:***:.*** 
              127  131 134         144   148 
CDK1 SRRVLHRDLKPQNLLIDDKGTIKLADFGLARAF 180 
CDK2 SHRVLHRDLKPQNLLINTEGAIKLADFGLARAF 179 
     *:**************: :*:************   
Figure 5-6 Residues that can be exploited by ATP competitive inhibitors 
Sequences are human CDK1 (Uniprot entry P06493) and human CDK2 (Uniprot entry 
P24941).  
 
One proposed method to evaluate the effective differences between kinase active sites 
is the “fingerprinting” approach (Echalier et al., 2014). According to this approach a 
wide panel of inhibitors was chosen to investigate chemical diversity of CDK active 
sites. In this study, the melting temperature of selected CDKs (CDK2, CDK4, CDK7 
and CDK9) and their complexes with cognate cyclins, was measured in the presence 
of different inhibitors. ΔTm (the difference between melting temperature of inhibitor 
bound form and non bound) was plotted to compare monomeric CDKs, phosphorylated 
forms and fully activated. From this analysis, it was found that CDKs in their monomeric 
forms significantly differ in their inhibitory profile with a lowest correlation coefficient of 
0.39 (CDK4 vs CDK7) and highest correlation coefficient of 0.74 (CDK2 vs CDK7) 
(Figure 5-6). In the fully activated, cyclin-bound state the correlation coefficient 
between the different profiles are substantially higher. The lowest correlation (0.73) is 
measured for pCDK2-cyclin A vs pCDK9-cyclin T and the highest (0.78) for pCDK2-
cyclin A vs pCDK4-cyclin D. These findings suggest that inhibitor binding properties do 
not only depend on the sequence of the CDK  ATP-binding site but also on the kinase 
conformational state.  The results also support the suggestion that, in an active state, 
two different CDKs become very similar in their inhibitor binding properties. Taken 
together, these studies lead to the conclusion that protein kinases in general, and 
CDKs in particular, are more available for selective inhibition in their monomeric, 
inactive state.  
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Figure 5-7 Comparison of the inhibitor binding profiles of different CDKs in 
their monomeric and cyclin bound forms. 
Numbers within the block indicate internal consistency of inhibitory fingerprints for each 
CDK or complex measured over two or three repeats. Numbers between the blocks  
shows the correlation of fingerprints between CDKs or CDK-cyclin complexes (Echalier 
et al., 2014). 
 
 Aims of the project 
As described in the CDK1 structural and functional study chapters, monomeric CDK1 
demonstrates conformational differences from CDK2. Apparent flexibility in the CDK1-
cyclin B complex has been proposed to explain functional flexibility of CDK1-cyclin B 
in comparison to CDK2-cyclin A. We propose that these plastic differences can result 
in different response to the binding of ATP-competitive inhibitors. CDK2 has recently 
been identified as a potential cancer target in cyclin E amplified ovarian cancer. 
However, CDK1, its close homologue, is essential for cell cycle progression and can 
generate toxic off-target effects when inhibited.  Consequently, the development of 
selective inhibitors that can discriminate CDK2 from CDK1 would be both highly 
desirable and extremely challenging, since the active sites of CDK1 and CDK2 differ 
only by two amino acids.  To explore the feasibility of selectively inhibiting CDK2, a 
number of inhibitors with different scaffolds were chosen to investigate the relative 
importance of sequence similarity versus conformational differences in binding to 
CDK1 versus CDK2. 
To structurally characterise the active sites of CDK1 and CDK2 in their monomeric and 
cyclin-bound states, monomeric and binary proteins were subjected to crystallisation 
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trials in the presence of the panel of inhibitors. To assess and compare chemical 
similarity of CDK1 and CDK2 and their complexes biophysical methods including DSF, 
ITC, SPR and DSC were employed. To explore the influence of the inhibitors on the 
kinase activity ADP-GloTM assay has been performed. 
 
5.2 Materials and Methods 
 Protein purification  
CDK1 that was phosphorylated on Thr161 (pCDK1) and non-phosphorylated CDK1 
were expressed and purified as described in Sections 2.2.5 and 2.2.6 and 
phosphorylated in a kinase incubation as described in Section 2.2.9. Cyclin B and 
CKS2 were expressed and purified as described in Sections 2.2.5 and 2.2.6. pCDK1-
cyclin B, CDK1-cyclin B-CKS2 and CDK1-CKS2 complexes were assembled as 
described in Section 2.2.11. Monomeric CDK2 was expressed in 
Rosetta2TM(DE3)pLysS cells using pGEX6p-1 as expression vector (Table in Annex) 
following a well established protocol (Welburn and Endicott, 2005). Phosphorylated 
CDK2 (on Thr160, pCDK2) and bovine cyclin A were expressed as described in Section 
2.2.4. To prepare the pCDK2-cyclin A complex, cell lysates were mixed post sonication 
in a culture ratio 1 : 2 pCDK2 : cyclin A to saturate the pCDK2 with excess cyclin A and 
then spun at 60,000 x g for 1h. The supernatant was collected and loaded onto a 
glutathione-sepharose column equilibrated in HBS (40mM HEPES, pH7.0, 200 mM 
NaCl, 0.01% MTG). The pCDK2-cyclin A complex was eluted with 20 mM glutathione 
in HBS and the GST tag subsequently cleaved with 3C protease in 1:50 w:w ratio, at 
4°C overnight. The complex was further purified by size exclusion chromatography 
using a Superdex 75 26_60 column equilibrated in HBS at room temperature. As the 
complex elutes from the column with the GST dimer, a subsequent subtractive step on 
a glutathione-sepharose column to remove the GST was required, the pCDK2-cyclin A 
being collected in the flow-through. 
 
 Preparation of inhibitors 
All inhibitors were dissolved in 100% DMSO to a concentration 50 mM and stored at -
20°C. The inhibitors used in this study are listed in Table 5-1. 
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Name Scaffold Chemical 
formulae 
Smiles string 
Flavopiridol Chromone C21H20 ClNO5 O=C1C=C(C2=CC=CC=C2Cl)OC3=C1
C(O)=CC(O)=C3[C@@H]4[C@H](O)CN
(C)CC4 
 
AZD5438 Pyrimidinamine C18H21N5O2S 
 
O=S(C1=CC=C(NC2=NC=CC(C3=CN
=C(C)N3C(C)C)=N2)C=C1)(C)=O 
 
CGP74514A Purine C19H24ClN7   
NC1=C2N=CN(CC)C2=NC(N([C@H]3[C
@@H](N)CCCC3)C4=CC=CC(Cl)=C4)=
N1 
 
SU9516 Indolinone C13H11N3O2 
 
O=C1NC2=C(C=C(OC)C=C2)/C1=C/C3
=CN=CN3 
 
Dinaciclib Pyrazole C21H28N6O2 
 
OCC[C@H]1N(C2=NC3=C(CC)C=NN3
C(NCC4=C[N+]([O-
])=CC=C4)=C2)CCCC1 
Table 5-1 ATP competitive inhibitors of CDK1 and CDK2. 
 
 Differential scanning fluorimetry (DSF) 
Experiments were performed using a Real-Time PCR system (QS7Flex, Applied 
Biosystems).  3 µM of pCDK1, pCDK2, pCDK1-Cyclin B or pCDK2-Cyclin A were 
mixed with SyPRO Orange (5 times dilution of the stock) (Invitrogen) fluorescent probe 
in DMSO (Sigma Aldrich) and the eight inhibitors of interest were added to final 
concentrations of 250, 100, 50, 10 or 2 μM in a total volume of 25 ul. The plates were 
equilibrated at 25°C for 5 min followed by heating at 1°C per 90 sec from 25 to 85°C. 
The fluorescence intensity was recorded using the ROX filters (excitation λ=470 nm, 
emission λ=586nm) every 90 sec. Results were analysed by Protein Thermal Shift 
Software 1.3 and the inflection point was calculated using the Boltzmann method. 
 Isothermal Titration Calorimetry  
ITC experiments were carried out at 30°C using a MicroCal ITC 200 (Malvern 
Instruments). CDK1, CDK1–cyclin B, CDK2 and CDK2–cyclin A at 10 μM were used 
as samples in the cell and five inhibitors were titrated as ligands in the syringe (100 
μM). Titrations were performed in 40 mM HEPES pH 8.0, 500 mM NaCl, 0.25% TCEP. 
For each experiment, 20 injections of inhibitor were performed, 1x 0.5 µL and 19x 2 µL 
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with 120 s interval between injections.  The thermograms were analysed by Origin 7.0 
(OriginLab Corp.) software using single binding-site model. 
 Surface plasmon resonance 
Experiments were performed on a Biacore S200 (GE Healthcare) at 20°C in buffer 
containing 20 mM HEPES pH 7.4, 150 mM NaCl, 0.01 % Tween. A CM5 BIAcore 
sensor chip was used for amine coupling of goat anti-GST antibody according to the 
GE Healthcare standard protocol.  50 μg/ml of GSTCDK1 or GSTCDK2 were 
immobilised on a surface of antibody at 5 μl/min for 480 s. Inhibitors were diluted 1:4 
in 20mM HEPES pH 7.4, 150 mM NaCl, 0.01 % Tween buffer to give a dilution series 
of 50000 nM, 12500 nM, 3125 nM, 781.25nM, 195.31 nM, 48.83 nM, 12.2 nM, 3.05 
nM0.76 nM, 0.19 nM and 0.05 nM using an Echo550 liquid handler (Labcyte). The 
inhibitors were flowed over the bound GSTCDK1 and GSTCDK2 at 30 μl/min for 60 
seconds. Dissociation was measured for 360 seconds. GST was loaded at a 
concentration of 20 μg/ml for 60 seconds at 30 μl/min and was used as a negative 
control. Binding to the GST control was subtracted from inhibitor binding sensorgrams 
to account for non-specific interactions and bulk effects. Kd values and dissociation 
rates were calculated using the rate equation implemented within the Biacore analysis 
software.   
                                                                            𝐾𝑑 =
𝑘𝑑
𝑘𝑎
    
    Equation 5-1 Binding constant determination. 
   Abbreviations: Kd –dissociations constant, kd –dissociation rate, ka –association rate. 
      
 ADP-GloTMkinase assay 
 Kinase reactions were carried out in 5 µl total volume at room temperature containing 
40 mM Tris-HCl pH 7.5, 20 mM MgCl2, 0.1 mg/ml BSA, using 4 nM pCDK1-Cyclin B or 
1.5 nM CDK2-Cyclin A. Kinase activity was measured towards 25 μM peptide 21 
(GPLGSMHPRVKEVRTDSGSLRRDMQPLSPIKVHERWSSATAGSAKRRLFGEDPP
KEMLMDKW) added to the CDK-Cyclin reaction in the presence of inhibitor (Table 5-
1) at concentrations 300, 240, 150, 90, 48, 24, 12, 6, 1.5, 0.75 nM. Reactions were  
initiated by the addition of 25 µM ATP. Assays were performed in white 384-well plates 
in duplicate.  Luminescence was detected using a PheraStar plate reader (BMG).  Km 
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and Vmax values were derived using GraphPad PRISM 6  and  were calculated using 
the Michaelis-Menten equation 3-1 as described in 3.2.15 
 Protein crystallography 
Sitting drop vapour diffusion crystallization trials were performed initially using a 
homemade screen designed from an initial hit from the Morpheus screen, (Molecular 
Dimensions, Newmarket, Suffolk, UK) condition B4 (0.1M MES/imidazole buffer (pH 
6.7), 6.5% MPD, 5% PEG 4K, 10% PEG1K). Further trials using a variety of 
commercially available screens, Index (Hampton Research, Aliso Viejo, USA), PACT 
premier™ HT-96 , Proplex, Morpheus and Structure (all from Molecular Dimensions, 
Newmarket, UK) were also carried out. Drops were dispensed by a TPP Labtech 
Mosquito LCP into MRC 96 wells plates by mixing 0.2 µl of complex and 0.2 µl of 
mother liquor. Plates were incubated at 4°C and monitored for 2 weeks.  Optimised 
crystallisation conditions for each complex are listed in Table 5.2. Crystals were 
mounted into a nylon crystal loop and cryo-cooled in liquid nitrogen prior to data 
collection.  
Protein Inhibitors Crystallisation condition 
CDK1-cyclin B-CKS2 Flavopiridol MESpH6.7, PEG1K 5%, PEG4K 10%, MPD 6.5% 
 Dinaciclib Poor diffraction 
 CGP74514A MESpH6.7, PEG1K 10%, PEG 4K  19.5%,MPD6.5 
 SU9516 Poor diffraction 
 AZD5438 MES pH6.3, PEG1K 5%, PEG4K 19%, MPD 
18.5% 
CDK1-CKS2 Flavopiridol Poor diffraction 
 Dinaciclib PACT premier TM (Molecular Dimensions), F5 
 CGP74514A Morpheus (Hampton Research), D10 
 SU9516 Dataset is not collected 
 AZD5438 Morpheus (Hampton Research), F10 
CDK2-cyclin A Flavopiridol 0.1 M HEPES pH7.0, 1 M AmSO4, 0.75 M KCl 
 Dinaciclib Dataset is not collected 
 CGP74514A 0.1 M HEPES pH7.0, 1.1 M AmSO4, 0.8 M KCl 
 SU9516 0.1 M HEPES pH7.0, 0.9 M AmSO4, 0.7 M KCl 
 AZD5438 0.1 M HEPES pH7.0, 0.6 M AmSO4, 0.9 M KCl 
CDK2 Flavopiridol Crystals were not obtained 
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 Dinaciclib PDB code: 4KD1 
 CGP74514A 0.1 M HEPES pH7.0, 1 M AmSO4, 0.9 M KCl 
 SU9516 PDB code: 3PY0 
 AZD5438 0.1 M HEPES pH 7.0, 0.8 M AmSO4, 0.9 M KCl 
Table 5-2 Crystal growth conditions. 
 
 
5.3 Results and Discussion 
 Description of the inhibitors chosen for the study 
The type I inhibitors that were chosen for this study have diverse scaffolds and 
collectively probe different parts of the ATP binding site.  Though they are all potent 
CDK ATP-competitive inhibitors they show differences in potency towards different 
CDK family members (Figure 5.7). 
5.3.1.1 Flavopiridol (Alvocidib) 
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4-
chromenone is an ATP-competitive inhibitor of CDK1, CDK2, CDK4 and CDK6 with  
some activity also against CDK7 (Table 5.3)(Whittaker et al., 2017).  Flavopiridol is an 
effective cytotoxic compound in human tumor models (Chipumuro et al., 2014). It was 
the first CDK inhibitor to be used in a clinical trial (Senderowicz, 1999), and was under 
development for treatment of acute myeloid leukemia and arthritis (Sekine et al., 2008) 
but its development was discontinued in 2012. 
5.3.1.2 AZD5438 
4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-N-(4-(methylsulfonyl)phenyl)pyrimidin-2-
amine was developed by AstraZeneca Ltd (UK) as a potent ATP competitive inhibitor 
of CDK1, CDK2 and CDK9 (Byth et al., 2009). It exhibits anti-proliferative activity in a 
range of human cell lines including lung, colorectal, breast, prostate, and hematologic 
tumors  (Natrajan et al., 2012).  
5.3.1.3  CGP74514A 
N-(cis-2-Aminocyclohexyl)-N-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine was 
developed by Novartis Pharma (Switzerland) as an ATP competitive CDK inhibitor that 
is cell penetrant, potent and most selective for CDK1 (Imbach et al., 1999). It has been 
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reported to induce apoptosis in several leukaemia cell lines (Yu et al., 2003) and to 
sensitize breast cancer cells to tumour necrosis factor-related apoptosis-inducing 
ligand (TRAIL) (Park et al., 2014).   
5.3.1.4 Su9516 
3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one is 
described as a highly selective ATP competitive CDK inhibitor, in particular targeting 
CDK2 and CDK1 and, to a lesser extent, CDK4, it has been explored as a potential 
cancer drug (Gao et al., 2006) (Lane et al., 2001). 
5.3.1.5  Dinaciclib (MK-7965, formerly SCH727965) 
2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-
5-yl]piperidin-2-yl]ethanol is a potent CDK2, CDK5, CDK1, CDK9 inhibitor developed 
by Merck&Co.Inc (Kenilworth, USA). It is active against a broad spectrum of human 
tumour cell lines (Parry et al., 2010) and acts in a dose dependant manner (Guzi et al., 
2011). It has been in a number of clinical trials since 2012 for different types of cancer 
and shows promising results for haematological malignancies (Blachly and Byrd, 
2013). 
1-Flavopiridol 
                                                 (Alvocidib) 
 
2-AZD5438 
 3-CGP74514A 
 
4-Su9516 
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                                                          5-Dinaciclib 
  
Figure 5-8 Structures and names of the inhibitors chosen for the study 
 
 CDK1-cyclin 
B 
CDK2-cyclin 
A 
CDK4-cyclin 
D 
CDK7-cyclin 
H 
CDK9-cyclin 
T 
Flavopiridol 27 405 132 514 11 
AZD5438 16 3 449 821 20 
CGP74514 25     
Su9516 40 22 200   
Dinaciclib 3 1   4 
Table 5-3 IC50s of the inhibitor panel towards different CDK complexes (Byth et 
al., 2009; Whittaker et al., 2017). 
 
 Effect of inhibitor binding on CDK1 and CDK2 thermal 
stability. 
The thermal stability of a protein in the presence of a diverse range of inhibitors can 
be used to characterise the inhibitor binding properties and consequently probe the 
physicochemical features of the active site (Najmanovich et al., 2007). Differential 
scanning fluorimetry (DSF) was employed to characterise changes in thermal stability 
of pCDK1 and pCDK2 alone and in a complex with their respective cyclins, in the 
presence of a diverse, small set of inhibitors (Figure 5-9). The melting temperatures of 
the CDKs and their complexes increase with increasing concentration of inhibitors until 
the CDK1 or CDK2 ATP-binding sites are saturated with inhibitor. For all inhibitor 
binding, saturation is reached at an inhibitor concentration of 100 μM. Consequently 
the Tm value at this inhibitor concentration was taken for comparative analysis of 
inhibitor-bound proteins (Figure 5-9). 
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Figure 5-9 Comparison of melting temperatures of pCDK1, pCDK2, pCDK1-
cyclin B and pCDK2-cyclin A 
Melting temperature measured by thermal denaturation assay using 3 μM of 
phosphorylated CDK1, CDK1 – cyclin B, CDK2 and CDK2-cyclin A represented by 
bars of a different colour in absence and after addition of 100 μM of the inhibitors. Bars 
representing melting temperature measured in the absence of the inhibitor, as a control 
for each inhibitor separately, contoured yellow. Bars representing melting temperature 
of the proteins in the presence of AZD5438 compound are coloured red, Dinaciclib are 
coloured purple, SU9515 are coloured black, Flavopiridol are coloured green, 
CGP745147 are coloured dark blue.    
 The ΔTm values presented in Table 5-4 were calculated as the difference between the 
apparent melting temperature of the protein in the presence of an inhibitor at 100 μM 
and the protein alone. All the inhibitors stabilised pCDK2 significantly. The highest 
values (13.6°C and 12.8°C) were measured in the presence of Dinaciclib and AZD5438 
respectively. The lowest ΔTm (8.4°C) was recorded in the presence of Flavopiridol. The 
melting temperature of pCDK2 rises by at least 6°C when it is bound to cyclin A 
confirming the model that CDKs are stabilised by cyclin binding (Brown et al., 2015). 
Moreover, pCDK2 in complex with cyclin A is stabilised further by inhibitor binding, 
although to a slightly lower extent then is monomeric pCDK2. As is the case for 
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monomeric pCDK2, Dinaciclib and AZD5438 provide the highest stabilization of 
pCDK2-cyclin A (Table 5-4). 
pCDK1 demonstrates a very different response in comparison to pCDK2. The 
monomeric form of pCDK1 is already less stable than monomeric pCDK2 by 5°C. In 
the presence of all inhibitors apart from Flavopiridol, its melting temperature 
decreases, indicating destabilisation of the protein (Table 5-4, Figure 5-9). When it is 
bound to cyclin B, CDK1 stability increases dramatically in the presence of all five 
inhibitors. For example by around 3°C bound to either CGP74514A or SU9516 and by 
9.6°C bound to Dinaciclib.  
Ihibitors  CDK2 ΔTmB CDK2-cyclinA 
ΔTmB 
CDK1 ΔTmB CDK1-cyclinB 
ΔTmB 
AZD5438 12.8±0.11 7.9±4.83 -1.8±0.11 4.8±7.92 
Dinaciclib 13.6±0.12 6.6±9.59 -0.4±0.12 9.6±6.6 
SU9516 10.6±0.21 4.8±3.48 -0.8±0.21 3.5±4.76 
Flavopiridol 8.4±0.25  6.1±7.44 1.4±0.36 7.4±6.15 
CGP74514A 9.7±0.11 3±3.27 -3.5±0.11 3.2±3.0 
Table 5-4 ΔTm values of pCDK2, pCDK2-cyclin A, CDK1, CDK2-cyclin B. 
ΔTm is the difference between the melting temperature of the protein in the presence 
of the inhibitor at the concentration 100μM and that in the presence of DMSO.  Values 
are calculated from results obtained from processing the DSF results in triplicate. 
Standard error of the mean calculated by Protein Thermal Shift Software 1.3. 
These results demonstrate that ATP competitive inhibitors stabilise pCDK2 and 
pCDK2-cyclin A. Remarkably, this stabilising effect of inhibitor binding is not observed 
for monomeric CDK1, but does occur when CDK1 is bound to cyclin B. As expected, 
binding of cyclin B to CDK1 generates a complex that is more stable than is monomeric 
CDK1. Taken together, monomeric pCDK1 differs from pCDK2 in its inhibitor binding 
profile while complexes respond to inhibitor binding in a very similar manner (Figure 5-
10).  
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Figure 5-10 Difference of ΔTm between pCDK1 and pCDK2 and pCDK1-cyclinB 
and pCDK2-cyclinA 
 
 Determining the affinity of CDK1-Cyclin B for inhibitors 
In order to provide more quantitative measures of the interactions between pCDK1 and 
pCDK2 and the panel of inhibitors, the more sensitive techniques of ITC and SPR were 
attempted.  ITC is a reliable method to determine the binding affinity between a protein 
and a small molecule. ITC experiments were completed by Daniel Woods and Mathew 
Martin as described in Section 5.2.6. Binding isotherms for pCDK1, pCDK1-cyclin B, 
pCDK2 and pCDK2-cyclin A binding to compound AZD5438 are displayed in Figure 
5.11. Binding isotherms for the rest of the chosen panel of inhibitors are presented in 
Appendix A.1 (Figures A-1, A-2, A-3, A-4). Control titrations were also carried out to 
confirm that there was no heat exchange accompanying the dilution of the inhibitor into 
the buffer (Appendix A.1, Figure A-5). The results (Figure 5.12) show that the inhibitor 
Kd values vary substantially, although all inhibitors bind very weakly to monomeric 
pCDK1. pCDK1 binding to cyclin B significantly improves inhibitor binding. Monomeric 
pCDK2 has greater affinity for each member of the panel of chosen inhibitors than 
pCDK1, and cyclin A binding further enhances those affinities. The Kd values for 
inhibitor binding to CDK1-cyclin B vary considerably but are similar for pCDK2–cyclin 
A. Generally it can be concluded that inhibitors bind more weakly to monomeric CDKs 
in comparison to the cyclin-bound forms confirming the results of the DSF experiments 
(Figure 5-13). 
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Figure 5-11 ITC to measure the affinity of CDK1 and CDK2 to a set of ATP-
competitive inhibitors. 
Binding isotherms are shown for titrations of monomeric pCDK1 (A), monomeric 
pCDK2 (B) pCDK1–cyclin B (C) and pCDK2–cyclin A (D) to AZD5438. Experiments 
were carried out at 30°C, with 10 μM CDK or CDK-cyclin in the cell and inhibitor at 100 
μM in the syringe. The measured enthalpy (ΔH) and stoichiometry of the reaction (N – 
number of binding sites) can be measured from which the equilibrium binding constants 
and changes of entropy (ΔS) can be derived. 
CDK1 pCDK1 – cyclin B 
pCDK2 pCDK2 – cyclin A 
 168 
 
 
Figure 5-12 Comparison of dissociation constant (Kd). 
Kd was measured by ITC for pCDK1, pCDK1-cyclin B, pCDK2 and pCDK2 – cyclin A 
bound to inhibitors. Values are provided in nM. 
To compare the results of DSF and ITC, values from each experiment were collated 
and plotted in Excel. The resulting analyses show similar trends when the relative 
affinity of monomeric and binary complex binding is evaluated by either ITC (Figure 5-
13 A) or DSF (Figure 5-13 B): the binary complexes, pCDK2-cyclin A and CDK1-cyclin 
B, bind to inhibitors with similar affinities, while monomeric pCDK2 and CDK1 differ in 
their affinities markedly. While this general trend is preserved between DSF and ITC 
studies, the more subtle differences in affinity of each protein species for the panel of 
inhibitors are not perfectly reproduced between the two techniques. 
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Figure 5-13 Difference between pCDK1 and pCDK2 and their complexes 
measured by DSF and ITC.   
Comparison of difference in melting temperature from DSF experiment (A) and Kd from 
ITC (B) between pCDK2 and pCDK1 and pCDK2 – cyclin A and pCDK1 – cyclin B. 
Fold difference between pCDK2 and pCDK1 identified blue and between pCDK2 and 
pCDK1 – orange. 
To confirm the ITC results, inhibitor binding to CDK1 and CDK2 was also assessed by 
SPR. GST-tagged CDK1 and CDK2 were immobilised to goat anti-GST antibody on 
the surface of a CM5 chip and inhibitors were subsequently flowed over to calculate 
the binding and dissociation kinetics. The character of GSTCDK1 and GSTCDK2 
binding to chosen compounds differ substantially, displaying different dissociation 
constants and different kinetics (Figure 5-14, also see Appendix A.1 Figures from A-6 
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to A-13). Nevertheless, subsets of inhibitor can be grouped in terms of the kinetics of 
their interactions with CDK2 and CDK1. For example, SU9516 and CGP 74514A 
(Appendix A.1, Figures A-10, A-12) bind with a fast-on fast-off kinetic to GSTCDK1, but 
a slow-on slow-off kinetic to GSTCDK2 (Appendix A.1, Figures A-11, A-13).  This is 
reflected in different Kds for the different proteins: the affinities of GSTCDK2 for 
SU9516 and CGP 74514A are 56 nM and 312 nM respectively, while the affinities of 
GSTCDK1 for these inhibitors are 2 μM and over 2 μM.  
The affinity of GSTCDK1 is higher to AZD5438, Dinaciclib and Flavopiridol than to 
SU9516 and CGP 74514A but still substantially lower than are the affinities of the same 
inhibitors for CDK2. According to the SPR results the GST-CDK2 binds with the highest 
affinity to AZD5438, Dinaciclib and SU9516. Interestingly, flavopiridol shows Kd value 
for GSTCDK1 and GSTCDK2 that differ least. Comparison of Kds for both proteins to 
the panel of inhibitors is shown in figure 5-16. 
 
Figure 5-14 Sensogram (A) and Response-Concentration plot (B) of AZD5438 
binding to GST–CDK1. 
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Kd (nM) 43.15 
Rmax (RU) 3.967 
offset (RU) 0.05316 
Chi² (RU²) 0.0376 
Figure 5-15 Sensogram (A) and Response-Concentration plot (B) of AZD5438 
binding to GST–CDK2. 
 
 
 
Figure 5-16 Dissociation constant (Kd) of pCDK1 and pCDK2 bound to 
inhibitors measured by SPR. 
Values are provided in nM. 
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Figure 5-17 Comparison of dissociation constant (Kd) measured by ITC and 
SPR. 
Kd is represented by the bars of the different colours, bars representing Kd for CDK1 
are coloured blue with red outline if measured by ITC and yellow if measured by SPR. 
Bars representing Kd for CDK2 are coloured green, with red outline if measured by ITC 
and yellow if measured by SPR.   
According to ITC and SPR experiments measuring affinity of selected inhibitors to 
CDK1 and CDK2 and their complexes with cognate cyclins, compounds show tighter 
binding in general to CDK2 in comparison to CDK1. Results of the ITC show that cyclin 
binding improves the inhibitor Kd values for both CDK family members, although more 
significantly for CDK1 in comparison to CDK2. Consequently, the affinity of inhibitor 
binding to monomeric forms differs substantially between CDK1 and CDK2 but when 
they are cyclin bound the differences are significantly smaller. These results confirm 
the idea of conformational changes that happen in CDKs due to cyclin binding that 
stabilise the protein in a form that is better predisposed toward inhibitor binding 
(Echalier et al., 2014). 
 Role of inhibition of pCDK1 and pCDK2 for its activity   
To investigate how structural differences and changes in thermal stability can be 
connected to the catalytic activity of both proteins when treated with selected inhibitors 
we have performed a kinase activity assay against a preferred peptide substrate 
derived from retinoblastoma protein p107 which has a canonical phosphorylation site, 
SPIK, and an intact RXL motif (Brown et al., 2015).  
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Inhibitors pCDK1 Standard 
deviation 
pCDK2 Standard 
deviation 
Flavopiridol 8.84 3.02 25.67 
 
4.74 
Dinaciclib 23.83 9.61 3.53 
 
0.21 
CGP74514A 833.4333 561.73 33.22 8.48 
 
SU9516 186.33 70.67 37.73 
 
4.54 
AZD5438 25.16 13.03 4.09 1.14 
Table 5-5 IC50 (nM) of pCDK1 and pCDK2 treated with ATP-competitive 
inhibitors 
 
Both complexes show differences in their inhibition by the panel of compounds, 
although all of the inhibitors, apart from flavopiridol, appear more selective against 
pCDK2 in comparison to pCDK1. The unusual CDK1-selectivity of flavopiridol was not 
anticipated from the previous DSF and SPR experiments, although flavopiridol, in 
contrast to the other compounds shows very similar Kd and melting temperature for 
both pCDK1–cyclin B and pCDK2-cyclin A complexes, suggesting similar selectivity. 
Also, according to the kinase assay, Dinaciclib and AZD5438 affect kinase activity of 
pCDK2–cyclin A the most and they are proved to be the tightest binders on ITC and 
also show highest melting temperature in DSF data. Interestingly, the activity of 
pCDK1–cyclin B and pCDK2– cyclin A in the presence of SU9516 and CGP74514 is 
the lowest amongst them all, consistent with the tight binding indicated by ITC and DSF 
as well. 
 Process of structure determination. 
The biophysical and biochemical experiments suggested that there may be differences 
between CDK1 and CDK2 in their inhibitor binding modes.  To assess these potential 
changes a systematic crystallisation screen was carried out to co-crystallise each 
inhibitor with monomeric CDK1 and CDK2 and with CDK1-Cyclin B-CKS2 and CDK2-
Cyclin A. Proteins were purified and complexes of CDK1-CKS2, CDK1–cyclin B–
CKS2, CDK2–cyclin A were prepared as described in Section 5.3.1 (Figure 5.18). All 
complexes produced crystals after a few rounds of optimisation (Figure 5.19). Normally 
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crystals appeared over one to two weeks in the different crystallisation conditions (see 
Table 5.2).  However, despite several repeats, not all of them diffracted to a resolution 
that allowed the structure to be solved. 
 
 
 
 
Figure 5-18 SDS PAGE of purified complexes CDK1 – CKS2, CDK1 – cyclin B, 
CDK2 – cyclin A. 
 
Inhibitors CDK1  - CKS2 CDK1 – B – CKS2 CDK2 – cyclin A 
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Flavopiridol 
 
Data collected at 
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2Å 
 
Data collected at 
2.52Å 
SU9516 
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not bound 
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Figure 5-19 Images of crystals used for structure determination. 
 
Data collection was performed at the Diamond Light Source (Didcot, UK) on beamlines 
I04-1 and I24 at 100 K using oscillation range 0.1° for a total oscillation of 200°. For 
the data processing Xia2 (Winter, 2010) and programs from CCP4i2 suite (Winn et al., 
2011) were used. Structures were determined by molecular replacement using Molrep 
(Vagin and Teplyakov, 1997) with CDK1–cyclin B–CKS2 (PDB code: 4YC3) as a 
search model for inhibitor bound complexes to CDK1–cyclin–CKS2, CDK1–CKS1 ( 
PDB code: 4YC6) as a search model for inhibitor bound CDK1– CKS2 and CDK2 – 
cyclin A (PDB code: 5IF1) for inhibitor bound CDK2 complexes. Solved structures 
underwent a few rounds of rebuilding in COOT (Emsley et al., 2010) and refinement 
by REFMAC5 (Murshudov et al., 1997), followed by final validation by MolProbity 
(Chen et al., 2010). Data collection, processing and statistics are provided in Appendix 
A.2 (Tables A-1, A-2, A-3 and A4). 
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 Structural analysis of CDK1-cyclin B-CKS2 complex bound to 
AZD5438, Flavopiridol and CGP74514A 
Structures have been solved at different resolution for different complexes of CDK1-
cyclin B-CKS2: at 2.7 Å for the AZD5438 bound structure, at 2.7 Å for the CGP74514A 
bound structure and at 2Å for Flavopiridol bound structure. The electron density for 
AZD5438 (Figure 5-20 A), Flavopiridol (Figure 5-20 B) and CGP7451A (Figure 5-20 C) 
was visible in the ATP binding sites of CDK1 and ligands were modelled using CCP4 
suites programs. Interactions between inhibitors and amino acids were analysed using 
CCP4mg within 5.5Å of a compound. Hydrogen bonds were assigned by CCP4mg 
based on the optimal distance of 3Å. Furthermore compound-aminoacid bonds were 
analysed by Poseview to represent key interactions in 2D (Stierand et al., 2006).  
A 
 
 
AZD5438 
B 
 
Flavopiridol (Alvocidib) 
 
 
C 
 
CGP74514A 
Figure 5-20 Structures of AZD5438, Flavopiridol (Alvocidib) and CGP74514A. 
Structures drawn in Chemdraw.  
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All three inhibitors occupy ATP binding pocket in a similar manner which is typical for 
Type I inhibitors. Inhibitors sit in a common plane and share a pose such that their 
pirimidineamine, chromone and purine groups pack towards the top of the pocket 
where gatekeeper residue Phe80 is located (Figure 5-21). All three inhibitors make a 
conserved hydrogen bond to the Leu83 of the hinge.  
A 
 
B 
 
Figure 5-21 Overlay of AZD5438, Flavopiridol and CGP 74514A in the ATP 
binding pocket of CDK1 bound to cyclin B and CKS2.   
AZD5438 is coloured blue, Flavopiridol is coloured green, CGP74514A coloured 
yellow. Residues of the CDK1 ATP binding pocket that form interactions with the 
inhibitors are identified.  
 
AZD5438 and CGP 74514A form hydrogen bonds to carbonyl moiety of Leu83 of 
CDK1-cyclin B-CKS1 and also to the hinge backbone, although the chromone core of 
Flavopiridol has only one hydrogen bond to the main chain of Leu83 (Figures 5-23) 
and is held in a hydrophobic pocket between Leu135, Ala31 and Ile10 by van der Waals 
forces.  The cyclohexane moiety of CGP74514A occupies the ribose binding pocket of 
CDK1, forming interactions with Gln132 while Flavopiridol and AZD5438 each form a 
network of interactions with Lys33 and Asp146 within the phosphate binding pocket 
through their piperidol and imidazole moieties. Towards the solvent exposed region of 
the active site, the methylsulfone group of AZD5438 forms a network of interactions 
between the two kinases lobes through Asp86 and the main chain of Ile10. Both 
Flavopiridol and CGP74514a harbour a chlorophenyl group in this region, however 
they adopt a different position. In Flavopiridol the chlorine atom is flipped in towards 
the inhibitor core to take advantage of interaction with Val18 and Ile10. With 
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CGP74514a the chlorophenyl group is twisted out, sitting up against the main chain of 
Met85. 
 
A 
 
B 
 
C 
 
D 
 
Figure 5-22 ATP binding pocket of CDK1 in complex with cyclin B and CKS2 
occupied by AZD5438. 
(A-B) Amino acids that form interactions with the inhibitor are identified. The inhibitor 
is displayed in ball and stick form and coloured green, oxygen is coloured red, nitrogen 
is coloured dark blue, and sulphur is coloured yellow. Electron density map 2Fo-Fc 
around the inhibitor shown as a wire in light blue with contour at 1 sigma.(C) The 
surface of CDK1 active site occupied by AZD5438 is coloured by the electrostatic 
potential with positive in blue and negative in red (D) Poseview created two 
dimensional diagram. Direct bonds are represented as dashed lines and interacting 
residues visualised as structure diagrams. Hydrophobic and van der Waals 
interactions are represented as green spines with amino acids involved identified   
(Stierand et al., 2006) 
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Figure 5-23 ATP binding pocket of CDK1 in complex with cyclin B and CKS2 
occupied by Flavopiridol. 
(A-B) Amino acids that form interactions with the inhibitor identified. The inhibitor is 
displayed in ball and stick form and coloured green, oxygen is coloured red, nitrogen 
is coloured dark blue, and sulphur is coloured yellow. Electron density map 2Fo-Fc 
around the inhibitor shown as a wire in light blue with contour at 1 sigma. (C) The 
surface of CDK1 active site occupied by Flavopiridol coloured by the electrostatic 
potential with positive in red and negative in blue. (D) Poseview created two 
dimensional diagram. Direct bonds are represented as dashed lines and interacting 
residues visualised as structure diagrams. Hydrophobic and van der Waals 
interactions represented as green spines with amino acids involved identified   
(Stierand et al., 2006). 
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Figure 5-24 ATP binding pocket of CDK1 in complex with cyclin B and CKS2 
occupied by CGP74514A. 
(A-B) Amino acids that form interactions with the inhibitor identified. The inhibitor is 
displayed in ball and stick form and coloured green, oxygen is coloured red, nitrogen 
is coloured dark blue, and sulphur is coloured yellow. Electron density map 2Fo-Fc 
around the inhibitor shown as a wire in light blue with contour at 1 sigma. (C) The 
surface of CDK1 active site occupied by AZD5438 coloured by the electrostatic 
potential with positive in red and negative in blue (D) Poseview created two 
dimensional diagram. Direct bonds are represented as dashed lines and interacting 
residues visualised as structure diagrams. Hydrophobic and van der Waals 
interactions represented as green spines with amino acids involved identified   
(Stierand et al., 2006). 
 
 
In the complexes bound to AZD5438 and Flavopiridol, the position of the P-loop follows 
the trend as for apo-CDK1-cyclin B-CKS2 with a phenyl ring accommodated within 
active site (Figure 5-25) and threonine 14 carbonyl group pointing out. However, the 
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position of the P-loop in CDK1-cyclin B-CKS2 bound to CGP74514A is different (Figure 
5-25), with the phenyl ring of Tyr15 pointing out of the active site and helping 
coordination of Glu163 on the activation segment. This conformation of the P-loop is 
also apparent in apo monomeric CDK1.  
 
 
Figure 5-25 Changes in P-loop position. 
CDK1 in complex with cyclin B and CKS2 bound to AZD5438 compound is coloured 
ice blue, CDK1 bound to Flavopiridol is coloured cyan, CDK1 bound to CGP74511A is 
coloured pink. 
 Structural analysis of CDK1-CKS2 complex bound to AZD5438 
and Dinaciclib  
Two structures of monomeric CDK1 have been solved bound to AZD5438 and 
Dinaciclib. Overall, the structure of CDK1 bound to Dinaciclib is very similar to the 
structure of the apo CDK1-CKS2 complex, apart from a small movement of the P-loop 
(about 2Å) towards the ATP binding site and a movement of the main chain of the hinge 
region towards the active site (about 1.5Å). The activation segment does not have 
supporting electron density in either structure. Dinaciclib is reportedly the most potent 
monomeric CDK1 inhibitor (Parry et al., 2010). It binds to CDK1 in a similar manner to 
the previously reported structures in complex with monomeric CDK2 and fully active 
complex of phosphorylated CDK2-cyclin E (Martin et al., 2013; Chen et al., 2016).   The 
aminopyrazolopyrimidine moiety of Dinaciclib forms two hydrogen bonds with the main 
chain Leu83 within the hinge region. The ethyl group adjoined to the pyrazolo core is 
positioned up against Phe80, while the core is sandwiched between the two lobes 
through hydrophobic and van der Waals interactions with Ala31, Ile10, and Leu135. 
The piperidine ring adopts the chair conformation and the pendent  2-hydroxyethyl 
group of the piperidine ring interacts with the conserved Lys33 residue and potentially 
forms an intramolecular hydrogen bond with the pyrazolo core. The pyridine oxide 
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group is solvent exposed due to its position in front of binding pocket, stacking up 
against the main chain of Met85 such that it seems to form interactions with Lys89 
(Figure 5-26).  
A 
 
B 
 
C 
 
D 
 
Figure 5-26 ATP binding pocket of CDK1 in complex with CKS2 occupied by 
Dinaciclib. 
 (A-B) Amino acids that form interactions with the inhibitor identified. The inhibitor is 
displayed in ball and stick form and coloured green, oxygen is coloured red, nitrogen 
is coloured dark blue, and sulphur is coloured yellow. Electron density map 2Fo-Fc 
around the inhibitor shown as a wire in light blue with contour at 1 sigma. (C) The 
surface of CDK1 active site occupied by Dinaciclib is coloured by the electrostatic 
potential with positive in red and negative in blue (D) Poseview created two 
dimensional diagram. Direct bonds are represented as dashed lines and interacting 
residues visualised as structure diagrams. Hydrophobic and van der Waals 
interactions represented as green spines with amino acids involved identified   
(Stierand et al., 2006) 
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Overall, the structure of CDK1 bound to AZD5438 is almost identical to the apo-
monomeric CDK1 structure, with a similar position of a P-loop and the main chain of 
the hinge region (Figure 5-27).  Due to the relatively small nature of AZD5438, this 
inhibitor does not extend enough towards the P loop to form the hydrogen bonds in 
that region. Instead, it forms connections along the hinge region. However, the 
AZD5438 pirimidineamine scaffold forms two hydrogen bonds with the main chain of 
Leu83 and the methylsulfonyl group makes additional hydrogen bonds towards the 
solvent exposed area. The AZD5438 imidazole moiety is involved in making 
hydrophobic and van der Waals connections to amino acids in the phosphate binding 
pocket. 
The position of the P-loop of CDK1 bound to Dinaciclib is pulled in towards the 
activation pocket with the phenyl ring of Tyr15 pointing out, as is the case when CDK1 
is bound to CGP74514A and apo monomeric CDK1. However, the P-loop of 
monomeric CDK1 bound to Dinaciclib is moved even further, by about 2Å, into the 
active site in comparison with apo monomeric CDK1. The conformation of the P-loop 
of CDK1 bound to AZD5438 resembles closely that of CDK1 in complex with cyclin B 
and CKS2, with the phenylalanine ring being tacked into the ATP binding site and the 
P loop pushed out. Although it has been hypothesised that the P-loop position towards 
the active site leads to inhibitors being more potent (Patel and Doerksen, 2010), that 
hypothesis is not supported by the structures reported here: CDK1 binds to two 
inhibitors of substantially different potency (Dinaciclib and CGP74514A) with P-loops 
in very similar conformations, although in the case of Dinaciclib the structure has been 
solved bound to the monomeric form and in case of CGP74514A to the CDK1-cyclin 
B complex. The structures of CDK1-cyclin B bound to either inhibitor were not obtained 
because crystals were too small. 
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Figure 5-27 ATP binding pocket of CDK1 in complex with CKS2 occupied by 
AZD5438. 
 (A-B) Amino acids that form interactions with the inhibitor identified. The inhibitor is 
displayed in ball and stick form and coloured green, oxygen is coloured red, nitrogen 
is coloured dark blue, and sulphur is coloured yellow. Electron density map 2Fo-Fc 
around the inhibitor shown as a wire in light blue with contour at 1 sigma. (C) The 
surface of CDK1 active site occupied by AZD5438 coloured by the electrostatic 
potential with positive in red and negative in blue. (D) Poseview created two 
dimensional diagram. Direct bonds are represented as dashed lines and interacting 
residues visualised as structure diagrams. Hydrophobic and van der Waals 
interactions represented as green spines with amino acids involved identified   
(Stierand et al., 2006). 
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Figure 5-28 Changes in P-loop position. 
Monomeric CDK1 bound to AZD5438 is coloured sea green, monomeric CDK1 bound 
to Dinaciclib is coloured gold. The distance between the respective αC atoms of Tyr15 
of each of the P-loops is measured by CCP4mg to be 5.3 Å.  
 
 Comparison of ATP binding pocket of monomeric CDK1 and 
CDK1 in complex with cyclin B 
This study was aiming to investigate how inhibitors with different scaffolds mould the 
ATP-binding sites of CDK1 and CDK2. Because of the differing plasticity of monomeric 
and cyclin bound CDKs, one objective of the study was to compare protein 
conformations and ligand poses when a specific inhibitor is bound to two different 
CDKs in their monomeric and cyclin-bound states. After a lot of effort, this objective 
was achieved for the inhibitor AZD5438, for which structures were determined in 
complex with CDK1-CKS2, CDK1-cyclin B-CKS2 and CDK2, CDK2-cyclin A was 
solved.   
Overall structures of monomeric CDK1 and CDK1 in complex with cyclin B bound to 
AZD5438 are similar, apart from some differences which are mainly related to cyclin B 
binding (Figure 5-29). As expected, cyclin B causes the CDK1 activation segment to 
become more ordered in the complex and “unwinds” the small α helix at the beginning 
thereof. Similarly, in the cyclin B-containing complex the C helix is moved towards the 
ATP binding pocket and the P-loop is better ordered.  The main chain of the P-loop is 
tacked in towards the ATP binding site by 3.7Å. The main chain of the hinge region 
follows the same path in the monomeric and binary structures.  The compound 
overlays very well in both structures and forms similar interactions. 
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Figure 5-29 Comparison of ATP binding pocket of CDK1 and CDK1-cyclin B 
occupied by AZD5438. 
(A) Overlay of CDK1 (ice blue) and CDK1-cyclin B-CKS2 (green) bound to AZD5438. 
(B) Amino acids from ATP binding pocket of CDK1-CKS2 that form interactions with 
the inhibitor. Inhibitor is displayed in ball and stick form and coloured green, oxygen is 
coloured red, nitrogen is coloured dark blue, and sulphur is coloured yellow. Electron 
density map 2Fo-Fc around the inhibitor shown as a wire in light blue with contour at 1 
sigma. (C) ATP binding pocket of CDK1-cyclin B-CKS2.  
Comparison of the AZD5438 complexes of monomeric CDK2 and CDK2 in complex 
with cyclin A follows the same trend as for CDK1 and CDK1-cyclin B (Figure 5-30). The 
ATP binding site forms similar interactions with AZD5438. The P-loop, however, 
displays larger differences between the monomeric and binary structures, moving by 
4.8 Å depending on whether cyclin A is present or not. 
 187 
 
A 
 
 
 
B 
 
C 
 
Figure 5-30 Comparison of ATP binding pocket of CDK2 and CDK2-cyclin A 
occupied by AZD5438. 
(A) Overlay of CDK2 and CDK2-cyclin A bound to AZD5438. (B) Amino acids from ATP 
binding pocket of CDK2 that form interactions with the inhibitor. Inhibitor is displayed 
in ball and stick form and coloured green, oxygen is coloured red, nitrogen is coloured 
dark blue, and sulphur is coloured yellow. Electron density map 2Fo-Fc around the 
inhibitor shown as a wire in light blue with contour 1 sigma. (C) ATP binding pocket of 
CDK2-cyclin A. 
From this comparative analysis, it can be concluded that the inhibitor bound structures 
of CDK1 and CDK2 are very similar in their ATP binding site in the monomeric form as 
well as in cyclin bound in terms of interactions made (Figure 5-31). Furthermore 
comparison of CDK1 and CDK2 structures reveal very close similarity. Consequently 
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the differences in biochemical properties of two must be deriving from factors other 
than the specific interactions made by the inhibitors in the ATP binding site. 
A 
 
B 
 
Figure 5-31 Overlay of CDK1 and CDK2 structures bound to AZD5438. 
CDK1 is displayed in ice blue and CDK2 is displayed in gold. AZD5438 compound 
represented in form of sticks and balls. Compound bound to CDK1 is coloured ice blue, 
compound bound to CDK2 is coloured gold. 
 
5.4  Conclusions 
The work produced for this chapter revealed very exciting results.  The comparison of 
melting temperatures of proteins bound to different inhibitors has shown not only the 
different level of stabilisation provided by different inhibitors, but also i) that cyclin-
binding enhances inhibitor binding, presumably by stabilising the CDK in 
conformation(s) compatible with optimising the inhibitor’s interactions, and ii) that 
monomeric CDK1 and CDK2 differ markedly in the affinity with which they are able to 
bind to inhibitors. ITC experiments measuring affinity between proteins and 
compounds have confirmed the preference of the inhibitors evaluated here to bind to 
CDK2 rather than CDK1. They have also confirmed and quantified the enhancement 
of inhibitor binding affinity in a cyclin bound form. These results also agree with 
published data that monomeric CDKs differ more in their inhibitor binding profile than 
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do CDKs when in complex with their cognate cyclins. We have also observed not only 
different affinity to inhibitors between CDK1 and CDK2 but also different kinetics of 
binding and dissociation by using Surface Plasmon Resonance. X-ray structure 
determination revealed only minor differences in compound binding between CDK1 
and CDK2 as well as between CDK1 and CDK1 – cyclin B and CDK2 and CDK2 – 
cyclin A.  This absence of significant differences in the bound structures supports the 
hypothesis that differences in affinity derive, instead, from differences in the 
conformational landscape of the whole CDK molecule in the bound and unbound 
states, rather than from the detailed geometries of the contacts made in the bound 
state.  
Therefore, the conclusion can be drawn that ATP binding sites can be explored by ATP 
competitive inhibitors to reveal both quantitatively and qualitatively different properties. 
Furthermore, we conclude that inhibitors bind much more weakly to monomeric CDK1 
in comparison to CDK2, while that differential interaction is largely removed by cyclin 
binding. Consequently, cyclin bound complexes do not differ so much in their ability for 
inhibitor binding.  Therefore, it may be possible to achieve selective inhibition of CDK2 
by targeting the monomeric form of the enzyme, exploiting conformational flexibility of 
the whole kinase molecules and not only that of the ATP binding site.   
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 Conclusions and further directions 
6.1 Conclusions 
CDK1 is the founding member of the cyclin dependent kinase family and the only 
essential CDK, which can substitute for the other interphase CDKs to ensure 
progression of the eukaryotic cell cycle. It has been proposed that this ability of CDK1 
to step in for another CDKs is driven, in part, by its flexibility in substrate selection. A 
few structures of CDKs have been solved in recent years to assist with understanding 
of their function as well as help with the design of drugs for use in disease therapy. 
The crystal structure of CDK1 has been reported in this study in a monomeric state as 
well as bound to its activator cyclin B. Monomeric CDK1 adopts a typical bi-lobal 
inactive CDK fold where the C-helix is moved out of the active site and the activation 
segment is disordered. The main dissimilarities between monomeric forms of CDK1 
and CDK2 can be noticed in the area of activation segment, αC helix and C-termini. 
The activation segments of both CDK2 and CDK1 begin with a small α helical structure 
that occludes the site occupied by the C-helix in the activated, cyclin-bound states of 
the enzymes. Residues 156-162 that encompass the site of phosphorylation within the 
activation segment of CDK1 do not have supporting electron density, suggesting that 
these residues are likely to be flexible and/or disordered in the monomeric state. A 
major difference between monomeric CDK1 and monomeric CDK2 can be observed 
in the conformation of the DFG motif, with phenylalanine side chain in CDK1 pointing 
out towards carbonyl moiety of Val64, while in CDK2 this side chain is rotated into the 
active site towards Asp185. A further structural feature specific to monomeric CDK1 is 
a small β hairpin formed by residues 40-46 that form the loop that preceded the C-
helix. The C terminus of CDK1, beginning at Leu290, is disordered but in CDK2 it forms 
the tail which spreads at the back of the structure towards the hinge. 
Overall, the structure of CDK1-cyclin B-CKS2 appeared to be distinctive from both the 
CDK2-cyclin A and CDK4-cyclin D structures, with a 30% smaller binding interface 
between CDK and cyclin in comparison to CDK2-cyclin A which leaves the activation 
segment more exposed to solvent. An interesting feature of the CDK1-cyclin B 
structure, that is shared with CDK4-cyclin D and CDK9-cyclin T but not present in 
CDK2-cyclin A, is a cleft between the C terminal lobe of CDK1 and cyclin B. The 
equivalent cleft in CDK9-cyclin T structure has been shown to play a role in binding of 
HIV regulatory protein TAT. By analogy, the cleft in CDK1 may play a role in mediating 
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interaction with as yet unidentified partners, a hypothesis which might be investigated 
in the future. The structure of CDK1-cyclin B-CKS2 was found not to be in a fully active 
conformation, although with activation segment being relatively well ordered. 
Comparison of positions of Thr 161 of CDK1-cyclin B-CKS2 and Thr of CDK2-cyclin A 
shows 5 Å distance between them in the superimposed structures. The change of 
position in two complexes suggests that one or both have to move for engaging CDK7-
cyclin H for phosphorylation productively. 
The structural findings prompted a series of experiments directed towards 
determination of the affinity between CDK1 and cyclin B in comparison to CDK2 and 
cyclin A by Isothermal Titration Calorimetry as well as the stability of the two complexes 
by Differential Scanning Fluorimetry. The results came into agreement with the 
structural outcomes, showing lower stability by about 5°C of the CDK1-cyclin B 
complex in comparison to CDK2-cyclin A.  
It has been demonstrated in the past that the Thr160 phosphorylation site of CDK2 is 
buried in the pCDK2-cyclin A complex and not accessible to dephosphorylation by λ 
phosphatase. As expected from the more open character of the CDK1-cyclin B 
complex, we found that the equivalent phosphorylated residue in the activation 
segment of CDK1 remains accessible to λ phosphatase-mediated dephosphorylation 
when in complex with cyclin B. 
The comparison of residues involved in CDK-cyclin binding between CDK1 and cyclin 
A, cyclin B and cyclin E has offered a possible explanation for the preferential binding 
of CDK1 to cyclin B and cyclin A. It has been noticed that the smaller residues Asn112, 
Ile 119 and Leu202 of cyclin E cannot contribute as much binding energy as the larger 
hydrophobic residues Tyr170, Tyr177 and Tyr258 in cyclin B. 
Experiments focused on investigating substrate preferences have confirmed a 
prediction made from the structure, namely that CDK1-cyclin B displays a more relaxed 
specificity towards amino acids around the site of phosphotransfer in comparison to 
CDK2-cyclin A. 
Another direction was taken to describe the binding properties of two CDK partner 
proteins RINGO/Speedy A and RGC32. The aim of the Speedy project was to express 
and purify a protein fragment containing a speedy box in amounts sufficient for 
biochemical, biophysical and structural characterisations. Despite extensive efforts, 
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protein was not expressed in the required amounts. Subsequently, the structure of a 
Speedy fragment in complex with CDK2 has been published recently. 
In agreement with cell-based experiments performed in the lab of Prof. Michelle West 
we have been able to demonstrate the binding between RGC32 and CDK1 by SPR. 
No binding has been detected between RGC32 and CDK2.  
The last chapter presents exciting work to dissect structural and functional differences 
between CDK1 and CDK2 in respect of their binding to a panel of inhibitors. Inhibitors 
were chosen to span diverse different scaffolds so as to probe the ATP binding site in 
different ways. In this collaborative study a number of biophysical and biochemical 
techniques were performed to investigate i) the inhibitors’ influence on stability of 
monomeric proteins and complexes by DSF, ii) the affinity of proteins towards the 
inhibitor panel by SPR and ITC, iii) the influence of the inhibitors on the kinase activity 
of CDK-cyclin complexes by ADP-GloTM assay, and iv) similarities and differences in 
inhibitor binding modes by X-ray crystallography. Results revealed that, despite 
relatively minor differences in binding interactions demonstrated by crystallography, 
inhibitors show markedly different affinities and kinetics of binding to the monomeric 
form of the CDKs, but tight and consistent binding to the cyclin-bound forms. All these 
findings lead to the conclusion that ATP-competitive inhibitors might exploit the 
conformational energetic landscape of the monomeric forms of CDKs to achieve 
potentially exquisitely selective inhibition. 
 
6.2 Future directions 
Some of the work attempted during the last few years has yielded promising leads that 
open up new lines of experimentation. The conclusions from it could lead to future 
possibilities to crystallise CDK1 in a fully active conformation, phosphorylated on Tyr 
161 which would give more understanding of its function in comparison to the other 
CDKs. Also, determination of the structure of CDK1 bound to cyclin A could be 
beneficial for understanding the impact of the cyclin partner on the choice of substrates 
by CDK1. Furthermore work is planned to investigate the binding of CDK1 to non-cyclin 
regulators as Ringo /Speedy A and perform CDK1-Speedy A crystallisation trials. 
Regarding RGC32 protein, alternative assays such as homogenous time resolved 
fluorescence (HTRF) can be performed to take the project forward. Finally, the work 
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presented here clearly demonstrates that whereas inhibitors struggle to discriminate 
between CDK2-cyclin A and CDK1-cyclin B, they can readily distinguish monomeric 
CDK2 from monomeric CDK1.  This observation opens up exciting possibilities for 
future development of inhibitors that target one or the other family member, which 
might in turn be used as pharmacological probes for their cellular roles and as starting 
points for drug discovery.  
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Appendix 
A.1 Additional results 
A.1.1 Results of ITC 
Binding isotherms of pCDK1, pCDK1-cyclin B, pCDK2 and pCDK2-cyclin A to 
Dinaciclib, SU9516, Flavopiridol, CGP7451.      
    
  
  
Figure A-1 ITC to measure the affinity of CDK1 and CDK2 to a set of ATP-
competitive inhibitors. Binding isotherms are shown for titrations of monomeric 
pCDK1 (A), monomeric pCDK2 (B) pCDK1–cyclin B (C) and pCDK2–cyclin A (D) 
to Dinaciclib.  
pCDK1 pCDK1 – cyclin B 
pCDK2 pCDK2 - cyclinA 
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Experiments were carried out at 30°C, with 10 μM CDK or CDK-cyclin in the cell and 
inhibitor at 100 μM in the syringe. The measured enthalpy (ΔH) and stoichiometry of 
the reaction (N – number of binding sites) can be measured from which the equilibrium 
binding constants and changes of entropy (ΔS) can be derived. 
  
  
Figure A-2 ITC to measure the affinity of CDK1 and CDK2 to a set of ATP-
competitive inhibitors. Binding isotherms are shown for titrations of monomeric 
pCDK1 (A), monomeric pCDK2 (B) pCDK1–cyclin B (C) and pCDK2–cyclin A (D) 
to SU9516. Experiments were carried out at 30°C, with 10 μM CDK or CDK-cyclin in 
the cell and inhibitor at 100 μM in the syringe. The measured enthalpy (ΔH) and 
stoichiometry of the reaction (N – number of binding sites) can be measured from which 
the equilibrium binding constants and changes of entropy (ΔS) can be derived. 
pCDK1 pCDK1 – cyclin B 
pCDK2 pCDK2 - cyclinA 
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Figure A-3 ITC to measure the affinity of CDK1 and CDK2 to a set of ATP-
competitive inhibitors. Binding isotherms are shown for titrations of monomeric 
pCDK1 (A), monomeric pCDK2 (B) pCDK1–cyclin B (C) and pCDK2–cyclin A (D) 
to Flavopiridol. Experiments were carried out at 30°C, with 10 μM CDK or CDK-cyclin 
in the cell and inhibitor at 100 μM in the syringe. The measured enthalpy (ΔH) and 
stoichiometry of the reaction (N – number of binding sites) can be measured from which 
the equilibrium binding constants and changes of entropy (ΔS) can be derived. 
pCDK1 pCDK1 – cyclin B 
pCDK2  pCDK2 – cyclin A 
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Figure A-4 ITC to measure the affinity of CDK1 and CDK2 to a set of ATP-
competitive inhibitors. Binding isotherms are shown for titrations of 
monomeric pCDK1 (A), monomeric pCDK2 (B) pCDK1–cyclin B (C) and pCDK2–
cyclin A (D) to CGP74514A. Experiments were carried out at 30°C, with 10 μM CDK 
or CDK-cyclin in the cell and inhibitor at 100 μM in the syringe. The measured 
enthalpy (ΔH) and stoichiometry of the reaction (N – number of binding sites) can be 
measured from which the equilibrium binding constants and changes of entropy (ΔS) 
can be derived. 
pCDK1 pCDK1 – cyclin B 
pCDK2 pCDK2 – cyclin 
A 
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CDK1 
CDK2 
     Dinaciclib          Su9516          Flavopiridol       AZD5438       CGP74154A     
 
 
Figure A-5 Binding isotherms of compound in 1%DMSO injected into buffer. 
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A.1.2 SPR sensograms  
A 
 
 
 
 
 
B 
 
 
 
 
 
Kd (nM) 1806 
Rmax (RU) 18.54 
offset (RU) 0.5891 
Chi² (RU²) 0.127 
 
 
 
 
Figure A-6 Sensogram (A) and Response-Concentration plot (B) of Dinaciclib 
binding to GSTCDK1. 
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Kd (nM) 78.61 
Rmax (RU) 3.767 
offset (RU) -0.333 
Chi² (RU²) 0.0409 
 
 
Figure A-7 Sensogram (A) and Response-Concentration plot (B) of Dinaciclib 
binding to GSTCDK2. 
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Kd (nM) 1080 
Rmax (RU) 17.67 
offset (RU) 0.4743 
Chi² (RU²) 0.662 
 
 
Figure A-8 Sensogram (A) and Response-Concentration plot (B) of Flavopiridol 
binding to GSTCDK1. 
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Kd (nM) 655.4 
Rmax (RU) 3.594 
offset (RU) -0.1677 
Chi² (RU²) 0.0778 
 
 
Figure A-9 Sensogram (A) and Response-Concentration plot (B) of Flavopiridol 
binding to GSTCDK2. 
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Kd (nM) 5839 
Rmax (RU) 19.17 
offset (RU) 0.7186 
Chi² (RU²) 0.22 
 
 
Figure A-10 Sensogram (A) and Response-Concentration plot (B) of Su9516 
binding to GSTCDK1. 
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Kd (nM) 56.19 
Rmax (RU) 4.459 
offset (RU) 0.4329 
Chi² (RU²) 0.294 
 
 
Figure A-11 Sensogram (A) and Response-Concentration plot (B) of Su9516 
binding to GSTCDK2. 
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Kd (nM) >10000 
Rmax (RU) 25.79 
offset (RU) 0.4478 
Chi² (RU²) 0.0933 
 
 
Figure A-12 Sensogram (A) and Response-Concentration plot (B) of 
CGP74514A binding to GSTCDK1. 
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Kd (nM) 312.1 
Rmax (RU) 4.589 
offset (RU) -0.2763 
Chi² (RU²) 0.0344 
 
 
Figure A-13 Sensogram (A) and Response-Concentration plot (B)of CGP74514A 
binding to GST–CDK2. 
 
A.2 Data collection and phasing statistics 
Datasets dls150516_CDK1_15_AZD5438 for CDK1-cyclin B-CKS2 AZD5438, 
dls250616_CDK1B_1_FLP for CDK1-cyclin B-CKS2 Flavopiridol and 
dls150516_CDK1B_11_CGP74514A CDK1-cyclin B-CKS2 CGP74514A were 
collected from single crystals on beamlines I03, I04 and I24 respectively, operating at 
0.969 Å and equipped with Pilatus 6M detectors (Broennimann et al., 2006). Typically 
2000 images were collected with an oscillation angle of 0.1° per image and an 
exposure time of 0.1 s. Data were imported from Xia (Winter, 2010) and processed 
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 207 
 
using programs of the CCP4 suite (Pointless/ Aimless (Evans, 2006; Evans, 2011)). 
The structures of CKS2 (PDB code 1BUH), CDK2 (PDB code 1HCK), human cyclin B 
(PDB code 2B9R) and cyclin-bound CDK2 (PDB code 1QMZ) were used as search 
models for molecular replacement by Phaser (McCoy et al., 2007). The structures were 
refined using cycles of manual rebuilding in COOT (Emsley et al., 2010) followed by 
refinement by Refmac5 (Murshudov et al., 1997). The final models were evaluated 
using Molprobity (Chen et al., 2010). Statistics for each data set are presented in Table 
A1.   
 CDK1-cyclinB-
CKS2 
AZD5438 
CDK1-CyclinB-CKS2  
Flavopiridol 
CDK1-CyclinB-CKS2  
CGP74514A 
Data collection 
Beamline I03 I04 I03 
Space group P 21 21 21 I 1 2 1 P 21 21 21 
Cell dimensions    
a, b, c (Å) 64.6, 68.2, 167.3 78.1, 53.8, 180.2 64.5, 68.2, 166.1 
α, β, ɣ (°) 90, 90, 90 90.0, 98.3, 90.0 90, 90, 90 
Resolution (Å) 83.80-2.65 (2.65-
2.65) 
89.17-2.00 (2.0-2.0) 83.18 (2.73-2.73) 
R-factor/R-free 0.194 /0.258 0.189 /0.240 0.197 /0.252 
Rmerge 0.122 (0.824) 0.087 (1.012) 0.267 (1.458) 
I/δ(I) 9 (1.9) 6.9 (1.1) 5.2 (1.3) 
Completeness (%) 98.2 (95.3) 100 (100) 100 (100) 
Redundancy 3.4 (3.4) 3.7 (3.7) 6.7 (5.5) 
Refinement 
No. reflections 21743 /1128 50412 /2485 20165 /989 
Rwork /Rfree 0.194 /0.258 0.189 /0.240 0.197 /0.252 
B-factors    
Protein (Chains A, 
B,C) 
48.2, 42.7, 55.6 45.1, 51.4, 57.1 54.4, 47.7, 65.4 
Ligand/ion 39.2 40.3 47.7 
Water 33.8 47.4 37.1 
No. atoms    
Protein (Chains A, 
B,C) 
4651, 4216, 1260 4699, 4226, 1239 4651, 4216, 1260 
Ligand/ion 48 45 52 
Water 62 194 76 
Root mean-squared 
deviations 
   
Bond lengths (Å) 0.0115 0.0163 0.0109 
Bond angles (°) 1.552 1.839 1.534 
Table A1 Summary of CDK1-cyclin B- CKS2 bound to AZD5438, Flavopiridol, 
CGP74514A X-ray data collection refinement statistics. 
CDK1-CKS2 AZD5438 data collected as described earlier on a single crystal at 100 K 
on a beamline I04-1, DLS, dataset called dls080517_CDK1_18_AZD. CDK1-cyclin B-
CKS2 Dinaciclib, data collected on a single crystal at 100 K on a beamline I24, DLS, 
dataset called dls240916_CDK1_6_dinacililib.  
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 CDK1-CKS2 AZD5438 CDK1-CKS2 Dinaciclib 
Data collection 
Beamline I04-1 I24 
Space group P 1 21 1 I 2 2 2 
Cell dimensions   
a, b, c (Å) 68.0, 149.2, 87.3 93.7, 97.2, 108.6 
α, β, ɣ (°) 90, 90, 90 90, 90, 90 
Resolution (Å) 87.35-2.75 (2.75-2.75) 72.43-2.33 (2.33-2.33) 
Rmerge 0.091 (0.842) 0.052 (0.42) 
I/δ(I) 8.8 (1.4) 10.8 (2.4) 
Completeness (%) 99.8 99.8 
Redundancy 3.8 (3.8) 1.9 (1.9) 
Refinement 
No. reflections 45022 /2187 21580 /1077 
Rwork /Rfree 0.225 /0.271 0.199 /0.250 
B-factors   
Protein (Chains A, B) 74.0, 72.1 47, 56 
Ligand/ion 83.8 47.7 
Water 52.2 40.7 
No. atoms   
Protein (Chains A, B) 4536, 1186 4586, 1164 
Ligand/ion 47 56 
Water 14 86 
Root mean-squared 
deviations 
  
Bond lengths (Å) 0.0117 0.0158 
Bond angles (°) 1.601 1.887 
 
Table A2 Summary of CDK1- CKS2 bound to AZD5438 and Dinaciclib X-ray data 
collection refinement statistics. 
CDK2-cyclin A AZD5438 data collected on a single crystal at 100 K on a beamline I03, 
DLS, dataset called dls250616_CDK2A_2_AZD. CDK2-cyclin A- Flavopiridol,data 
collected on a single crystal at 100 K on a beamline I04-1, DLS, dataset called 
dls100716_CDK2A_1_flavopiridol. CDK2-cyclin A Su9516 data collected on a single 
crystal at 100 K on a beamline I04-1, DLS and dataset called 
dls100716_CDK2A_5_SU9516.  
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 CDK2-cyclinA 
AZD5438 
CDK2-CyclinA  
Flavopiridol 
CDK2-CyclinA 
Su9516 
Data collection 
Beamline I03 I04-1 I04-1 
Space group P 21 21 21 P 21 21 21 P 21 21 21 
Cell dimensions    
a, b, c (Å) 74.3,133.2,148.1 75.2,136.2,150.0 75.4,135.8,149.6 
α, β, ɣ (°) 90,90,90 90,90,90 90,90,90 
Resolution (Å) 99.26-1.99 101.04-2.52 100.77-2.00 
Rmerge 0.099 (1.252) 0.275 (2.581) 0.085 (0.984) 
I/δ(I) 12.1 (1.2) 8.5 (1.5) 12.1 (2.1) 
Completeness (%) 98.6 (93.2) 100 (100) 100 (100) 
Redundancy 6.5 (4.6) 7.5 (7.7) 7.3 (7.3) 
Refinement 
No. reflections 99925 / 4909 52814 /2638 104286 / 5195 
Rwork /Rfree 0.191 / 0.229 0.194 /0.236 0.187 / 0.220 
B-factors    
Protein (Chains A, 
B) 
31.6, 34.2 38.0, 43.5 34.4, 36.7 
Ligand/ion 32.0 31.5 30.5 
Water 37.2 30.1 43.2 
No. atoms    
Protein (Chains A, 
B) 
4687, 4146 4690, 4136 4628, 4136 
Ligand/ion 48 45 
 
30 
Water 545 72 
 
538 
Root mean-
squared 
deviations 
   
Bond lengths (Å) 0.0178 0.0141 0.0188 
Bond angles (°) 1.899 1.698 1.804 
Table A3 Summary of CDK2-cyclin A bound to AZD5438, Flavopiridol and 
Su9516 X-ray data collection refinement statistics. 
 
           
CDK2-cyclin A AZD5438 data collected on a single crystal at 100 K on a beamline I04, 
DLS, dataset called dls040317_CDK2_25_AZD5438. CDK2-cyclin A CGP74514A 
data collected on a single crystal at 100 K on a beamline I04, DLS, dataset called 
dls040317_CDK2_29_CGP74514A.  
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 CDK1-CKS2 AZD5438 CDK1-CKS2 CGP74514A 
                                                      Data collection 
Beamline I04 I04 
Space group P 21 21 21 P 21 21 21 
Cell dimensions   
a, b, c (Å) 53.3, 71.3, 72.1  53.3, 71.9, 72.4 
α, β, ɣ (°) 90, 90, 90 90, 90, 90 
Resolution (Å) 50.75-1.50 51.08-1.30 
Rmerge 0.05 (1.14)  0.039 (0.905) 
I/δ(I) 13.5 (1.5)       15.5 (1.3) 
Completeness (%) 100 (100) 100 (100) 
Redundancy   
Refinement 
No. reflections 44735 /2227 69081 / 3600 
Rwork /Rfree   0.189 /0.234 0.186 /0.216 
B-factors   
Protein (Chain A) 34.0 28.2 
Ligand/ion       26.9 25.4 
Water 38.6 37.5 
No. atoms   
Protein (Chain A) 4681  4502  
Ligand/ion 47  52  
Water 9  211  
Root mean-squared 
deviations 
  
Bond lengths (Å) 0.0215 0.0256 
Bond angles (°) 2.237 2.457 
Table A4 Summary of CDK2 bound to AZD5438 and CGP74514A X-ray data 
collection refinement statistics. 
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